Document:

Exhibit 10.8

 

ASSIGNMENT OF LICENSE AGREEMENT

 

This Assignment Agreement,
effective as of March 15, 2016 (the “Effective Date”), is entered into between Tallikut Pharmaceuticals, Inc. (“Tallikut”),
a corporation existing under the laws of Delaware, and Accelerated Pharma, Inc. (“API”), a corporation existing under
the laws of Delaware.

 

WHEREAS, pursuant
to that certain License Agreement between AnorMED Inc. (“AnorMED”) and NeoRx Corporation (“NeoRx”), dated April
2, 2004, as amended by that certain Amendment No. 1 to License Agreement, dated September 18, 2006, between AnorMED and Poniard
Pharmaceuticals, Inc., as successor-in-interest to NeoRx (“Poniard”) (as amended, the “License Agreement,”
a copy of which is attached hereto as Exhibit 1), Poniard obtained a license from AnorMED to certain patent rights, technical
data, and information related to picoplatin (also referred to as AMD473) (the “AnorMED Patents”);

 

WHEREAS, Encarta,
Inc. (“Encarta”) acquired all of Poniard’s right, title and interest in and to all assets related to picoplatin, including
Poniard’s licensed rights to the AnorMED Patents, pursuant to that certain Assert Purchase Agreement between Poniard (assignment
for the benefit of creditors), LLC and Encarta, dated June 20, 2013;

 

WHEREAS, Tallikut subsequently acquired
Encarta, including its licensed rights to the AnorMED Patents;

 

WHEREAS, AnorMED, including its
assets related to picoplatin, was acquired by Genzyme Corp., which was acquired by Sanofi;

 

WHEREAS, Tallikut sublicensed its
licensed rights to the AnorMED Patents to API pursuant to that certain Exclusive License Agreement dated June 17, 2014; and

 

WHEREAS, Tallikut desires to assign
the License Agreement, including its rights to the AnorMED Patents, to API;

 

NOW, THEREFORE, in consideration
of the mutual covenants and promises herein contained, the parties hereto agree as follows.

 

Section
1.        Tallikut warrants and represents that the License Agreement is in full force and effect and is fully assignable.
Tallikut further warrants and represents that rights in the License Agreement herein transferred are free of liens, encumbrances
or adverse claims. The License Agreement has not been modified (except to the extent of the above-referenced amendment) and remains
in effect pursuant to the terms contained therein. Tallikut hereby assigns its entire right, title, and interest in and to, and
its obligations under, the License Agreement to API (the “Assignment”).

 

Section
2.        API hereby accepts the Assignment, and agrees to assume, perform, and comply with and to be bound by all of the
terms, covenants, agreements, provisions, and conditions of the License Agreement as of the Effective Date.

 

    	Assignment of License Agreement	 	Page 1 of 2

     

    

 

Section
3.        Tallikut shall remain bound by any payment obligations to AnorMED under the License Agreement relating to the period
prior to the Effective Date, and Tallikut shall remain liable to AnorMED for any claims arising out of such rights prior to the
Effective Date.

 

Section
4.        Tallikut hereby represents and warrants that it has the full right to convey the right, title, and interest herein assigned
and that Tallikut has not executed and will not execute any agreement in conflict herewith.

 

Section 5.        Tallikut
hereby represents and warrants that it has received the necessary consent to assign the License Agreement, as required under Section
19.1 of the License Agreement.

 

Section
6.        This Assignment Agreement and the obligations of Tallikut and API hereunder
shall be binding upon and inure to the benefit of Tallikut and API and their respective successors and assigns, and may not be
modified or amended in any manner other than by a written agreement signed by the party to be charged therewith. Tallikut and
API agree to execute any and all other assignments, documents, certificates and other instruments as may at any time be deemed
reasonably necessary to further evidence or consummate this Assignment Agreement.

 

IN WITNESS WHEREOF, the parties have executed
this Assignment Agreement effective as of the Effective Date.

 

	TALL1KUT P ARMACEUTICALS, INC.	ACCELERATED PHARMA INC.

 

	By:	/s/ Fred Craves	 	By:	/s/ Michael Fonstein
	 	 	 	 	 
	Name:	Fred Craves	 	Name:	Michael Fonstein
	 	 	 	 	 
	Title:	Chairman of the Board	 	Title:	Chief Executive Officer

 

    	Assignment of LICENSE Agreement	 	Page 2 of 2

     

    

 

 

 

ANORMED
INC. 

 

AND

 

NEORX
CORPORATION

 

 

 

 

LICENSE

 

AGREEMENT

 

 

 

     

    	 	 	 

    

 

LICENSE
AGREEMENT  

 

TABLE OF CONTENTS

 

	Article 1 DEFINITIONS	1
	1.1	Definitions	1
	1.2	Other Definitions	6
	 	 	 
	Article 2 DEVELOPMENT PROGRAM	6
	2.1	Development Program	6
	2.2	AnorMED Assistance	6
	2.3	Progress Reports	6
	2.4	Committee; Committee Meetings	7
	 	 	 
	Article 3 GRANT OF LICENSE	7
	3.1	Grant of License	7
	3.2	Right to Grant Sublicenses	7
	3.3	Reservation of Rights	8
	3.4	Transfer of Information	8
	 	 	 
	Article 4 COMMERCIALIZATION	8
	4.1	Diligence in Commercialization	8
	4.2	Decision Not to Commercialize	9
	 	 	 
	Article 5 SUPPLY OF LICENSED COMPOUNDS AND LICENSED PRODUCTS	9
	5.1	Supply of AMD473	9
	5.2	Supply of Licensed Product	9
	5.3	Delivery	9
	5.4	Permits and Licenses	10
	 	 	 
	Article 6 LICENSE FEES	10
	6.1	Additional Definitions	10
	6.2	Initial License Fee	10
	6.3	Milestone Payments	10
	6.4	Form of Milestone Payments	11
	6.5	Notice of Milestone and Payment	11
	6.6	Nature of Payments	11
	 	 	 
	Article 7 ROYALTY PAYMENTS	11
	7.1	ICR Agreement	11
	7.2	Basic Royalty	12
	7.3	Sublicensing Royalty	12
	7.4	Third Party License Fees and Royalties	13
	7.5	Royalty Payments Upon Termination	13
	 	 	 
	Article 8 PAYMENT TERMS	13
	8.1	Invoices and Payments	13
	8.2	Payment of Royalties	14
	8.3	Currency of Payment	14
	8.4	Currency Transfer Restrictions	14
	8.5	Taxes	14
	8.6	Net Sales Reports	14
	8.7	Accounts and Audit	15
	8.8	Confidentiality of Reports	16
	8.9	Interest	16

 

     

    	 	 	 

    

 

	Article 9 INTELLECTUAL PROPERTY	16
	9.1	Existing Intellectual Property	16
	9.2	Ownership of New Inventions	16
	9.3	Improvements	17
	9.4	Trademarks	17
	 	 	 
	Article 10 PATENTS; PROSECUTION AND LITIGATION	17
	10.1	Prosecution of Patents	17
	10.2	Patent Review and Recommendations	18
	10.3	Patent Costs	19
	10.4	Right to Assume Prosecution	19
	10.5	Third Party Claims of Infringement	19
	10.6	Infringement by Third Parties	20
	10.7	Cooperation; Costs and Awards	20
	10.8	Cooperation with Other Licensees	21
	10.9	Interference Proceedings	21
	10.10	Status of Proceedings	 
	 	 	 
	Article 11 CONFIDENTIALITY; PUBLICITY; PUBLICATIONS	21
	11.1	Obligation of Confidentiality	21
	11.2	Permitted Disclosures	21
	11.3	Disclosure with Consent	 
	11.4	Ownership of Confidential Information	22
	11.5	Press Releases	22
	11.6	Publication	22
	11.7	Duration of Obligation	22
	 	 	 
	Article 12 LEGAL AND REGULATORY	22
	12.1	Compliance with Laws	 
	12.2	AMD473 Regulatory Activities	23
	12.3	Regulatory Program Progress Reports	24
	12.4	Safety	24
	12.5	Recalls	24
	 	 	 
	Article 13 REPRESENTATIONS, WARRANTIES AND COVENANTS	24
	13.1	AnorMED’s Representations, Warranties and Covenants	24
	13.2	NeoRx’ Representations, Warranties and Covenants	25
	13.3	No Warranty	25
	 	 	 
	Article 14 TERM AND TERMINATION	25
	14.1	Expiration	25
	14.2	Termination	26
	14.3	Termination by NeoRx	26
	14.4	Termination for Breach	27
	14.5	Termination on Bankruptcy	27
	14.6	Payments on Termination	28
	14.7	Inventory	28
	14.8	Survival	28
	 	 	 
	Article 15 INDEMNIFICATION	29
	15.1	Indemnification of AnorMED	29
	15.2	Indemnification of NeoRx	29
	15.3	Clinical Trials	29
	15.4	Unauthorized Commerce Indemnity	30
	15.5	Indemnification Procedure	30

 

    - ii - 

     

    

 

	Article 16 REPRESENTATIONS AND WARRANTIES OF NEORX	30
	16.1	Representations and Warranties	30
	 	 	 
	Article 17 REPRESENTATIONS AND WARRANTIES OF ANORMED	33
	17.1	Representations and Warranties	33
	 	 	 
	Article 18 REGISTRATION RIGHTS	34
	 	 
	Article 19 MISCELLANEOUS	34
	19.1	Assignment; Inurement	34
	19.2	Dispute Resolution	34
	19.3	Entire Agreement	35
	19.4	Force Majeure	35
	19.5	Further Assurances	35
	19.6	Governing Law	35
	19.7	Insurance	36
	19.8	Notices	36
	19.9	Change of Address	36
	19.10	Rights and Remedies	36
	19.11	Severability	36
	19.12	Counterparts; Facsimile	37

 

EXHIBITS

 

	Exhibit A	AnorMED Patents
	 	 
	Exhibit B	Development Program
	 	 
	Exhibit C	Evaluation Process
	 	 
	Exhibit D	Press Release

 

    - iii - 

     

    

 

LICENSE
AGREEMENT

 

THIS
LICENSE AGREEMENT (this “Agreement”) is entered into as of 4-2-2004, (the “Effective Date”)
by and among ANORMED INC. (“AnorMED”), a corporation organized and existing under the laws of Canada
and having an office at #200 - 20353 64th Ave, Langley, BC Canada V2Y 1N5 and NEORX CORPORATION (“NeoRx”),
a corporation organized and existing under the laws of the State of Washington, United States of America, and having an office
at 300 Elliott Avenue West, Suite 500, Seattle, Washington, USA 98119-4114.

 

RECITALS

 

WHEREAS:

 

A.           Effective
November 15, 1989, The Institute of Cancer Research: Royal Cancer Hospital and Johnson- Matthey PLC entered into a Collaboration
Agreement, as amended effective as of February 25, 1998 and March 24, 1998 (collectively, the “ICR Agreement”);

 

B.           Effective
June 28, 1996, all rights and obligations of Johnson Matthey PLC under the ICR Agreement with respect to a drug compound known
as AMD473, including, without limitation, the exclusive right to develop and commercialize AMD473, were assigned to AnorMED;

 

C.           From
its own independent research program and the research conducted under the ICR Agreement, AnorMED has valuable patent rights, technical
data and information relating to AMD473 and analogs or derivatives or backup compounds of AMD473; and

 

D.           NeoRx
desires to acquire from AnorMED a license to develop, manufacture and commercialize products incorporating AMD473 and/or its analogs,
derivatives and backup compounds, upon the terms and conditions set forth herein.

 

NOW,
THEREFORE, for and in consideration of the mutual covenants, rights and obligations contained in this Agreement and other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

Article
1 DEFINITIONS.

 

		1.1	Definitions.

 

In
this Agreement, the following words will have the meanings set out below:

 

		(a)	"Affiliate"
                                         shall mean, with respect to any Person, any Person directly or indirectly controlled
                                         by, controlling or under common control with such Person. For the purposes of this definition,
                                         except as otherwise expressly set out in this Agreement, “control”
                                         shall mean direct or indirect beneficial ownership of 50% or greater interest in the
                                         income of such Person or such other relationship as, in fact, constitutes actual control;

 

		(b)	“AMD473”
                                         shall mean the compound having the chemical name [SP-4-3]-amminedichloro(2- methylpyridine)platinum(II);

 

		(c)	“AnorMED
                                         Know-How” shall mean all Know-How that is or becomes owned and/or controlled
                                         by AnorMED as at the Effective Date and/or during the Term that relates to a Licensed
                                         Compound or a Licensed Product and that is necessary to make, have made, use, sell, offer
                                         for sale or import the Licensed Compound or the Licensed Product in the Territory in
                                         the Field;

 

     

    	 	 	 

    

 

		(d)	“AnorMED
                                         Patents” shall mean:

 

		(i)	the
                                         Patents identified in Exhibit A attached to this Agreement,

 

		(ii)	any
                                         Patents that claim any patentable improvements to the Patents identified in Exhibit
                                         A attached to this Agreement made by the parties during the Term, whether jointly
                                         or solely by a party, and

 

		(iii)	any
Patents that AnorMED owns or otherwise controls during the Term that relates to a Licensed Compound or a Licensed Product and
that is necessary to make, have made, use, sell, offer for sale or import the Licensed Compound or the Licensed Product in the
Territory in the Field, to the extent that AnorMED possesses the ability to grant access, a license or a sublicense (as applicable)
without violating the terms of any written agreement with a Third Party;

 

		(e)	“Business
                                         Day” shall mean any day other than a day which is a Saturday, Sunday or astatutory
                                         holiday in the Province of British Columbia, Canada or the State of Washington, USA;

 

		(f)	“Competition”
                                         shall mean, in respect of a particular country in the Territory, sales of any finished
                                         drug product (other than a Licensed Product) containing AMD473 or any analogues or derivatives
                                         or backup compounds of AMD473, the making, having made, using, selling, offering for
                                         sale or importing of which would infringe a Valid Claim of one or more of the AnorMED
                                         Patents in such country, where such sales are equal to or greater than 10% of the unit
                                         sales volume of a Licensed Product in such country;

 

		(g)	“Confidential
                                         Information” shall mean all information, data and records, whether written
                                         or oral, which is obtained by a receiving party (AnorMED or NeoRx, as the case may be)
                                         from a disclosing party (AnorMED or NeoRx, as the case may be). Information shall not
                                         be considered "Confidential Information" to the extent that when considered
                                         as a whole and in the context disclosed, the information:

 

		(i)	is in the public domain at the time of disclosure,

 

		(ii)	subsequently becomes part of the public domain throughno
act or fault of the receiving party or its agents or employees,

 

		(iii)	can be demonstrated by the receiving party’s written
records to have been known or otherwise available to the receiving party prior to the disclosure by the disclosing party,

 

		(iv)	can be demonstrated by the receiving party’s written
records to have been subsequently provided to the receiving party, without restriction, by a Third Party who has the right to
make such disclosure,

 

		(v)	is subsequently and independently developed by employees
of the receiving party or Affiliates (for this purpose, “control” in the definition of Affiliate shall mean direct
or indirect beneficial ownership of 35% or greater interest in the income of a Person or such other relationship as, in fact,
constitutes actual control) of the receiving party who had no knowledge of the information disclosed, as demonstrated by the receiving
party’s written records, or

 

		(vi)	is required to be disclosed by law or government regulation(s),
provided that the receiving party gives the disclosing party prompt notice of the required disclosure in order to allow the disclosing
party to seek protective treatment.

 

A combination of features will
not be deemed within the foregoing exceptions merely because individual features are in the public domain or in the possession
of the receiving party unless the combination itself is in the public domain or in the possession of the receiving party;

 

		(h)	“Current
                                         Market Price” shall have the meaning set out in Subsection 6.1(b);

 

		(i)	“Development
                                         Program” shall have the meaning set out in Section 2.1;

 

		(j)	“FDA”
                                         shall mean the United States Food and Drug Administration or any successor agency thereof;

 

		(k)	“Field”
                                         shall mean the use of a Licensed Compound or a Licensed Product for the diagnosis, prevention
                                         and/or treatment of any human disease;

 

    	 	- 2 -	 

     

    

 

		(l)	“First Commercial
                                         Sale” shall mean the first sale of a Licensed Product by NeoRx or an Affiliate
                                         or a sublicensee of NeoRx in a country in the Territory following the receipt or issuance
                                         of Regulatory Approval for the Licensed Product in that country or, if no such Regulatory
                                         Approval or similar marketing approval is required, the date upon which the Licensed
                                         Product is first commercially launched in such country. For the purposes of the definition
                                         of “First Commercial Sale”, “control” in the definition
                                         of Affiliate shall mean direct or indirect beneficial ownership of 35% or greater interest
                                         in the income of a Person or such other relationship as, in fact, constitutes actual
                                         control;

 

		(m)	“GAAP” or “generally accepted
accounting principles” shall mean the conventions, rules and procedures that define accounting practices as established,
and revised or amended, by the Financial Accounting Standards Board;

 

		(n)	“ICR”
                                         shall mean The Institute of Cancer Research: Royal Cancer Hospital, London, United Kingdom;

 

		(o)	“ICR Agreement” means the Collaboration
Agreement between ICR and Johnson Matthey PLC dated November 15th, 1989, as amended by Letter Agreement dated February 25th, 1998
and by Amendment dated March 24, 1998;

 

		(p)	“IND” shall mean an Investigational
New Drug Exemption under 21 C.F.R. 355(i) pursuant to the rules
and policies of the FDA and such equivalent regulations or standards of countries outside the United States as may be applicable
to the activities conducted hereunder;

 

		(q)	“Intellectual Property” shall mean any
discoveries, improvements, patents, patent applications, copyrights, copyright applications, industrial designs, industrial design
applications, mask works, trademarks, trademark applications and trade secrets;

 

		(r)	“Know-How” shall mean any and all data,
results, instructions, processes, formulae, trade secrets, expert opinions, regulatory submissions and other information (in written
or other tangible form) including, without limitation, any chemical, pharmacological, toxicological, pre-clinical, clinical, assay,
control and manufacturing data, biological materials, manufacturing or related technology, analytical methodology, chemical and
quality control procedures, protocols, techniques, improvements, results and reports of experimentation and testing;

 

		(s)	“Licensed Compound” shall mean AMD473,
and any analogues or derivatives or backup compounds of AMD473, the making, having made, using, selling, offering for sale or
importing of which would, but for the license granted herein, infringe a Valid Claim of one or more of the AnorMED Patents;

 

		(t)	“Licensed Product” shall mean any pharmaceutical
compositions approved as a drug in the Territory in dosage form in any formulation that contains a Licensed Compound as an active
ingredient and that are packaged and labelled for sale to the ultimate customer for use in the Field;

 

		(u)	“NDA” means a complete New Drug Application
and all supplements thereto filed with the FDA including all documents, data, and other information concerning a Licensed Product
which are necessary for, or included in, FDA approval to market such Licensed Product as more fully defined in 21 C.F.R. §
314.5 et seq and such equivalent regulations or standards of countries outside the United States as may be applicable to
activities anticipated hereunder;

 

		(v)	“Net Sales” shall mean the gross invoiced
sales price for Licensed Product sold or otherwise transferred to end users of the Licensed Product, less:

 

		(i)	credits or allowances, if any, given or made for purchase charge backs, price reductions,
                                                                                 returns, rebates, rejections, recall or destruction of spoiled, damaged, out-dated, returned or otherwise unacceptable
                                                                                 product (voluntarily made or requested or made by quantity, trade, an appropriate governmental agency, subdivision or
                                                                                 department) on account of or in relation to the invoiced sales price of Licensed Products,

 

		(ii)	if actually allowed or given

 

		(A)	allowances and/or incentives,

 

		(B)	price reductions, and

 

		(C)	rebates,

 

on account of or in relation to
the invoiced sales price of Licensed Products,

 

    	 	- 3 -	 

     

    

 

		(iii)	any duty, tax, excise or governmental charge upon or measured
by the production, sale, transportation, delivery or use of Licensed Products related to or based upon sales of Licensed Products
(including value added taxes but excluding taxes on net income), and

 

		(iv)	transportation and handling charges or allowances (freight,
postage, shipping and insurance), if any, incurred on account of or in relation to the invoiced sales price of Licensed Products.

 

Any Licensed Product sold or otherwise
transferred in other than an arm’s-length transaction or for other property (e.g., barter) or at less than fair market value
shall be deemed invoiced at its fair market price in such country of sale or transfer.

 

“Net Sales” shall
not include any amount for:

 

		(v)	the transfer of free samples of Licensed Product for marketing
purposes or on compassionate grounds and, prior to marketing, clinical trial materials, and

 

		(vi)	the sale or other transfer of Licensed Product by or between
Affiliates unless the receiving party is the end user of the Licensed Product, provided that any subsequent resale or re-transfer
of such Licensed Product to an end user of the Licensed Product shall be included in “Net Sales.”

 

For the purposes of the definition
of “Net Sales”, “control” in the definition of Affiliate shall mean direct or indirect beneficial
ownership of 35% or greater interest in the income of a Person or such other relationship as, in fact, constitutes actual control;

 

		(w)	“Patent”
                                         shall mean:

 

		(i)	any issued patent or patent application,

 

		(ii)	all continuations and continuations-in-part applications to the issued patentor patent
                                                                                  application set out in Paragraph (i) (solely to the extent such continuations-in-part applications contain subject matter on
                                                                                  which claims issuing obtain the benefit of a priority date of any patent or patent application set out in Paragraph
                                                                                  (i)),

 

		(iii)	all divisions, patents of addition, reissues, renewals and extensions of any of the
                                                                                   patent, patent application, continuations and continuations-in-part applications set out in Paragraphs (i) and (ii), and

 

		(iv)	all foreign counterparts of any of the foregoing (including,
without limitation, European Supplementary Protection Certificates or its equivalent);

 

		(x)	"Person"
                                         shall mean and include any individual, corporation, partnership, firm, joint venture,
                                         syndicate, association, trust, government body and any other form of entity or organization;

 

		(y)	“Phase II”
                                         shall mean that portion of the FDA submission and approval process which provides
                                         for the initial trials of a Licensed Compound and/or Licensed Product on a limited
                                         number of patients for the purposes of determining dose and evaluating safety and efficacy in
                                         the proposed therapeutic indication as more fully defined in 21 C.F.R. § 312.21(b),
                                         and such equivalent regulations or standards of countries outside the United States as
                                         may be applicable to activities conducted hereunder;

 

		(z)	“Phase III”
                                         shall mean that portion of the FDA submission and approval process which provides for
                                         continued trials of a Licensed Compound and/or Licensed Product on sufficient numbers
                                         of patients to establish the safety and efficacy of a Licensed Compound and/or Licensed
                                         Product and generate, if required, pharmacoeconomics data to support regulatory approval
                                         in the proposed therapeutic indication as more fully defined in 21 C.F.R. § 312.21(c),
                                         and such equivalent regulations or standards of countries outside the United States as
                                         may be applicable to activities conducted hereunder;

 

		(aa)	“Prime
                                         Rate” shall mean the rate of interest that the Royal Bank of Canada has announced
                                         as the prime rate as the reference rate to determine interest payable on commercial loans
                                         to its most creditworthy customers on the last Business Day of the calendar quarter immediately
                                         preceding the date of the amount due under the Agreement;

 

		(bb)	“Recall”
                                         shall mean:

 

    	 	- 4 -	 

     

    

 

		(i)	any action to recover possession of any Licensed Product
shipped to Third Parties (for this purpose, the definition of Third Parties shall not include any Affiliate, where “control”
in the definition of Affiliate shall mean direct or indirect beneficial ownership of 35% or greater interest in the income of
a Person or such other relationship as, in fact, constitutes actual control); or

 

		(ii)	any action by the FDA or any other applicable governmental
or regulatory agency in any jurisdiction, to detain or destroy quantities of any Licensed Product intended for commercial sale
or distribution of such Licensed Product or to prevent release of such Licensed Product for commercial sale or distribution.

 

“Recalled”
 and “Recalling”
shall have comparable meanings;

 

		(cc)	“Regulatory
                                         Approval” shall mean any and all approvals (including pricing and reimbursement
                                         approvals), licenses, registrations or authorizations of any federal, state, provincial
                                         or local regulatory agency, department, bureau or other governmental entity, necessary
                                         for the commercial manufacture, use, storage, import, transport, marketing, and sale
                                         or distribution of a Licensed Product in a country or regulatory jurisdiction in the
                                         Territory in the Field;

 

		(dd)	“Sublicensing
                                         Milestone Revenue” shall mean all revenues (including profits on the commercial
                                         manufacture by NeoRx or its Affiliates of Licensed Compounds and Licensed Products),
                                         receipts, monies, milestone payments and research fees (in respect of research fees,
                                         only to the extent that same are in excess of reimbursement for the direct costs and
                                         indirect costs of research and development or pursuit of Regulatory Approval undertaken
                                         by NeoRx or its Affiliates pursuant to a written research or development plan), payments
                                         (including amounts received from the sale of shares in the capital stock of NeoRx in
                                         excess of the Current Market Value for such shares), license fees and the fair market
                                         value of all other consideration collected or received by NeoRx or its Affiliates whether
                                         by way of cash, or credit or any barter, benefit, advantage, or concession relating to
                                         any sublicense agreements relating to any Valid Claims which form a part of the AnorMED
                                         Patents licensed to NeoRx under Section 3.1, the AnorMED Know-how licensed to NeoRx
                                         under Section 3.1, or otherwise to any Licensed Products. For the purposes of the definition
                                         of “Sublicensing Milestone Revenue”, the term “indirect costs”
                                         shall mean costs incurred for the benefit of the Development Program or the commercialization
                                         of a Licensed Product, excluding directly identified costs (direct costs), and including
                                         facility rental costs; utilities costs; laboratory and manufacturing equipment depreciation;
                                         and salaries, vacation pay, sick leave pay, health insurance premiums, FICA taxes (or
                                         their equivalent) and pension costs for employees, but only to the extent that such employees’
                                         work benefits the Development Program or the commercialization of a Licensed Product.
                                         For the avoidance of doubt:

 

		(i)	milestone payments collected or received by NeoRx or its
Affiliates for reaching an annual, cumulative or otherwise measured sales-related milestone criteria shall be included in the
calculation of Sublicensing Milestones Revenue and not Sublicensing Sales Revenue, and

 

		(ii)	Sublicensing
Milestone Revenue shall exclude all Sublicensing Sales Revenue.

 

For the purposes of the
                                         definition of “Sublicensing Milestone Revenue”, “control”
                                         in the definition of Affiliate shall mean direct or indirect beneficial ownership of
                                         35% or greater interest in the income of a Person or such other relationship as, in fact,
                                         constitutes actual control. In the event of any dispute regarding whether any cash, or
                                         credit or any barter, benefit, advantage, or concession should be included in Sublicensing
                                         Milestone Revenue, or the fair market value of any consideration collected or received
                                         by NeoRx or its Affiliates by way of credit or any barter, benefit, advantage, or concession,
                                         such dispute shall be resolved pursuant to Section 19.2;

 

		(ee)	“Sublicensing
                                         Sales Revenue” shall mean all revenues, receipts, monies, payments and royalties
                                         collected or received by NeoRx or its Affiliates whether by way of cash, or credit or
                                         any barter, benefit, advantage, or concession calculated as a percentage of Net Sales
                                         of Licensed Products by sublicensees of NeoRx or NeoRx’ Affiliates. For the purposes
                                         of the definition of “Sublicensing Sales Revenue”, “control”
                                         in the definition of Affiliate shall mean direct or indirect beneficial ownership of
                                         35% or greater interest in the income of a Person or such other relationship as, in fact,
                                         constitutes actual control. In the event of any dispute regarding whether any cash, or
                                         credit or any barter, benefit, advantage, or concession should be included in Sublicensing
                                         Sales Revenue, or the fair market value of any consideration collected or received by
                                         NeoRx or its Affiliates by way of credit or any barter, benefit, advantage, or concession,
                                         such dispute shall be resolved pursuant to Section 19.2;

 

    	 	- 5 -	 

     

    

 

		(ff)	“Terra” shall have the meaning set forth
in Section 14.1;

 

		(gg)	“Territory” shall mean world-wide, except
Japan;

 

		(hh)	“Third Party” shall mean any Person
other than NeoRx, AnorMED or their respective Affiliates; and

 

		(ii)	“Valid Claim” shall mean, with respect
to each country in the Territory:

 

		(i)	a claim of a pending patent application, provided that
the patent application has not been pending for longer than 7 years after the date from which such application claims priority,
and

 

		(ii)	a claim of an issued, unexpired patent or a claim of an
issued, unexpired patent term extended by the European Supplementary Protection Certificate(s) or its equivalent,

 

that has not
been:

 

		(iii)	permanently revoked, held invalid, unpatentable or unenforceable
by a final decision of a court or governmental agency of competent jurisdiction, which decision is unappealable or was not appealed
within the time allowed therefor, or

 

		(iv)	admitted in writing to be invalid or unenforceable by the
holder(s) by reissue, disclaimer or otherwise.

 

		1.2	Other Definitions.

 

Any words defined elsewhere in
this Agreement shall have the particular meaning assigned to the words thereto.

 

Article 2 DEVELOPMENT PROGRAM.

 

		2.1	Development Program.

 

NeoRx, at its cost and expense,
in its commercially reasonable discretion, shall conduct research and development to evaluate the use of the Licensed Compound
and/or the Licensed Product (the “Development Program”), including but not limited to human clinical studies
through to NDA approval for the Licensed Compound and/or the Licensed Product, including the clinical studies set out in Exhibit
B.

 

		2.2	AnorMED Assistance.

 

		(a)	AnorMED, at NeoRx’ written request, shall provide
to NeoRx, for a period of six (6) months commencing on the Effective Date, reasonable technical assistance of up to one half of
one full time equivalent (FTE) located at AnorMED’s Langley facilities to assist NeoRx in the transfer to NeoRx of technical
information relating to the AnorMED Patents and AnorMED Know-How licensed to NeoRx under this Agreement.

 

		(b)	Following the expiration of six (6) months after the Effective
Date or if NeoRx’ requirements for additional reasonable technical assistance during the first six (6) months exceed one
half of one FTE, AnorMED will provide, upon written request from NeoRx, additional reasonable technical assistance of up to 2
FTEs located at AnorMED’s Langley facilities, which AnorMED will charge to NeoRx at the rate of US$250,000 per FTE, to:

 

		(i)	participate with and, at NeoRx’ written request,
advise NeoRx in carrying out the Development Program; and

 

		(ii)	assist NeoRx, at NeoRx’ written request, in determining
its requirements of Licensed Compound and other materials for the Development Program.

 

    	 	- 6 -	 

     

    

 

		2.3	Progress Reports.

 

		(a)	NeoRx shall keep AnorMED informed of the progress of the
development and commercialization of the Licensed Compounds and/or the Licensed Products, and NeoRx shall provide to AnorMED,
on a calendar quarterly basis, a written report updating AnorMED on NeoRx’ progress thereon during the past calendar quarter.

 

		(b)	In the event that AnorMED grants licenses to Third Parties
under the AnorMED Patents outside the Territory, AnorMED shall provide to NeoRx, on a calendar quarterly basis or as soon as practicable
after receipt from such Third Parties, written reports setting out the information provided by such Third Party licensees on their
progress in the development and commercialization of the Licensed Compounds and/or the Licensed Products during the past calendar
quarter.

 

		(c)	The written reports provided under this section shall include
the then current technical status of the development of the Licensed Compounds and the Licensed Products, including results achieved,
the major activities the party providing the report (or its licensees and sublicensees, as the case may be) has undertaken to
promote, market, sell or otherwise commercialize the Licensed Products, and any other pertinent information relating to the development,
manufacturing and commercialization of the Licensed Compounds and the Licensed Products, including, but not limited to, a summary
of clinical data, preclinical data, clinical protocols, the status of regulatory filings in the Territory and discussions with
potential sublicensees or marketing partners.

 

		(d)	Notwithstanding the reporting requirements set out herein,
each party agrees to use reasonable efforts to provide to the other party during the Term prompt written notice of material events
in the development and commercialization of the Licensed Compounds and Licensed Products.

 

		2.4	Committee; Committee Meetings

 

The parties shall establish a committee
composed of an equal number of representatives, but not to exceed three (3) representatives from each party, which representatives
may be replaced by the appointing party at any time for the purpose of communication between the parties regarding the progress
of development and commercialization activities with respect to Licensed Products. Such committee shall meet at least two (2) times
per calendar year, either in person or by teleconference, at such time and location as may be mutually agreed by the parties and
provide the parties with a forum to update each other regarding:

 

		(a)	the global clinical plans and the results of preclinical
studies and clinical trials of NeoRx and of AnorMED’s Japanese licensee, if any;

 

		(b)	NeoRx’ strategic marketing plans and the relative
merits of NeoRx’ potential sublicensees and marketing partners to the extent AnorMED is not developing or commercializing
a competing product or technology; and

 

		(c)	the progress of the development and commercialization of
the Licensed Compounds and/or Licensed Products by NeoRx and by AnorMED’s Japanese licensee, if any.

 

Neither party will be obligated
under this Section 2.4 to disclose its Confidential Information if such Confidential Information is not directly relevant to the
license granted to NeoRx under Article 3 of this Agreement. In no event are the communications between the parties intended to
abrogate the parties' discretion and independence in conducting their business activities.

 

Article 3 GRANT OF LICENSE.

 

		3.1	Grant of License.

 

Subject to the terms and
conditions in this Agreement, AnorMED hereby grants to NeoRx an exclusive, royalty-bearing license, with the right to grant sublicenses,
under the AnorMED Patents and the AnorMED Know-How to research, develop, make, have made, use, have used, sell, have sold, offer
for sale, import and export the Licensed Compound and/or the Licensed Product in the Field in the Territory for the Term.

 

    	 	- 7 -	 

     

    

 

		3.2	Right to Grant Sublicenses.

 

		(a)	NeoRx shall have the right to grantsublicenses of the
licenseunder Section 3.1 to any Person, without the consent of AnorMED, provided that where NeoRx grants a sublicense to its
Affiliates, the obligations and liabilities of such Affiliates and NeoRx under this Agreement shall be joint and several and AnorMED
shall not be obliged to seek recourse against an Affiliate before enforcing its rights against NeoRx. For greater certainty it
is hereby confirmed that any default or breach by an Affiliate of NeoRx of any term of this Agreement will also constitute a default
by NeoRx under this Agreement.

 

		(b)	NeoRx shall furnish to AnorMED a copy of each sublicense
agreement entered into hereunder within 30 days after execution thereof, provided that such copy may be redacted to exclude provisions
relating to any drugs or products that are not Licensed Compounds or Licensed Products, but which shall include all provisions
required to confirm compliance with this Agreement, including the calculation of royalties and the conduct of audits hereunder.
All sublicense agreements furnished to AnorMED hereunder shall be deemed to be the Confidential Information of NeoRx and shall
be subject to AnorMED’s obligation of confidentiality under Article 11, and for the purpose of such obligation, NeoRx hereby
agrees that AnorMED may provide to ICR, pursuant to the ICR Agreement, a copy of each such sublicense agreement.

 

		(c)	NeoRx shall include in each sublicense agreement (including
                                                                             any sublicense granted to an Affiliate) covenants by the sublicensee that are consistent with the terms and
                                                                             conditions set out in this Agreement and that upon termination of this Agreement, such sublicense agreement shall be
                                                                             automatically converted to a direct license from AnorMED.

 

		3.3	Reservation of Rights.

 

AnorMED hereby reserves the right to use
and license the AnorMED Patents and AnorMED Know-How:

 

		(a)	for non-commercial research and testing in the Territory;

 

		(b)	to make or have made Licensed Compound or Licensed
                                                                             Product in the Territory for use outside of the Territory; and

 

		(c)	for any and all uses outside of the Territory.

 

In connection with Subsection 3.3(b) above,
where AnorMED or any of its Affiliates desire to contract with a Third Party (other than AnorMED’s licensees outside the
Territory) for the manufacture of Licensed Compound and/or Licensed Product for use outside the Territory, NeoRx shall have a right
of first negotiation to manufacture Licensed Compound and/or Licensed Product for AnorMED for use outside the Territory in which
case the transfer price to be charged by NeoRx for the supply of Licensed Compound and/or Licensed Product will be NeoRx’
manufacturing costs plus ten percent (10%), provided such price is competitive.

 

		3.4	Transfer of Information.

 

After the Effective Date, AnorMED shall
promptly deliver to NeoRx copies of the AnorMED Know-How, in written or other tangible form, together with assistance in connection
therewith in accordance with Section 2.2.

 

Article 4 COMMERCIALIZATION

 

		4.1	Diligence in Commercialization.

 

		(a)	In the event that the clinical studies conducted by NeoRx under this Agreement
                                                                             demonstrate the requisite safety and efficacy reasonably required for commercialization of a Licensed Product, NeoRx
                                                                             shall, at its sole cost and expense, utilize commercially reasonable efforts and sound and reasonable business practice and
                                                                             judgment in developing and promoting, marketing, selling and otherwise commercializing the Licensed Product in the Field in
                                                                             the Territory, including obtaining the appropriate Regulatory Approvals therefor, to meet or cause to be met the
                                                                             market demand for the Licensed Products.

 

		(b)	NeoRx agrees that it will utilize sound and reasonable business practice and
                                                                             judgment in determining the countries in the Territory in which it desires to sell the Licensed Product and it will
                                                                             use commercially reasonable efforts to achieve the First Commercial Sale of the Licensed Product in such countries within
                                                                             nine (9) months after obtaining Regulatory Approval for the sale of the Licensed Product in such countries, in
                                                                             accordance with the normal practices and standards established by NeoRx or its marketing partner or sublicensee for such
                                                                             country, as the case may be.

 

    	 	- 8 -	 

     

    

 

		(c)	For the purposes of Subsection 4.1(b), NeoRx or its marketing
partner or sublicensee, as the case may be, shall not be in breach of its obligations under Subsection 4.1(b) during any particular
period during the Term where it determines utilizing sound and reasonable business practice and judgment that a decision of a
relevant governmental authority in a country relating to the price or reimbursement for a Licensed Product renders the commercial
sale of the Licensed Product commercially unviable in the country during such period.

 

		4.2	Decision Not to Commercialize.

 

		(a)	If NeoRx, in its sole discretion, at any time during the
Term determines for any reason not to proceed with the commercialization of a Licensed Product in a particular country in the
Territory, NeoRx agrees to promptly disclose any such determination to AnorMED.

 

		(b)	In the event that NeoRx determines that it will not commercialize
a Licensed Product in one or more of the following major countries or jurisdictions in the Territory:

 

		(i)	the United States;

 

		(ii)	Canada;

 

		(iii)	France.

 

		(iv)	Germany;

 

		(v)	Italy;

 

		(vi)	Spain; and

 

		(vii)	United Kingdom.

 

NeoRx shall provide written
notice of the determination to AnorMED, and such notice shall be deemed to be notice under Section 14.3 that NeoRx desires to
terminate the license granted to NeoRx under Section 3.1 in
respect of the Licensed Compound and the Licensed Product in those countries or jurisdictions. In such event, the Territory
shall be deemed to be reduced in scope to exclude from the Territory the country specified in the notice. Upon the expiration
of the notice period set out in Section 14.3, the specified country or jurisdiction shall be excluded from the Territory and
NeoRx’ rights and obligations in respect of the excluded country or jurisdiction shall be governed by Subsection
14.3(d).

 

Article 5 SUPPLY OF LICENSED
COMPOUNDS AND LICENSED PRODUCTS.

 

		5.1	Supply of AMD473.

 

In consideration of the initial
license fees paid by NeoRx to AnorMED under Section 6.2 prior to commercialization of a Licensed Product, AnorMED agrees to supply
to NeoRx, free of charge, on an “AS IS” basis, such quantities of AMD473 as AnorMED has on hand in its inventories
as of the Effective Date. NeoRx shall be responsible for paying all shipping costs, insurance premiums, customs charges, taxes,
duties or other charges that may apply to the supply of AMD473 hereunder, and if any such amounts are paid by AnorMED, NeoRx shall
promptly reimburse AnorMED for any such amounts upon request. The foregoing shall be AnorMED’s sole obligation to NeoRx with
respect to the supply of any quantity of AMD473 or any other Licensed Compound.

 

		5.2	Supply of Licensed Product.

 

Except for the manufacture of one
batch of AMD473 formulated as an intravenous (iv) drug product in accordance with the Letter Agreement between the parties having
an effective date of February 2, 2004 and under which NeoRx will pay for all out-of-pocket expenses incurred by AnorMED associated
with the manufacture, labeling, packaging, testing shipping and stability study for such batch of AMD473, NeoRx shall be responsible
for the manufacture and processing of all developmental and commercial supplies of all Licensed Products in the Field in the Territory,
at its cost and expense.

 

    	 	- 9 -	 

     

    

 

		5.3	Delivery.

 

		(a)	AnorMED shall deliver any AMD473 to be supplied hereunder
to NeoRx-designated facilities, at NeoRx’ sole cost and expense, F.C.A. in accordance with the shipping specifications therefor.
In the absence of written and timely transport carrier and/or delivery instructions from NeoRx, AnorMED shall have the right to
make commercially reasonable arrangements therefor.

 

		(b)	Title to and risk of loss for all AMD473 delivered hereunder
shall pass to NeoRx upon transfer to a common carrier under Subsection 5.3(a).

 

		5.4	Permits and Licenses.

 

		(a)	AnorMED shall be responsiblefor obtaining all necessary
import and/or export licenses or permits (if applicable) for the supply of AMD473 under Section 5.1. NeoRx shall
be responsible for the payment of all import and/or export fees, taxes or duties, etc., in connection with such supply and delivery
to NeoRx of AMD473.

 

		(b)	Except as otherwise provided in Subsection 5.4(a), NeoRx shall be responsible for obtaining
                                                                             all necessary import and/or export licenses or permits (if applicable) and for the payment of all import and/or export fees,
                                                                             taxes or duties in connection with the supply and delivery to NeoRx of all developmental and commercial supplies of all
                                                                             Licensed Compounds and/or Licensed Products.

 

Article 6 LICENSE FEES.

 

		6.1	Additional Definitions.

 

For the purposes
of this Agreement:

 

		(a)	“Common Shares” means common shares
in the capital stock of NeoRx;

 

		(b)	“Current Market Price” of the Common
Shares on any date means the volume-weighted average of the Daily Closing Prices for the 10 consecutive Trading Days immediately
preceding such date, provided that if the Common Shares are not listed on any stock exchange, the “Current Market Price”
shall be determined by agreement between the board of directors of AnorMED and the board of directors of NeoRx, acting in good
faith;

 

		(c)	“Daily Closing Price” for each Trading
Day shall mean the last reported sales price for sales of Common Shares on NASDAQ on which such shares are listed and posted for
trading; and

 

		(d)	“Trading Day” shall mean any day on
which NASDAQ is open for business and on which Common Shares have been traded.

 

		6.2	Initial License Fee.

 

NeoRx shall
pay to AnorMED, an initial license fee of US$2,000,000, payable as follows:

 

		(a)	upon execution of this Agreement, US$1,000,000 in cash
by bank transfer to the co-ordinates given by AnorMED to NeoRx; and

 

		(b)	within five (5) Business Days after execution of this Agreement,
US$1,000,000 in unregistered Common Shares, where the number of Common Shares payable is determined by dividing US$1,000,000 by
the Current Market Price of a Common Share as of the Effective Date and disregarding any remaining fractional Common Share.

 

		6.3	Milestone Payments.

 

In consideration
of the license granted under Article 3, NeoRx shall pay to AnorMED the following milestone payments upon the first occurrence of
each of the development and commercialization milestones set forth below:

 

		(a)	US$1,000,000 upon successful completion of a Phase II study
or initiation of a Phase III study by NeoRx or any of its Affiliates for a Licensed Compound or a Licensed Product;

 

		(b)	US$2,000,000 upon submission to the FDA of a NDA for a
Licensed Product by NeoRx or any of its Affiliates;

 

		(c)	US$5,000,000 upon receipt of Regulatory Approval from the
FDA for a Licensed Product in respect of a filing made by NeoRx or any of its Affiliates seeking approval to market a Licensed
Product;

 

    	 	- 10 -	 

     

    

 

		(d)	US$2,000,000 upon achieving annual Net Sales by NeoRx and
its Affiliates of US$50,000,000 in the United States for any or all Licensed Products; and

 

		(e)	US$3,000,000 upon achieving annual Net Sales by NeoRx and
its Affiliates of US$100,000,000 in the United States for any or all Licensed Products.

 

For the purposes of this Section
6.3, “control” in the definition of Affiliate shall mean direct or indirect beneficial ownership of 35% or greater
interest in the income of a Person or such other relationship as, in fact, constitutes actual control.

 

		6.4	Form of Milestone Payments.

 

		(a)	Each milestone payment to be made by NeoRx under Subsections
6.3(a) and 6.3(b) shall be made, in NeoRx' sole discretion, either:

 

		(i)	in cash, by bank transfer to the co-ordinates given by
AnorMED to NeoRx; or

 

		(ii)	in a combination of:

 

		(A)	cash, payable as set out above, and

 

		(B)	the issuance of the number of Common Shares having a value
equivalent to the amount to be paid in Common Shares determined by dividing such amount by the Current Market Price of a Common
Share as of the date of achievement of the applicable milestone and disregarding any remaining fractional Common Share,

 

provided that a minimum of 15%
of the amounts set out in Subsections 6.3(a) and 6.3(b), as applicable, shall be paid in cash.

 

		(b)	Each milestone payment to be made by NeoRx under Subsections
6.3(c), 6.3(d) and 6.3(e) shall be made in cash, by certified cheque payable to the order of AnorMED or by bank transfer to the
co-ordinates given by AnorMED to NeoRx.

 

		6.5	Notice of Milestone and Payment.

 

For each milestone payment to be
made by NeoRx under Section 6.3:

 

		(a)	NeoRx shall provide prompt written notice to AnorMED of
the achievement of the milestone setting out the milestone achieved and whether the milestone payment will be made in cash or
in Common Shares;

 

		(b)	if required by the parties, AnorMED will provide a written
invoice to NeoRx for the applicable milestone payment; and

 

		(c)	notwithstanding the terms of any invoice provided under
Subsection 6.5(b), NeoRx shall provide to AnorMED the full amount of the milestone payment, whether in cash and/or Common Shares,
within 60 days after the achievement of the milestone.

 

		6.6	Nature of Payments.

 

The payments set forth in Sections
6.2 and 6.3 shall be non-refundable and shall not be creditable against royalties payable by NeoRx to AnorMED pursuant to Article
7.

 

Article 7 ROYALTY PAYMENTS.

 

		7.1	ICR Agreement.

 

AnorMED agrees that it shall pay
all royalties arising from NeoRx’ activities under this Agreement that are or will be due and payable to Third Parties
arising from any and all agreements entered into by AnorMED prior to the Effective Date, including, without limitation, the ICR
Agreement.

 

    	 	- 11 -	 

     

    

 

		7.2	Basic Royalty.

 

In consideration of the license
granted under Article 3, NeoRx shall pay to AnorMED, without duplication, in respect of each Licensed Product:

 

		(a)	in each country in the Territory where the Licensed Product sold is covered by one or more
                                                                             Valid Claims within the AnorMED Patents described in Paragraph 1.1 (ii)(ii) of the definition of Valid Claim, either in the
                                                                             country of manufacture or of in the country of sale, a royalty of 15.0% of Net Sales of such Licensed Product by NeoRx and
                                                                             its Affiliates; and

 

		(b)	in each country in the Territory where the Licensed Product
sold is covered by one or more Valid Claims within the AnorMED Patents described in Paragraph 1.1 (ii)(i) of the definition of
Valid Claim, but not a Valid Claim within the AnorMED Patents described in Paragraph 1.1 (ii)(ii) of the definition of Valid Claim,
either in the country of manufacture or of in the country of sale, and no Competition exists in the country of sale, a royalty
of 15.0% of Net Sales of such Licensed Product by NeoRx and its Affiliates; and

 

		(c)	in each country in the Territory where the Licensed Product
sold is covered by one or more Valid Claims within the AnorMED Patents described in Paragraph 1.1 (ii)(i) of the definition of
Valid Claim, but not a Valid Claim within the AnorMED Patents described in Paragraph 1.1 (ii)(ii) of the definition of Valid Claim,
either in the country of manufacture or of in the country of sale, and Competition exists in the country of sale, a royalty of
7.0% of Net Sales of such Licensed Product by NeoRx and its Affiliates; and

 

		(d)	in each country in the Territory where there is no Valid
Claim either in the country of manufacture or in the country of sale, but AnorMED Know-How is necessary to make, have made, use,
sell, offer for sale or import the Licensed Product, either in the country of manufacture or of in the country of sale, a royalty
of 7.0% of Net Sales of such Licensed Product by NeoRx and its Affiliates;

 

in each of Subsections 7.2(a),
7.2(b), 7.2(c) and 7.2(d), until the later of either:

 

		(e)	the date of expiration of the last Valid Claim within the
AnorMED Patents covering the Licensed Product in the country of manufacture or sale, as applicable; or

 

		(f)	the expiration of 15 years after First Commercial Sale
of such Licensed Product in the country of sale. 

 

For the purposes of this Section
7.2, “control” in the definition of Affiliate shall mean direct or indirect beneficial ownership of 35% or
greater interest in the income of a Person or such other relationship as, in fact, constitutes actual control. For purposes of
clarification, no multiple royalties shall be due or payable under this Section 7.2 because the sale or manufacture of any Licensed
Product is or shall be covered by more than one Valid Claim within the AnorMED Patents in the country of manufacture and/or the
country of sale.

 

		7.3	Sublicensing Royalty.

 

In consideration of the license
granted under Article 3, NeoRx shall pay to AnorMED, without duplication, in respect of any Licensed Compound and/or Licensed Product:

 

		(a)	a royalty of 25.0% of Sublicensing Milestone Revenue collected
or received; and

 

		(b)	a royalty of 25.0% of Sublicensing Sales Revenue collected
or received, provided that the payment set out in this Subsection 7.3(b) shall be subject to an minimum calendar quarterly payment
equal to the cumulative sum of:

 

		(i)	in each country in the Territory where a Licensed Product
sold is covered by one or more Valid Claims within the AnorMED Patents described in Paragraph 1.1(ii)(ii) of the definition
of Valid Claim, either in the country of manufacture or of in the country of sale, an amount equal to 8.0% of Net Sales of such
Licensed Product by any sublicensee of NeoRx and its Affiliates; and

 

		(ii)	in each country in the Territory where the Licensed Product
sold is covered by one or more Valid Claims within the AnorMED Patents described in Paragraph 1.1(ii)(i) of the definition of
Valid Claim, but not a Valid Claim within the AnorMED Patents described in Paragraph 1.1 (ii)(ii) of the definition of Valid Claim,
either in the country of manufacture or of in the country of sale, and no Competition exists in the country of sale, an amount
equal to 8.0% of Net Sales of such Licensed Product by any sublicensee of NeoRx and its Affiliates; and

 

    	 	- 12 -	 

     

    

 

		(iii)	in each country in the Territory where the Licensed Product
sold is covered by one or more Valid Claims within the AnorMED Patents described in Paragraph 1.1(ii)(i) of the definition of
Valid Claim, but not a Valid Claim within the AnorMED Patents described in Paragraph 1.1(ii)(ii) of the definition of Valid Claim,
either in the country of manufacture or of in the country of sale, and Competition exists in the country of sale, an amount equal
to 4.0% of Net Sales of such Licensed Product by any sublicensee of NeoRx and its Affiliates; and

 

		(iv)	in each country in the Territory where there is no
Valid Claim either in the country of manufacture or in the country of sale, but AnorMED Know-How is necessary to make, have made,
use, sell, offer for sale or import the Licensed Product, either in the country of manufacture or of in the country of sale, an
amount equal to 4.0% of Net Sales of such Licensed Product by any sublicensee of NeoRx and its Affiliates;

 

in each of Subsections 7.3(a) and
7.3(b), until the later of either:

 

		(c)	the date of expiration of the last Valid Claim within the
AnorMED Patents covering the Licensed Product in the country of manufacture or sale, as applicable; or

 

		(d)	the expiration of 15 years after First Commercial Sale
of such Licensed Product in the country of sale.

 

For the purposes
of this Section 7.3, “control” in the definition of Affiliate shall mean direct or indirect beneficial ownership
of 35% or greater interest in the income of a Person or such other relationship as, in fact, constitutes actual control. For purposes
of clarification, no multiple royalties shall be due or payable under this Section 7.3 because the sale or manufacture of any
Licensed Product is or shall be covered by more than one Valid Claim within the AnorMED Patents in the country of manufacture
and/or the country of sale.

 

		7.4	Third Party License Fees and Royalties.

 

AnorMED and NeoRx agree that where
Patent rights of a Third Party, excluding Patent rights of a Third Party under sublicenses held as of the Effective Date by NeoRx
or its Affiliates (for this purpose, “control” in the definition of Affiliate shall mean direct or indirect beneficial
ownership of 35% or greater interest in the income of a Person or such other relationship as, in fact, constitutes actual control),
covering either the composition of matter of a Licensed Compound or the use of the Licensed Compound should exist in any country
in the Territory, and if in NeoRx’ reasonable judgement it would be impractical or impossible for NeoRx to commercialize
a Licensed Product incorporating the Licensed Compound without obtaining a license under such Patent rights, then for each such
Licensed Product on a calendar quarterly basis, NeoRx shall be entitled to a credit against royalties payable to AnorMED under
either Sections 7.2 or 7.3 on account of such Licensed Product in such country, equal to fifty percent (50%) of the royalties paid
by NeoRx under such license in respect of such Licensed Product in such country in the calendar quarter for which such royalties
are paid, provided that, for any calendar quarter, the aggregate credit hereunder for a Licensed Product in any country shall not
exceed 50% of the royalty determined under Sections 7.2 and 7.3 for that country.

 

		7.5	Royalty Payments Upon Termination.

 

If this Agreement is terminated
in accordance with Article 14 with respect to all or some of the Licensed Products, NeoRx shall continue to pay AnorMED all amounts
earned pursuant to this Article 7 prior to the date of termination and any amounts earned thereafter as a result of sales of residual
inventory of such terminated Licensed Products. In addition, NeoRx shall continue to pay to AnorMED all amounts payable hereunder
with respect to Licensed Products, if any, with respect to which this Agreement is not terminated.

 

Article 8 PAYMENT TERMS.

 

		8.1	Invoices and Payments.

 

AnorMED shall provide to NeoRx
invoices setting out any amounts owed by NeoRx to AnorMED under this Agreement, including, without limitation, payments in respect
of assistance provided under Section 2.2 and patent prosecution and maintenance under Article 10. All such amounts shall be due
and payable 30 days after receipt of the date of the invoice. Invoices for FTE reimbursement and patent prosecution and maintenance
will be invoiced quarterly and be accompanied by a statement detailing the actual hours incurred during the quarter.

 

    	 	- 13 -	 

     

    

 

		8.2	Payment of Royalties.

 

All royalties payable under Sections
7.2 and 7.3 shall be payable within 60 days after the last day of the calendar quarter during the royalty periods set out therefor.
NeoRx will provide to AnorMED within 30 days after the last day of each calendar quarter, an estimate of the royalties payable
by NeoRx under this Agreement for such calendar quarter.

 

		8.3	Currency of Payment.

 

All amounts payable to AnorMED
under this Agreement shall be payable in United States Dollars, by bank transfer of immediately available funds to a bank account
designated by AnorMED, at AnorMED’s option. Calendar quarterly sales amounts shall be translated from other currencies to
U.S. Dollars by using an average rate of exchange computed using the rate of exchange quoted under Foreign Exchange in the Wall
Street Journal as of the end of the current quarter plus the rate of exchange as of the end of the immediately preceding quarter
and dividing by 2.

 

		8.4	Currency Transfer Restrictions.

 

If in any country payment or transfer
of funds out of such country is prohibited by law or regulation, the parties hereto shall confer regarding the terms and conditions
on which Licensed Products shall be sold in such countries, including the possibility of payment of royalties to AnorMED in local
currency to a bank account in such country or the renegotiation of royalties for such sales, and in the absence of any other agreement
by the parties, such funds payable to AnorMED shall be deposited by NeoRx in whatever currency is allowable in a bank designated
in that country as acceptable to AnorMED.

 

		8.5	Taxes.

 

		(a)	For the purposes
                                         of this Section 8.5, “Taxes” shall include costs, expenses, taxes,
                                         tariffs, customs duties, brokerage fees, insurance premiums and other charges, including,
                                         without limitation, social services taxes, goods and services tax, value added, excise
                                         and other sales taxes.

 

		(b)	AnorMED shall be responsible for and shall pay all Taxes
assessed or levied in connection with any activities performed by AnorMED or payments made to AnorMED under this Agreement.

 

		(c)	NeoRx shall be responsible for and shall pay all Taxes
assessed or levied in connection with any activities performed by NeoRx under this Agreement.

 

		(d)	If any law or regulation in any country requires the withholding
by NeoRx of any Taxes due on payments to be remitted to AnorMED under this Agreement, such Taxes shall be deducted from the amounts
paid to AnorMED, provided that NeoRx shall take all reasonable measures to reduce the amount of such Taxes. If the Taxes are deducted
from the amounts paid to AnorMED, NeoRx shall furnish AnorMED the originals of all official receipts for such Taxes and such other
evidence of such Taxes and payment thereof as may be reasonably requested by AnorMED and shall provide any reasonable assistance
or co-operation which may be requested by AnorMED in connection with any efforts by AnorMED to obtain a credit for such Taxes,
including the characterization of payments made hereunder so that it may take advantage of any and all benefits under any tax
treaty between Canada and any foreign countries.

 

		8.6	Net Sales Reports.

 

		(a)	NeoRx agrees to submit to AnorMED, concurrently with the
quarterly royalty payments made pursuant to Section 8.2, written reports (consistent with GAAP) setting out for the calendar quarter,
for each type of Licensed Product:

 

		(i)	all amounts received by NeoRx and/or its Affiliates from
the sale of the Licensed Product to end-users of the Licensed Product;

 

		(ii)	details of the quantities of the Licensed Product sold
in each country in the Territory, whether sold by NeoRx or its Affiliates or any sublicensees;

 

    	 	- 14 -	 

     

    

 

		(iii)	the amount of any deductions taken from the amounts received
by NeoRx and/or its Affiliates, as applicable, from the sale of the Licensed Product to end users of the Licensed Product in calculating
Net Sales of the Licensed Product;

 

		(iv)	the amount of any deductions taken from the amounts received
by any sublicensees from the sale of the Licensed Product to end users of the Licensed Product in calculating Net Sales of the
Licensed Product by such sublicensees;

 

		(v)	the amount of Net Sales for the Licensed Product by NeoRx
and its Affiliates;

 

		(vi)	the amount of Net Sales for the Licensed Product by any
sublicensees;

 

		(vii)	the amount of Sublicensing Milestone Revenue received;

 

		(viii)	the amount of Sublicensing Sales Revenue received;

 

		(ix)	the amount of any Third Party royalties payable for the
Licensed Product; and

 

		(x)	the royalties due and payable to AnorMED pursuant to Sections
7.2 and 7.3.

 

For the purposes of this Subsection
8.6(a), “control” in the definition of Affiliate shall mean direct or indirect beneficial ownership of 35%
or greater interest in the income of a Person or such other relationship as, in fact, constitutes actual control.

 

		(b)	AnorMED shall submit to NeoRx a detailed statement of account
within 60 days after the close of each calendar quarter during the Term for:

 

		(i)	any costs or expenses incurred related to the prosecution
and maintenance of the AnorMED Patents; and

 

		(ii)	any charges for AnorMED assistance under Section 2.2.

 

NeoRx’ obligation to reimburse AnorMED’s costs and expenses for the prosecution and maintenance of the AnorMED
Patents shall be as set forth in Article 10.

 

		8.7	Accounts and Audit.

 

		(a)	Each party shall maintain, during the Term and for a period
of at least three (3) years thereafter, accurate and complete records in accordance with GAAP of all transactions relating to
the subject matter of this Agreement, including:

 

		(i)	in the case of NeoRx, records of all sales of Licensed
Products in the Territory and the collection or receipt of Sublicensing Milestone Revenue and Sublicensing Sales Revenue, which
shall show the manufacturing, sales, use and other disposition of Licensed Products in sufficient detail to determine the royalties
payable to AnorMED pursuant to Sections 7.2 and 7.3, if any; and

 

		(ii)	in the case of AnorMED, records of all costs and expenses
relating to the prosecution and maintenance of the AnorMED Patents.

 

		(b)	During the Term of
                                         this Agreement and for a period of three (3) years thereafter, each party (in this section,
                                         the “Audited Party”) shall permit the other party (in this section,
                                         the “Requesting Party”), on reasonable advance written notice, but
                                         in no event less than ten (10) Business Days, and at the Requesting Party’s cost
                                         and expense, to arrange for the books and records maintained by the Audited Party pursuant
                                         to Subsection 8.7(a) relating to the subject matter of this Agreement to be examined
                                         from time to time during the Audited Party’s regular business hours, but not more
                                         than once a year, by an independent accounting firm selected by the Requesting Party
                                         and reasonably acceptable to the Audited Party, provided that such independent accounting
                                         firm and its accountants are bound by an obligation of confidentiality to disclose to
                                         the Requesting Party only whether the royalty statements and payments made by the Audited
                                         Party under this Agreement are accurate and, if not accurate, any evidence of non-compliance
                                         with the terms and conditions of this Agreement. Any such examination shall be restricted
                                         to records relating to the subject matter of this Agreement covering the preceding three
                                         (3) year period. The Requesting Party shall provide to the Audited Party a copy of any
                                         audit reports prepared under this subsection.

 

    	 	- 15 -	 

     

    

 

		(c)	In the event the report demonstrates that NeoRx has underpaid
AnorMED, NeoRx shall pay the amount of such underpayment immediately and where AnorMED is the Requesting Party, to the extent
such underpayment is more than 5% for the audited period, NeoRx shall reimburse AnorMED for the expense of the audit.

 

		(d)	In the event the report demonstrates that NeoRx has overpaid
AnorMED, NeoRx may deduct from future amounts owed to AnorMED such overpayments and where NeoRx is the Requesting Party, to the
extent such overpayment is more than 5% for the audited period, AnorMED shall reimburse NeoRx for the expense of the audit.

 

		8.8	Confidentiality of Reports.

 

Each party agrees that:

 

		(a)	the information set forth in the reports required by Sections
8.6 and 8.7; and

 

		(b)	the records subject to examination under Section 8.7; shall
be subject to the obligations of confidentiality set out in Article 11 and shall be maintained in confidence by the receiving
party and by any independent accounting firm selected by such party, shall not be used by such party or such accounting firm for
any purpose other than verification of the performance by the other party of its obligations hereunder, and shall not be disclosed
by the receiving party or such accounting firm to any other person except for purposes of enforcing this Agreement.

 

		8.9	Interest.

 

NeoRx shall pay interest at
a fixed rate per annum equal to two percentage points (2%) in excess of the Prime Rate in effect on the date such amounts not
paid were due under this Agreement, or the maximum permissible rate allowed by law (which under the state of Washington shall
be deemed to be the laws relating to the permissible rate of interest on commercial loans), whichever is less, computed on
the basis of the actual number of days elapsed and a year of 365 days and continuing until such amounts have been paid.

 

Article 9 INTELLECTUAL PROPERTY.

 

		9.1	Existing Intellectual Property.

 

As between NeoRx and AnorMED:

 

		(a)	title to, and ownership or control of all rights in and
to all Intellectual Property owned or licensed by NeoRx (other than rights licensed to NeoRx by AnorMED) shall at all times remain
with NeoRx and no rights in or to any such Intellectual Property shall vest in AnorMED; and

 

		(b)	title to and ownership or control of all rights in and
to all Intellectual Property owned or licensed by AnorMED (other than rights licensed to AnorMED by NeoRx) shall at all times
remain with AnorMED and, except as expressly granted under this Agreement, no rights in or to any such Intellectual Property shall
vest in NeoRx.

 

		9.2	Ownership of New Inventions.

 

		(a)	During the Term, each of the parties shall promptly disclose
to the other in a timely fashion all inventions and discoveries arising from the performance of the Development Program or other
development activities relating to Licensed Compounds and Licensed Products.

 

		(b)	The parties agree that, except as otherwise specifically
set out in this Agreement, as between NeoRx and AnorMED, all right, title and interest in and to all Know-How created or developed
by a party during the Term shall be owned by the creating or developing party and shall be treated as such party’s Confidential
Information under this Agreement. For greater certainty, without limiting the generality of the foregoing, all data, results,
regulatory submissions and reports arising from the performance of the Development Program and NeoRx’ other development
activities under this Agreement shall be the property of NeoRx.

 

		(c)	NeoRx and AnorMED acknowledge and agree that:

 

    	 	- 16 -	 

     

    

 

		(i)	AnorMED and its
licensees outside of the Territory will require access to NeoRx’ Know-How and Patents (including Patents for Improvements
under Section 9.3) arising from the performance of the Development Program and NeoRx’ other development activities under
this Agreement and NeoRx hereby grants to AnorMED a non-exclusive royalty-free license (with the right to sublicense) to use NeoRx’
Know-How and Patents arising from the performance of the Development Program and NeoRx’ other development activities under
this Agreement, including, without limitation, data, results, regulatory submissions and reports, for the development and commercialization
of the Licensed Compounds and/or Licensed Products (including the filing of regulatory submissions) outside of the Territory; and

 

		(ii)	NeoRx and its
sublicensees in the Territory desire access to any Know-How and Patents (including Patents for Improvements under Section 9.3)
created by AnorMED’s licensees outside the Territory in the development of the Licensed Compounds and Licensed Products and
AnorMED agrees to use commercially reasonable efforts to include in any license agreement with such licensees, a royalty-free non-exclusive
license to AnorMED (with the right to sublicense) to use the licensee’s Know-How and Patents created in the development of
the Licensed Compounds and Licensed Products, including, without limitation, data, results, regulatory submissions and reports,
for the development and commercialization of the Licensed Compounds and/or Licensed Products (including the filing of regulatory
submissions) in the Territory.

 

		9.3	Improvements

 

		(a)	For
                                         the purposes of this Section 9.3, “Improvements” means, in respect
                                         of any Patents, any and all patents and any and all patent applications that claim priority
                                         to such Patents (whether complete or incomplete or whether filed or unfiled) including,
                                         but not limited to, provisional, non-provisional, continuations and continuations-in-part
                                         applications, and divisional patent applications and registrations in any jurisdiction
                                         world-wide.

 

		(b)	To
                                         the extent possible andunless precluded by any present or future agreement of NeoRx
                                         or its sublicensees, any Improvements made by NeoRx to any United States Patent within
                                         the AnorMED Patents, whether solely or jointly with any Person shall be solely owned
                                         by AnorMED. NeoRx and/or its sublicensees shall assign or cause to be assigned to AnorMED
                                         all right, title and interest in and to such Improvements, which shall be added to Exhibit
                                         A and automatically included in the license granted by AnorMED to NeoRx under Section
                                         3,1. Each party shall co-operate with the other in seeking applicable Patent coverage
                                         for such Improvements.

 

		(c)	The parties acknowledge
and agree that the ownership of any Improvements made to any Patent within the AnorMED Patents, other than Improvements made to
any United States Patent within the AnorMED Patents, shall be governed by the laws of inventorship applicable to the country or
jurisdiction of the applicable Patent.

 

		9.4	Trademarks.

 

		(a)	NeoRx, as it
deems appropriate, may originate, select, apply to register and maintain one or more trademarks or tradenames under which the Licensed
Products will be marketed and sold or otherwise distributed in the Territory. NeoRx will own and/or control any such trademarks
and tradenames and will be solely responsible for all decisions relating to the prosecution, defense, maintenance and costs of
such trademarks and tradenames, at its cost and expense.

 

		(b)	Except
                                         in the event of termination as provided in Article 14, neither party shall have any right
                                         to use any trademark
                                         or tradename of the other party.

 

Article
10 PATENTS; PROSECUTION AND LITIGATION.

 

		10.1	Prosecution
of Patents.

 

		(a)	AnorMED shall
have the right to prosecute and maintain each Patent within the AnorMED Patents and except as otherwise provided in this Article
10 shall do so in a timely manner.

 

    	 	- 17 -	 

     

    

 

		(b)	At any time during the Term, NeoRx, in NeoRx’ sole discretion, may determine that any particular
Patent within the AnorMED Patents in any particular country in the Territory should not be prosecuted or maintained for legal or
commercial reasons and, in such event, shall so notify AnorMED. Upon receipt of such notice, any Patents identified in such notice
shall remain or be deemed to remain within the AnorMED Patents for the purposes of the grant of rights by AnorMED to NeoRx pursuant
to Article 3 of this Agreement and NeoRx’ obligations pursuant to Subsections 7.2(a), 7.2(b) and 7.2(c) for the payment of
royalties for any such Patents shall remain unchanged and continue at the royalty rate for such Patent as of the date of NeoRx’
notice to AnorMED, provided that where the discontinuance of the prosecution or maintenance of the Patent is due to reasons of
lack of patentability, invalidity or unenforceability of the Patent, NeoRx’ obligations pursuant to Subsection 7.2(d) for
the payment of royalties for AnorMED Know-How shall apply. AnorMED, at AnorMED’s cost and expense and in AnorMED’s
sole discretion, may continue prosecution and/or maintenance of any particular Patent identified in such notice

 

		(c)	At any time during the Term, NeoRx, in NeoRx’ sole discretion, may request, by written notice
delivered to AnorMED, that AnorMED seek patent protection in one or more countries in the Territory not then covered by the Patents
within the AnorMED Patents. Upon receipt of such notice, AnorMED shall take reasonable steps to apply for patent protection in
such countries.

 

		10.2	Patent Review and Recommendations.

 

		(a)	Except for AnorMED Patents for which NeoRx has discontinued prosecution or maintenance under Subsection
10.1(b), NeoRx shall have the right to review all Patents and other proceedings, communications, reports and observations relating
to the AnorMED Patents in the Territory and to provide comments and recommendations to AnorMED with respect thereto, which comments
and recommendations shall be adopted, incorporated and/or acted upon by AnorMED, provided that such comments and recommendations
are reasonable.

 

		(b)	Except for AnorMED Patents for which NeoRx has discontinued prosecution or maintenance under Subsection
10.1(b), AnorMED shall promptly disclose to NeoRx, keep NeoRx fully informed of, and supply to NeoRx in a timely fashion:

 

		(i)	the complete texts of each Patent within the AnorMED Patents;
and

 

		(ii)	all information received concerning:

 

		(A)	the institution or possible institution of any interference, opposition, re-examination, reissue,
revocation, nullification or any official proceeding involving any Patent within the AnorMED Patents, and

 

		(B)	the course of substantive patent prosecution or other substantive proceedings related to any Patent
within the AnorMED Patents,

 

including
by providing NeoRx with copies of substantive communications, search reports and Third-Party observations submitted to or received
from patent offices in the Territory, but excluding any such information that is subject to attorney-client privilege.

 

		(c)	Except for AnorMED Patents for which NeoRx has discontinued prosecution or maintenance under Subsection
10.1(b), AnorMED shall cooperate with NeoRx and use reasonable efforts to obtain any applicable term extension for any Patent within
the AnorMED Patents covering a Licensed Product in the Territory. In connection with such efforts, NeoRx, within one (1) calendar
month after obtaining Regulatory Approval for a Licensed Product any country in the Territory, shall provide to AnorMED information
reasonably required by AnorMED or otherwise requested by AnorMED to apply for the European Supplementary Protection Certificate
or its equivalent in respect of such Licensed Product marketed in such country in the Territory.

 

		(d)	Each party shall hold all information disclosed to it by the other party under this section as
Confidential Information
under Article 11.

 

    	 	- 18 -	 

     

    

 

		10.3	Patent Costs.

 

NeoRx
shall be responsible for all costs and expenses actually incurred by AnorMED after the Effective Date for all services provided
by outside legal counsel, consultants and patent agents in connection with the AnorMED Patents in the Territory, including, but
not limited to, the drafting, prosecution, obtaining patent term extensions and maintenance, and, to the extent that AnorMED actually
pays any such costs, NeoRx shall promptly reimburse AnorMED for such costs and expenses upon written request from AnorMED. Notwithstanding
the previous sentence, in the event that NeoRx provides written notice to AnorMED identifying any particular Patent in accordance
with Section 10.1(b), NeoRx shall have no such responsibility or obligation with respect to any particular Patent identified in
such notice after the date of receipt of such notice by AnorMED.

 

		10.4	Right to Assume Prosecution.

 

		(a)	The parties acknowledge and agree that AnorMED may, in the ordinary course of prosecuting AnorMED’s
patent portfolio and after the Effective Date of this Agreement and in the reasonable opinion of AnorMED’s patent counsel
or patent agent, take such actions in the ordinary course (including discontinuance of a Patent application) that do not materially
impair the scope of Patent coverage provided to NeoRx in the Field and the AnorMED Patents remain adequate for the uses of the
AnorMED Patents contemplated by NeoRx, pursuant to the license granted under Section 3.1.

 

		(b)	In the event that AnorMED intends to finally abandon any Patent within the AnorMED Patents in any
country in the Territory, AnorMED shall promptly notify NeoRx, and thereafter NeoRx shall have a right to assume any and all prosecution
and/or maintenance activities with respect to such Patents in such country. All rights granted to NeoRx with respect to such Patent
within the AnorMED Patents in such country shall continue in force provided that NeoRx assumes, at its own expense, responsibility
for the prosecution and maintenance of such Patents in such country, and provided that if there are Third Parties with legal interests
in any such Patents outside the Territory, the costs of the prosecution and maintenance of such Patents shall be shared by NeoRx
and AnorMED on a basis to be mutually agreed to by the parties taking into account the rights in such AnorMED Patent granted to
NeoRx and the Third Parties respectively. If the parties cannot agree on an allocation of the costs of the prosecution and maintenance
of such AnorMED Patent, the dispute shall be resolved in accordance with Section 19.2.

 

		10.5	Third Party Claims of Infringement

 

In
the event that any Third Party brings a claim against AnorMED or NeoRx or any of their respective Affiliates (for this purpose,
“control” in the definition of Affiliate shall mean direct or indirect beneficial ownership of 35% or greater interest
in the income of a Person or such other relationship as, in fact, constitutes actual control) that the manufacture, use, sale,
distribution, marketing or importation of a Licensed Compound or a Licensed Product infringes rights in Intellectual Property
owned or otherwise controlled by such Third Party (an “Infringement Suit”), the following shall apply:

 

		(a)	the party receiving a claim, or learns of the threat of such a claim, shall give the other party
prompt written notice detailing as many facts as possible concerning the claim;

 

		(b)	NeoRx, in its sole discretion, shall have the first right, but not an obligation, to defend against
the Infringement Suit;

 

		(c)	if NeoRx does not take steps to defend against the Infringement Suit within 90 days after the date
that notice thereof was received from or delivered to AnorMED, AnorMED may take such legally permissible action as it deems necessary
or appropriate to defend against the Infringement Suit, but shall not be obligated to do so;

 

		(d)	the party defending against the Infringement
                                         Suit (in this section, the “Litigating Party”) shall have the right
                                         to control such litigation and shall bear all legal expenses (including court costs and
                                         legal fees), but it shall have no right to settle any dispute in any manner which would
                                         abridge the rights of the other party under this Agreement. By way of example and not
                                         by way of limitation, neither party may stipulate or admit to the invalidity or unenforceability
                                         of any right in Intellectual Property. Before any action is taken by either party which
                                         could abridge the rights of the other party hereunder, the parties agree to, in good
                                         faith, consult with each other with a goal of adopting a mutually satisfactory position;

 

    	 	- 19 -	 

     

    

 

		(e)	the Litigating Party shall keep the other party fully informed of the actions and positions taken
or proposed to be taken by the Litigating Party and the actions and positions taken by all other parties to such litigation; and

 

		(f)	in the event that NeoRx defends against the Infringement Suit, AnorMED may elect to participate
formally in the Infringement Suit to the extent that the court may permit, provided that any additional expenses generated by AnorMED’s
formal participation shall be paid by AnorMED.

 

		10.6	Infringement by Third Parties.

 

In
the event that either party reasonably believes that a Third Party is or may be infringing, encroaching or violating any Patent
within the AnorMED Patents, then such party shall promptly notify the other party in writing of such infringement, encroachment
or violation, and the following shall apply:

 

		(a)	subject to Subsection 10.6(b), in the event of any infringement, encroachment or violation of any
Patent within the AnorMED Patents in the Territory:

 

		(i)	NeoRx, in its sole discretion, shall have the first right, but not an obligation, to take or not
take whatever action it believes appropriate, and

 

		(ii)	if NeoRx does not commence action directed toward restraining or enjoining such infringement within
90 days after the date that notice thereof was received from or delivered to AnorMED, AnorMED may take such legally permissible
action as it deems necessary or appropriate to enforce such Patent within the AnorMED Patents and restrain such infringement;

 

		(b)	in the event of any infringement, encroachment or violation of any Patent within the AnorMED Patents
in a country for which NeoRx has discontinued prosecution or maintenance of such Patent under Subsection 10.1(b):

 

		(i)	AnorMED, in its sole discretion, shall have the first right, but not an obligation, to take or
not take whatever action it believes appropriate, and

 

		(ii)	if AnorMED does not commence action directed toward restraining or enjoining such infringement
within 90 days after the date that notice thereof was received from or delivered to NeoRx, NeoRx may take such legally permissible
action as it deems necessary or appropriate to enforce such Patent within the AnorMED Patents and restrain such infringement;

 

		(c)	the party taking action against an alleged infringer shall have the right to control such action
and shall bear all legal expenses (including court costs and legal fees), but it shall have no right to settle any dispute in any
manner which would abridge the reserved rights of the other party under this Agreement. By way of example and not by way of limitation,
neither party may stipulate or admit to the invalidity or unenforceability of any patent. Before any action is taken by either
party which could abridge the rights of the other party hereunder, the parties agree to consult, in good faith, with a goal of
adopting a mutually satisfactory position; and

 

		(d)	the party taking action shall keep the other party fully informed of the actions and positions
taken or proposed to be taken by it and the actions and positions taken by all other parties to such litigation.

 

		10.7	Cooperation;
Costs and Awards.

 

		(a)	Each party agrees to co-operate reasonably with the other party in any action the other party defends
or prosecutes pursuant to Sections 10.5 and 10.6, including, without limitation, supplying essential documentary evidence and making
essential witnesses then in its employment available.

 

		(b)	The Parties agree that all amounts awarded by way of judgement, settlement or compromise in respect
of any action conducted hereunder, after payment or reimbursement of the parties’ respective costs and expenses arising from
such action, shall be allocated 70% to the party controlling the action and 30% to the other party.

 

    	 	- 20 -	 

     

    

 

		10.8	Cooperation with Other Licensees

 

NeoRx
acknowledges that AnorMED may grant licenses to Third Parties under the AnorMED Patents outside the Territory, and that such licenses
may include rights to permit such Third Parties to defend or enforce Patents within the AnorMED Patents. To the extend that AnorMED
grants to a Third Party any license including rights to defend or enforce Patents within AnorMED Patents, NeoRx will use commercially
reasonable efforts to cooperate with AnorMED and such Third Party in the defense or enforcement of such Patents and, in connection
with such efforts, will use good faith efforts to determine, jointly with AnorMED and such Third Party, the course of action, if
any, necessary or appropriate to defend or enforce such Patents, as applicable; provided that AnorMED includes provisions in its
license with such Third Party no less restrictive and comparable to this Section 10.8.

 

		10.9	Interference Proceedings.

 

In
the event that a party becomes aware of the declaration of any interference proceeding by any patent authority in the Territory
with respect to any Patent within the AnorMED Patents, such party shall promptly notify the other party in writing. AnorMED shall
have the right to represent and manage AnorMED’s and NeoRx’ interests in such proceeding. AnorMED and NeoRx shall assist
one another and co-operate in any such proceeding.

 

		10.10	Status of Proceedings.

 

The
parties shall keep one another informed of the status of all of their respective activities regarding any litigation or settlement
thereof concerning any Licensed Compound and/or Licensed Product.

 

Article
11 CONFIDENTIALITY; PUBLICITY; PUBLICATIONS.

 

		11.1	Obligation of Confidentiality.

 

It
is contemplated that in the course of the performance of this Agreement each party may, from time to time, disclose Confidential
Information to the other. Each party agrees:

 

		(a)	to keep and use in strict confidence all Confidential Information of the other party and to not,
without the prior written consent of the other party, disclose any such Confidential Information to any person or entity other
than its Affiliates (for this purpose, “control” in the definition of Affiliate shall mean direct or indirect beneficial
ownership of 35% or greater interest in the income of a Person or such other relationship as, in fact, constitutes actual control),
corporate counsel, employees and contractors who are under an obligation of confidentiality on terms substantially similar to those
set out in this Agreement, who have been informed of the confidential nature of the Confidential Information and who require such
information in the performance of their duties;

 

		(b)	not to use, copy, duplicate, reproduce, translate or adapt, either directly or indirectly, any
of the Confidential Information of the other party for any purpose other than the development and commercialization of the Licensed
Compounds and the Licensed Products under this Agreement, without the other party’s prior written approval;

 

		(c)	that all copies, duplicates, reproductions, translations or adaptations of any Confidential Information
of the other party permitted to be made hereunder shall be clearly labelled as confidential; and

 

		(d)	to use commercially reasonable efforts consistent with such party’s ordinary business practices
to prevent material in its possession that contains or refers to Confidential Information of the other party from being discovered,
used or copied by Third Parties and that it shall use reasonable steps to protect and safeguard all Confidential Information of
the other party in its possession from all loss, theft or destruction.

 

Upon
the termination of this Agreement, each party shall promptly return all Confidential Information to the disclosing party; provided
that each party may retain one (1) archival copy thereof to permit such party to monitor compliance with its obligations under
this Article 11, or as may be required by applicable law.

 

    	 	- 21 -	 

     

    

 

		11.2	Permitted Disclosures.

 

Nothing
herein shall be construed as preventing NeoRx from disclosing any Confidential Information received from AnorMED to any of its
Affiliates, sub-licensees or distributors, provided each Affiliate, sub-licensee and distributor has undertaken in writing a similar
obligation of confidentiality and non-use with respect to the Confidential Information, with AnorMED stated as a third-party beneficiary
thereof. For the purpose of this Section 11.2, “control” in the definition of Affiliate shall mean direct or indirect
beneficial ownership of 35% or greater interest in the income of a Person or such other relationship as, in fact, constitutes actual
control.

 

		113	Disclosure with Consent.

 

A
party receiving Confidential Information may, with the written consent of the disclosing party, disclose such Confidential Information
to entities or persons other than its corporate counsel, employees and contractors, on such terms and conditions as the disclosing
party may specify.

 

		11.4	Ownership of Confidential Information.

 

All
Confidential Information disclosed by one party to the other shall remain the Intellectual Property of the disclosing party.

 

		11.5	Press Releases.

 

		(a)	The parties intend to issue a press release on the Effective Date regarding this Agreement and
the relationship of the parties in the form set out in Exhibit
D. Thereafter, during the Term, the parties agree that no press release, public announcement or publication regarding
this Agreement or the relationship of the parties not previously made public shall be made unless mutually agreed to, in writing,
prior to the release or dissemination of any such press release, public announcement or publication, such agreement not to be unreasonably
withheld or delayed .

 

		(b)	Notwithstanding Subsection 11.5(a), each party shall have a right to issue press releases, public
announcements or publications regarding this Agreement or the relationship of the parties without a requirement of consent of the
other party to the extent that information in any such press release, public announcement or publication has been previously made
public or released or to the extent as may be legally required by, for example, the rules and regulations of the Securities and
Exchange Commission or similar federal, state or foreign authorities, as determined in good faith by the disclosing party.

 

		(c)	Notwithstanding Subsection 11.5(a), each party agrees to use reasonable good faith efforts to notify
the other party when it releases any information relating to this Agreement, including any previously approved information and
any information required to be disclosed by the rules and regulations of the Securities and Exchange Commission or similar federal,
state or foreign authorities, and will promptly provide a copy of any such disclosure to the other party.

 

		11.6	Publication.

 

Neither
party shall publish or provide public disclosure of any invention related to any Licensed Compound or any Licensed Product that
is not the subject of a filed patent application without at least 60 days prior written notice of such planned publication or disclosure
sent to the other party. In the event any such dissemination is determined by the other party to be detrimental to its Intellectual
Property position, the disseminating party shall delay such publication for a period sufficient, but in no event greater than an
additional 60 days, to allow the other party to take the steps necessary to protect such Intellectual Property, including the filing
of any Patent applications and/or deletion of the other party’s Confidential Information.

 

		11.7	Duration of Obligation

 

Unless
otherwise agreed by the parties in writing, the obligations of the parties relating to Confidential Information set out in this
Article 11 shall survive the expiration or termination of this Agreement for a period of ten (10) years.

 

    	 	- 22 -	 

     

    

 

Article 12 LEGAL AND REGULATORY.

 

		12.1	Compliance with Laws.

 

NeoRx
shall at all times in manufacturing, handling, loading, labeling, shipping and delivering Licensed Products under this Agreement
and in otherwise carrying out its obligations under this Agreement:

 

		(a)	comply with all applicable laws, rules, regulations or other requirements applicable to NeoRx’
business and to the manufacturing, handling, loading, labeling, shipping and delivering of Licensed Compounds and/or Licensed Products
to be supplied under this Agreement; and

 

		(b)	obtain and maintain in full force and effect all applicable licenses, permits, certificates, authorizations
or approvals from all governmental authorities necessary to conduct its business and manufacture, handle, load, label, ship and
deliver Licensed Compounds and/or Licensed Products to be supplied under this Agreement.

 

In
particular, but without limiting the generality of the foregoing, NeoRx shall at all times comply with all environmental laws and
obtain and maintain in full force and effect all licenses, permits, certificates, authorizations or approvals required by environmental
laws, including those relating to the handling, generation, transportation, treatment, storage and disposal or other management
of waste and regulated substances, including, without limitation, hazardous and toxic substances.

 

		12.2	AMD473 Regulatory Activities.

 

		(a)	In connection with the Development Program and the commercialization of Licensed Products, in order
to support NeoRx’ regulatory filings, NeoRx shall have copies of and access to originals of the following information, as
exists on the Effective Date:

 

		(i)	all regulatory dossiers submitted to regulatory authorities
in respect of AMD473, provided:

 

		(A)	all such regulatory dossiers may be redacted to remove information that is:

 

		(1)	proprietary to AnorMED’s Third Party partner(s) and not applicable to AMD473, or

 

		(2)	proprietary to AnorMED and not applicable to AMD473, and

 

		(B)	such dossiers not controlled by AnorMED will be provided only in the event that AnorMED’s
partners that control such dossiers provide prior written approval, which approval AnorMED will use reasonable commercial efforts
to obtain;

 

		(ii)	all AMD473 drug safety filings by AnorMED;

 

		(iii)	all AMD473 drug safety data produced by or on behalf of AnorMED in order to support AnorMED’s
or its Third Party partners’ filings on AMD473 or improvements thereto;

 

		(iv)	all correspondence directly related to AMD473 to and from all regulatory agencies in the Territory;

 

		(v)	summaries of all substantive verbal or oral comments and commitments to regulatory
                                                                                 authorities, if any; and

 

		(vi)	copies of any manufacturing records for the Licensed Product in AnorMED’s possession.

 

		(b)	In order to support AnorMED’s or its licensees’ filings on Licensed Compounds and Licensed
Products outside the Territory, AnorMED shall have access to:

 

		(i)	all regulatory dossiers, including clinical reports and submission data, submitted to regulatory
authorities in respect of Licensed Compounds and Licensed Products, provided:

 

		(A)	all such regulatory dossiers may be redacted to remove information that is:

 

		(1)	proprietary to NeoRx’ Third Party partner(s) and not applicable to Licensed Compounds or
Licensed Products, or

 

		(2)	proprietary to NeoRx and not applicable to Licensed Compounds or Licensed Products, and

 

		(B)	such dossiers not controlled by NeoRx will be provided only in the event that NeoRx’ partners
that control such dossiers provide prior written approval, which approval NeoRx will use reasonable commercial efforts to obtain;

 

    	 	- 23 -	 

     

    

 

		(ii)	any necessary drug safety data produced by or on behalf of NeoRx during the Development Program
or other development activities under this Agreement in respect of Licensed Compounds and Licensed Products; and

 

		(iii)	any correspondence to and from all regulatory agencies in the Territory related to Licensed Compounds
and Licensed Products;

 

for
the purpose of fulfilling regulatory requirements for the Licensed Compounds and Licensed Products outside of the Territory.

 

		(c)	AnorMED will use commercially reasonable efforts to include in any license agreement with AnorMED’s
licensees outside of the Territory for the development of the Licensed Compounds and Licensed Products provisions no less restrictive
and comparable to this Subsection 12.2(b) for access to information of AnorMED’s licensee of the type described in Subsection
12.2(b) for use by NeoRx for the purpose of fulfilling regulatory requirements for the Licensed Compounds and Licensed Products
in the Territory.

 

		12.3	Regulatory Program Progress Reports.

 

NeoRx
shall keep AnorMED informed of the progress of its efforts to obtain Regulatory Approval for Licensed Products, and NeoRx shall
provide AnorMED with a written report summarizing NeoRx’ progress thereon on an annual basis, unless such progress has been
previously summarized in the quarterly reports provided pursuant to Section 2.3.

 

		12.4	Safety.

 

During
the Term, each party shall within a reasonable time inform the other party of any information that it obtains or develops regarding
the safety of any Licensed Compound or Licensed Product and shall promptly report to the other party any confirmed information
of serious or unexpected reactions or serious or unexpected adverse events related to the utilization or medical administration
of such Licensed Compound or Licensed Product. Each party will provide the other with annual reports and any required interim reports
describing any other side effects related to the utilization or medical administration
of such Licensed Compound or Licensed Product, which would allow appropriate reporting in their respective territories in accordance
with ICH guidelines or other relevant guidelines.

 

		12.5	Recalls.

 

		(a)	If either party has grounds to believe that a Recall should be conducted, the party with such belief
shall immediately notify the other party in writing of such grounds.

 

		(b)	In the event of any Recall or other similar governmental action with respect to any Licensed Product
in the Territory, AnorMED shall provide NeoRx with reasonable co-operation and take such other actions in connection therewith
as NeoRx may reasonably request. NeoRx shall have the sole responsibility to implement any Recall in respect of Licensed Products.

 

		(c)	In the event of any Recall or other similar governmental action outside the Territory with respect
to any Licensed Products, NeoRx shall provide AnorMED with reasonable co-operation in connection therewith.

 

Article
13 REPRESENTATIONS, WARRANTIES AND COVENANTS.

 

		13.1	AnorMED’s Representations, Warranties and Covenants.

 

AnorMED
hereby represents, warrants and covenantsto NeoRx as follows:

 

		(a)	AnorMED has been duly organized and is validly subsisting and in good standing in its jurisdiction
of organization and has the power to carry on the business as now being conducted by it;

 

		(b)	AnorMED has obtained all necessary consents, approvals and authorizations required to be obtained
by AnorMED in connection with the execution and delivery of this Agreement and has the right to enter into this Agreement, and
this Agreement is a legal and valid obligation binding upon AnorMED and enforceable in accordance with its terms;

 

    	 	- 24 -	 

     

    

 

		(c)	AnorMED is the owner of, or otherwise has a right to grant licenses under, the AnorMED Know-How
and the AnorMED Patents;

 

		(d)	AnorMED does not own or otherwise control any Patent relating to the Licensed Compound or the Licensed
Product except for the Patents within the AnorMED Patents;

 

		(e)	AnorMED is not aware of any grounds to support any argument for finding any patent within the AnorMED
Patents invalid or unenforceable;

 

		(f)	AnorMED has not entered into and is not subject to any agreement under which it has licensed in
the Field in the Territory any rights to a Third Party under the AnorMED Know-How or the AnorMED Patents to make, use, offer for
sale, sell or import any Licensed Compound or any Licensed Product;

 

		(g)	AnorMED has not received any written notice, and is not aware, of any infringement with respect
to any of the AnorMED Patents;

 

		(h)	AnorMED has not made as of the Effective Date and will not make during the Term any commitment
to any Third Party that is inconsistent with or in derogation of the rights granted by AnorMED to NeoRx or AnorMED's obligations
under this Agreement; and

 

		(i)	AnorMED is not subject to any obligation that would prevent it from entering into or carrying out
its obligations under this Agreement, and this Agreement does not conflict with, violate, or breach or constitute a default or
require any consent under, any contractual obligation or court or administrative order by which such Party is bound.

 

		13.2	NeoRx’
Representations, Warranties and Covenants.

 

NeoRx
hereby represents, warrants and covenants to AnorMED as follows:

 

		(a)	NeoRx has been duly organized and is validly subsisting and in good standing in its jurisdiction
of organization and has the power to carry on the business as now being conducted by it;

 

		(b)	NeoRx has the right to enter into this Agreement and this Agreement is a legal and valid obligation
binding upon NeoRx and enforceable in accordance with its terms;

 

		(c)	NeoRx has not made and will not make
any commitments to Third Parties inconsistent with or in derogation of NeoRx’ obligations under this Agreement and NeoRx is not
subject to any obligations that would prevent it from entering into or carrying out its obligations under this Agreement; and

 

		(d)	NeoRx shall utilize sound and reasonable business practice and judgment in the performance of the
Development Program, including the conduct of clinical studies thereunder, and in the commercialization of the Licensed Compounds
and/or the Licensed Products.

 

		13.3	No
Warranty.

 

ANORMED
AND NEORX EACH MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, AND DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, OTHER
THAN THOSE EXPRESSLY SET FORTH IN THIS AGREEMENT, WITH RESPECT TO THE LICENSED COMPOUNDS, THE LICENSED PRODUCTS, THE ANORMED PATENTS,
THE ANORMED KNOW-HOW OR THE LIKELIHOOD OF SUCCESS IN THE DEVELOPMENT AND COMMERCIALIZATION OF ANY LICENSED PRODUCT, INCLUDING WITHOUT
LIMITATION ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

 

Article
14 TERM AND TERMINATION.

 

		14.1	Expiration.

 

This
Agreement shall commence on the Effective Date and shall continue in full force and effect until expiration of NeoRx’ obligation
to pay to AnorMED royalties pursuant to Sections 7.2 and 7.3 (the “Term”). Upon expiration of the Term, NeoRx
shall have a fully paid, royalty-free right to make, have made, use, have used, sell, have sold, offer for sale and import Licensed
Compounds and Licensed Products without further obligation to AnorMED.

 

    	 	- 25 -	 

     

    

 

		14.2	Termination.

 

This
Agreement may be terminated by either party only in accordance with the terms and conditions set out in this Article 14.

 

		14.3	Termination by NeoRx.

 

NeoRx
may terminate this Agreement:

 

		(a)	in its entirety, at any time upon 120 days prior written notice of such termination to AnorMED;
or

 

		(b)	in respect of the development and/or commercialization of any or all Licensed Compounds and/or
Licensed Products in any country or countries in the Territory, at NeoRx’ option, at any time after both the receipt of NDA
approval of the Licensed Product in the United States and the receipt of the equivalent health regulatory approval in the European
Union, upon 180 days prior written notice of such termination to AnorMED;

 

in
which case:

 

		(c)	in the event NeoRx terminates this Agreement in its entirety, then without further action on the
part of either party:

 

		(i)	all rights and licenses granted by AnorMED to NeoRx pursuant to this Agreement shall revert to
AnorMED and NeoRx shall retain no rights therein,

 

		(ii)	to the extent permitted by applicable law and regulation, all regulatory licenses and filings related
to any Licensed Compounds and/or Licensed Products shall be transferred in good faith from NeoRx to AnorMED at no cost,

 

		(iii)	all rights in and to any trademarks and tradenames used in the development and commercialization
of the Licensed Compounds and/or Licensed Products in the Territory, shall be assigned from NeoRx (or its Affiliates) to AnorMED
at no cost,

 

		(iv)	the license granted by NeoRx to AnorMED under Subsection 9.2(c) shall be automatically converted
to a worldwide license at no cost, and

 

		(v)	in the event that AnorMED or its licensees outside the Territory utilize any patented inventions
developed by NeoRx under this Agreement, AnorMED and NeoRx shall in good faith negotiate a reasonable royalty recognizing the relative
contributions of each party to such inventions;

 

		(d)	in the event NeoRx terminates this Agreement in respect of the development and/or commercialization
of any particular Licensed Compounds and/or Licensed Products in a country or countries, then without further action on the part
of either party:

 

		(i)	the Territory shall be deemed to be reduced in scope, in respect of the terminated Licensed Compound
and/or Licensed Product only, to exclude those countries where NeoRx determines that it will not develop or commercialize such
Licensed Compound and/or Licensed Product that is the subject of the termination,

 

		(ii)	the rights and licenses granted by AnorMED to NeoRx pursuant to this Agreement that are the subject
of the termination shall revert to AnorMED and NeoRx shall retain no rights therein in those countries that are excluded from the
Territory,

 

		(iii)	to the extent permitted under applicable law and regulation, all regulatory licenses and filings
related to such Licensed Compounds and/or Licensed Products that are the subject of the termination in countries that are excluded
from the Territory shall be transferred in good faith from NeoRx (or its Affiliates) to AnorMED at no cost,

 

		(iv)	all rights in and to any trademarks and tradenames used in the development and commercialization
of the Licensed Compounds and/or Licensed Products that are the subject of the termination in countries that are excluded from
the Territory shall be assigned from NeoRx (or its Affiliates) to AnorMED at no cost, and

 

    	 	- 26 -	 

     

    

 

		(v)	the license granted by NeoRx to AnorMED under Subsection 9.2(c) shall be automatically expanded
to include those countries that are newly excluded from the Territory at no cost; and

 

		(e)	in respect of the area terminated, NeoRx will, at its sole cost and expense, promptly wind down
any pre-clinical and clinical studies and programs then in effect and will safely withdraw and follow-up subjects from any such
clinical studies to the effective date of termination or, if such withdrawal cannot be made as of the effective date of termination,
the subjects will be withdrawn over a period of time mutually agreed by the parties, based upon an evaluation of risks to subjects
and the timelines required in the applicable clinical study protocol.

 

		14.4	Termination for Breach.

 

		(a)	If either party materially breaches this Agreement (which shall exclude bankruptcy of a party)
and if the breach is not cured within 60 days after receiving written notice from the other party with respect to the breach, except
as otherwise set out in this Agreement, this Agreement shall automatically terminate at the end of the 60 day period.

 

		(b)	Notwithstanding Subsection 14.4(a), if either party disputes the breach and so notifies the other
party in writing within the 60 day cure period, this Agreement shall not be automatically terminated pending adjudication and resolution
of the disputed breach pursuant to Section 19.2 or a court of competent jurisdiction, as the case may be.

 

		(c)	If AnorMED terminates this Agreement for breach by NeoRx under this Section 14.4, then without
further action on the part of either party:

 

		(i)	all rights and licenses granted by AnorMED to NeoRx pursuant to this Agreement shall revert to
AnorMED and NeoRx shall retain no rights therein;

 

		(ii)	to the extent permitted under applicable law and regulation, all regulatory licenses and filings
related to any Licensed Compounds and/or Licensed Products shall be transferred in good faith from NeoRx (or its Affiliates) to
AnorMED at no cost;

 

		(iii)	all rights in and to any trademarks and tradenames used in the development and commercialization
of the Licensed Compounds and/or Licensed Products in the Territory, shall be assigned from NeoRx (or its Affiliates) to AnorMED
at no cost;

 

		(iv)	the license granted by NeoRx to AnorMED under Subsection 9.2(c) shall be automatically converted
to a worldwide license at no cost; and

 

		(v)	NeoRx will, at its sole cost and expense, promptly wind down any pre-clinical and clinical studies
and programs then in effect and will safely withdraw and follow-up subjects from any such clinical studies to the effective date
of termination or, if such withdrawal cannot be made as of the effective date of termination, the subjects will be withdrawn over
a period of time mutually agreed by the parties, based upon an evaluation of risks to subjects and the timelines required in the
applicable clinical study protocol.

 

		(d)	If NeoRx terminates this Agreement for breach by AnorMED under this Section 14.4, NeoRx may elect,
in NeoRx’ sole discretion, without further action on the part of either party, that all rights and licenses granted by AnorMED
to NeoRx pursuant to this Agreement, including, without limitation, any and all regulatory licenses and filings shall continue
as exclusive royalty-bearing licenses from AnorMED to NeoRx on the terms and conditions set out in this Agreement, except that
AnorMED and NeoRx shall in good faith attempt to negotiate a reasonable reduction in the royalty rates set out under Sections 7.2
and 7.3.

 

		14.5	Termination on Bankruptcy.

 

To
the extent permitted under applicable law, either party may terminate this Agreement if at any time during the Term the other party
files in any court or agency pursuant to any statute or regulation of the United States or of any individual state or foreign country:

 

		(a)	a petition in bankruptcy or insolvency;

 

		(b)	a petition for reorganization in connection with a bankruptcy or insolvency;

 

    	 	- 27 -	 

     

    

 

		(c)	a petition for an arrangement in connection with a bankruptcy or insolvency;

 

		(d)	a petition for the appointment of a receiver or trustee of the party or of its assets;

 

		(e)	if the other party proposes a written agreement of composition or extension of its debts;

 

		(f)	if the other party is served with an involuntary petition
against it, filed in anyinsolvency proceeding, and the petition is not dismissed within 60 days after the filing thereof;

 

		(g)	if the other party proposes or is a party to any dissolution or liquidation; or

 

		(h)	if the other party makes an assignment for the benefit of creditors.

 

To
the extent consistent with applicable law, termination by a party under this Section 14.5 will be considered termination for breach
under Section 14.4 and the consequences of termination and parties’ respective rights and remedies will be as set out in
Section 14.4, except that no notice and cure time for the breach shall be required and, in the event of termination for AnorMED’s
bankruptcy, there shall be no reduction in the royalty rates under Sections 7.2 and 7.3.

 

		14.6	Payments on Termination.

 

Upon
termination of this Agreement, AnorMED shall have the right to retain any sums already paid by NeoRx under this Agreement, and
NeoRx shall pay all sums accrued hereunder as of the effective date of such termination or accrued under this Agreement after the
effective date of such termination as a result of such termination, such as the cost of winding down any preclinical and clinical
studies and programs then in effect and any other wind down costs, but shall have no obligation to make any payments that would
have accrued if termination of this Agreement had not occurred.

 

		14.7	Inventory.

 

		(a)	Subject to Subsection 14.7(b), notwithstanding the expiration
or earlier termination of this Agreement, NeoRx may continue to use any Licensed Products held in inventory by it in accordance
with the terms and conditions of the licenses granted under Sections 3.1, including the use of Licensed Products in the winding
down of clinical studies and programs under Paragraphs 14.3(e) and 14.4(c)(v), or as otherwise required to comply with regulatory
requirements.

 

		(b)	In the event of the termination of this Agreement by AnorMED
for material breach by NeoRx, NeoRx shall, at AnorMED’s option:

 

		(i)	destroy any Licensed Products held in inventory by NeoRx,
or

 

		(ii)	provide such Licensed Products to AnorMED at a price to be negotiated in good faith between the parties,

 

provided
that NeoRx may retain a reasonable quantity of such Licensed Products for use in accordance with the terms and conditions of the
licenses granted under Sections 3.1 for humanitarian and compassionate reasons for supply to physicians and other health service
providers who, at the time of termination of this Agreement, are treating patients using a Licensed Product, to continue and complete
the treatment of those existing patients. All sales of such Licensed Product shall be subject to royalty payments in accordance
with Article 7.

 

		14.8	Survival.

 

Expiration
or early termination of this Agreement shall not relieve either party of its obligations incurred prior to such expiration or early
termination. In addition, the following provisions shall survive any expiration or early termination of this Agreement:

 

		(a)	Section 1.1 (Definitions);

 

		(b)	Section
7.5 (Royalty Payments Upon Termination);

 

		(c)	Section
8.7 (Accounts and Audit)
and 8.8 (Confidentiality of Reports);

 

		(d)	Article
9 (Intellectual Property);

 

    	 	- 28 -	 

     

    

 

		(e)	Section 10.9 9
                                                           (Interference Proceedings) to the extent any interference proceedings are called prior to the effective date of
                                                           termination;

 

		(f)	Article
11 (Confidentiality; Publicity; Publications);

 

		(g)	Sections 12.5 (Recalls)
to the extent any Recall is instituted on Licensed Product sold or otherwise distributed by NeoRx prior to the effective date of
termination;

 

		(h)	Sections
14.6 (Payments on Termination)
14.7 (Inventory)
and 14.8 (Survival);

 

		(i)	Article 15 (Indemnification);
and

 

		(j)	Sections
19.2 (Dispute Resolution),
19.3 (Entire Agreement),
19.6 (Governing Law),
19.8 (Notices), 19.9
(Change of Address),
19.10 (Rights and Remedies)
and 19.11 (Severability).

 

Further,
Section 10.3 (Patent Costs) shall
survive any expiration or termination of this Agreement solely with respect to the payment and reimbursement of any Patent-related
costs and expenses that were incurred prior to the effective date of termination or expiration. Sections 3.1 (Grant
of License) shall survive any termination by NeoRx for breach by AnorMED under Section 14.4 or, subject to applicable
law, for insolvency or bankruptcy by AnorMED under Section 14.5.

 

Article
15 INDEMNIFICATION.

 

		15.1	Indemnification
of AnorMED.

 

NeoRx
shall indemnify and hold AnorMED, its Affiliates, and each of their officers, directors, employees, agents, consultants and contractors
(the “AnorMED Indemnified Parties”) harmless from and against any claim, action, liability, damage, loss, cost
or expense (including reasonable attorneys’ fees) (“Loss”) arising from or related to:

 

		(a)	the exercise of the license granted to NeoRx under this Agreement, including the development, testing,
manufacturing, sale and/or recall of the Licensed Compounds and/or the Licensed Products by NeoRx, its Affiliates and its sublicensees
as of or after the Effective Date;

 

		(b)	any breach or violation by NeoRx of, or failure to properly perform, any covenant or agreement
made in this Agreement; or

 

		(c)	any breach by NeoRx of any of its representations or warranties made in this Agreement;

 

unless
and to the extent such Loss arises from or is related to the gross negligence, wilful misconduct or fraud of the AnorMED Indemnified
Parties.

 

		15.2	Indemnification
of NeoRx.

 

AnorMED
shall indemnify and hold NeoRx, its Affiliates, and each of their officers, directors, employees, consultants and contractors (the
“NeoRx Indemnified Parties”) harmless from and against any Loss arising from or related to:

 

		(a)	the development, testing, manufacturing, sale and/or recall of the Licensed Compounds and/or the
Licensed Products by AnorMED, its Affiliates and its licensees prior to the Effective Date;

 

		(b)	any breach or violation by AnorMED of, or failure to properly perform, any covenant or agreement
made in this Agreement; or

 

		(c)	any breach by AnorMED of any of its representations or warranties made in this Agreement;

 

unless
and to the extent such Loss arises from or is related to the gross negligence, wilful misconduct or fraud of the NeoRx Indemnified
Parties.

 

		15.3	Clinical
Trials.

 

NeoRx
acknowledges and agrees that AnorMED shall have no liability for, no responsibility for and no control over the conduct of in
vivo, animal or human clinical studies conducted by or on behalf of NeoRx and/or its Affiliates or their respective
sublicensees utilizing the Licensed Compounds and the Licensed Products in the Field. The performance of any human clinical studies
in respect to the use of the Licensed Compounds and the Licensed Products in the Field shall be the sole responsibility of NeoRx.

 

    	 	- 29 -	 

     

    

 

		15.4	Unauthorized Commerce Indemnity.

 

In
addition, NeoRx agrees to indemnify and hold harmless the AnorMED Indemnified Parties and will defend them from and against any
and all Losses arising out of or relating to the alleged or actual unapproved or unauthorized use by NeoRx or its Affiliates or
their respective sublicensees of Licensed Product prior to Regulatory Approval.

 

		15.5	Indemnification Procedure.

 

If
a party eligible for indemnification under this Article 15 (in this section, an “Indemnified
Party”), receives any written claim which it believes gives rise to indemnification under this Article 15, the
Indemnified Party shall give notice of the claim to the other party (the “Indemnifying
Party”), including full particulars of the claim to the extent known to the Indemnified Party, provided, however,
that the failure to give timely notice as contemplated hereby shall not release the Indemnifying Party from any liability to indemnify
any persons indemnified under this Article 15 to the extent such failure does not compromise the Indemnifying Party’s ability
to prosecute such claim, and, subject to Article 10 in respect of infringement claims and infringement actions, the following shall
apply:

 

		(a)	the Indemnifying Party shall have the right, by prompt notice to the Indemnified Party, to assume
the defense of the claim with counsel reasonably satisfactory to the Indemnified Party, and at the Indemnifying Party’s cost
and expense;

 

		(b)	if the Indemnifying Party does not so assume the defense of the claim, the Indemnified Party may
assume the defense with counsel of its choice at the Indemnifying Party’s cost and expense;

 

		(c)	if the Indemnifying Party assumes the defense of the claim, the Indemnified Party may participate
therein through counsel of its choice, but the cost of such counsel shall be borne solely by the Indemnified Party;

 

		(d)	the Indemnified Party shall render all reasonable assistance to the Indemnifying Party and all
out-of-pocket costs of this assistance shall be borne solely by the Indemnifying Party; and

 

		(e)	no claim shall be settled other than by the party defending the claim, and then only with the consent
of the other party, which shall not be unreasonably withheld, provided that the Indemnified Party shall have no obligation to consent
to any settlement of any claim which imposes on the Indemnified Party any liability or obligation which cannot be assumed and performed
in full by the Indemnifying Party, and provided further that refusal of the Indemnified Party to consent to any settlement agreed
to by the Indemnifying Party shall limit the Indemnifying Party’s obligation under this Article 15 to the terms refused by
the Indemnified Party.

 

Article
16 REPRESENTATIONS AND WARRANTIES OF NEORX.

 

		16.1	Representations and Warranties

 

NeoRx
hereby represents and warrants the following as of the date hereof and as of the date that each milestone payment is made in shares
of NeoRx Common Shares pursuant to Sections 6.3(a) and 6.3(b) (each a “Share
Payment Date”):

 

		(a)	Corporate Organization and Authority. NeoRx:

 

		(i)	is a corporation duly organized, validly existing, authorized to exercise all its corporate powers,
rights and privileges, and in good standing in the State of Washington; and

 

		(ii)	has corporate power and authority to enter into this Agreement and to carry out the transactions contemplated
herein.

 

		(b)	Authorization. All necessary corporate action on the part of NeoRx for the execution and delivery
of this Agreement has been taken and all necessary corporate action on the part of NeoRx for the issuance and delivery of the Common
Shares being issued on each Share Payment Date shall have been taken prior to such Share Payment Date. This Agreement constitutes
a valid and legally binding obligation of NeoRx enforceable in accordance with its terms, except as may be limited by bankruptcy,
reorganization, insolvency, moratorium and similar laws of general application relating to or affecting the enforcement of rights
of creditors, and except as enforceability may be limited by principles of public policy, and to rules of law governing specific
performance, injunctive relief and other equitable remedies.

 

    	 	- 30 -	 

     

    

 

		(c)	No Conflicts; Required Filings.

 

		(i)	The performance by NeoRx of this
                                         Agreement and the transactions contemplated herein do not violate, or constitute a default
                                         under, and will not result in any violation of or constitute a default under, with or
                                         without the passage of time or the giving of notice of (1) any provision of NeoRx’s
                                         charter or bylaws as in effect on the relevant Share Payment Date; (2) any provision
                                         of any judgment, decree or order to which NeoRx is a party or by which it or any of its
                                         properties is bound; (3) any contract, obligation or commitment to which NeoRx is a party
                                         or by which it or any of its properties is bound, which violation or default would, individually
                                         or in the aggregate, (A) prevent or materially delay consummation of the transactions
                                         contemplated under this Agreement, (B) otherwise have a material adverse effect on the
                                         ability of NeoRx to perform its obligations under this Agreement and (C) individually
                                         or in the aggregate, result in any change, event, development, effect or condition that
                                         is or is reasonably likely to be materially adverse to the assets, liabilities, business,
                                         financial condition or results of operations of NeoRx (each of the foregoing items in
                                         (A), (B) or (C) being referred to herein as “Material Adverse Effect”);
                                         or (4) any statute, rule or governmental regulation applicable to NeoRx, which violation
                                         or default would, individually or in the aggregate, have a Material Adverse Effect.

 

		(ii)	The execution, delivery and performance
                                         by NeoRx of this Agreement and the transactions contemplated herein do not and will not
                                         require any consent, approval, authorization or permit of, or filing with or without
                                         notification to, any governmental or regulatory authority, United States or foreign,
                                         except (1) as may be required by the Hart-Scott-Rodino Antitrust Improvements Act of
                                         1976, as amended, together with the rules and regulations thereunder, and any similar
                                         foreign antitrust law or regulation (“Antitrust Laws”); (2) for applicable
                                         requirements, if any, of the Securities Act of 1933, as amended, including the rules
                                         and regulations promulgated thereunder (the “Securities Act”), or
                                         securities laws of the various states of the United States (the “Blue Sky Laws”);
                                         and (3) where the failure to obtain such consents, approvals, authorizations or permits,
                                         or to make such filings or notifications, would not have a Material Adverse Effect.

 

		(d)	Capital Stock. NeoRx has reserved a sufficient number of shares of Common Shares for issuance to
AnorMED in accordance with NeoRx’s obligations under this Agreement on or prior to each of the Share Payment Dates.

 

		(e)	Validity of Common Shares. The Common Shares issued on each Share Payment Date, when issued, sold
and delivered in accordance with the terms and for the consideration set forth in this Agreement, shall be duly and validly issued
and outstanding, fully paid, nonassessable and free and clear of all security interests, pledges, mortgages, liens, taxes, proxies,
charges, adverse claims of ownership or use, and restrictions, including pre-emptive rights, rights of first refusal and other
similar rights, restrictions on the resale, use, voting, receipt of income or other exercise of any attributes of ownership and
restrictions on transfer, defects of title or other encumbrance of any kind or character entitling any person to purchase or acquire
an ownership interest in any of such Common Shares, other than restrictions on transfer set forth in this Agreement and under federal
and state securities laws.

 

		(f)	SEC Filings; Financial Statements.

 

		(i)	NeoRx has timely
                                         filed all forms, reports and documents required to be filed by it with the Securities
                                         and Exchange Commission (the “SEC”) since December 31, 2002 (the “SEC
                                         Reports”) including, its (1) most recent Annual Report on Form 10-K; (2) each
                                         Quarterly Report on Form 10-Q filed with the SEC since the date of its most recent Annual
                                         Report on Form 10-K; (3) most recent proxy statement for the annual meeting of stockholders;
                                         and (4) all Current Reports on Form 8-K filed with the SEC since the date of NeoRx’s
                                         most recent report on Form 10-Q. NeoRx has filed additional reports and documents with
                                         the SEC that may be accessed at www.sec.gov. As of their respective dates, the SEC Reports:
                                         (A) were prepared in accordance with the requirements of the Securities Exchange Act
                                         of 1934, as amended (the “Exchange Act”); and (B) did not at the time
                                         they were filed contain any untrue statement of a material fact or omit to state a material
                                         fact required to be stated therein or necessary in order to make the statements therein,
                                         in light of the circumstances under which they were made, not misleading. Except to the
                                         extent that information contained in any SEC Report has been updated, revised, supplemented
                                         or amended by a later-filed SEC Report, none of the SEC Reports contains an untrue statement
                                         of material fact or omits to state a material fact required to be stated therein or necessary
                                         in order to make the statements therein, in light of the circumstances under which they
                                         were made, not misleading. As of the date of this Agreement, no subsidiary of NeoRx is
                                         subject to the reporting requirements of the Exchange Act.

 

    	 	- 31 -	 

     

    

 

		(ii)	Each of the financial statements (including, in each case, any notes thereto) contained in the
SEC Reports (collectively, the “Financial
Statements”) (1) complied as to form in all material respects with the published rules and regulations of the
SEC applicable thereto; (2) were prepared in accordance with generally accepted accounting principles applied on a consistent basis
throughout the periods covered (except as may be indicated in the notes to such financial statements or, in the case of unaudited
statements, as permitted by Form 10-Q of the SEC, and except that the unaudited financial statements may not contain footnotes
and are subject to normal and recurring year-end adjustments that did not and will not, individually or in the aggregate, be material
in amount); and (3) fairly present in all material respects the consolidated financial position of NeoRx as of the respective dates
thereof and the consolidated results of operations and cash flows of NeoRx for the periods covered thereby. The auditors who have
certified the financial statements of NeoRx contained in the SEC Reports are independent public accountants as required by the
Securities Act and the rules and regulations thereunder. Except as disclosed in the SEC Reports and except for matters which are
not, individually or in the aggregate, reasonably expected to have a Material Adverse Effect, NeoRx has no obligations or liabilities,
whether or not accrued, contingent or otherwise and whether or not required to be disclosed.

 

		(g)	Sarbanes-Oxley. NeoRx’s principal executive officer and principal financial officer have
evaluated the effectiveness of NeoRx’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) described in the SEC Reports, and the conclusions regarding the effectiveness of the disclosure controls and procedures
set forth in the SEC Reports are true and correct in all material respects. The Chairman and Chief Executive Officer and the Vice
President, Finance of NeoRx have signed, and NeoRx has furnished to the SEC, all certifications required by Section 906 of the
Sarbanes-Oxley Act of 2002; such certifications contain no qualifications or exceptions to the matters certified therein, except
as to knowledge, and have not been modified or withdrawn; and neither NeoRx nor any of its officers has received notice from any
governmental entity questioning or challenging the accuracy, completeness, content, form or manner of filing or submission of such
certifications.

 

		(h)	Private Offering. Subject to the accuracy of AnorMED’s representations set forth in Section
17.1(c), Section 17.1(f) and Section 17.1(h), the offer, sale and issuance of the Shares in accordance with the terms of this Agreement
is in compliance with all applicable laws, exempt from the registration requirements of Section 5 of the Securities Act and exempt
from applicable state registration or qualification requirements, other than those with which NeoRx has complied or will comply.

 

		(i)	NASDAQ Compliance, NeoRx’s Common Shares are registered pursuant to Section 12(g) of the
Exchange Act and is listed on the NASDAQ SmallCap Market, and NeoRx has taken no action designed to, or likely to have the effect
of, terminating the registration of the Common Shares under the Exchange Act or delisting the Common Shares from the NASDAQ SmallCap
Market.

 

		(j)	Investment Company. NeoRx is not an “investment company” or an “affiliated person”
of, or “promoter” or “principal underwriter” for an investment company, within the meaning of the Investment
Company Act of 1940, as amended.

 

		(k)	Litigation. Except as disclosed in the SEC Reports, there
is no legal action, suit, arbitration or other legal, administrative or governmental proceeding pending or, to NeoRx’s knowledge,
threatened against NeoRx that could reasonably be expected to have a Material Adverse Effect.

 

    	 	- 32 -	 

     

    

 

Article
17 REPRESENTATIONS AND WARRANTIES OF ANORMED.

 

		17.1	Representations and Warranties

 

AnorMED
hereby represents and warrants to NeoRx the following:

 

		(a)	Authorization. All necessary corporate action on the part of AnorMED for the execution, delivery
and performance of its obligations under this Agreement and for the consummation of the transactions contemplated hereby has been
taken. This Agreement constitutes a valid and legally binding obligation of AnorMED enforceable in accordance with its terms.

 

		(b)	Corporate Organization and Authority. AnorMED is a corporation duly organized, validly existing,
and in good standing under the laws of Canada. AnorMED has the corporate power, authority and capacity to execute and deliver this
Agreement and to perform its obligations under this Agreement and any document contemplated to be delivered hereby.

 

		(c)	Purchase Entirely for Own Account. This Agreement is made with AnorMED in reliance upon AnorMED’s
representation to NeoRx, which by AnorMED’s execution of this Agreement AnorMED hereby confirms, that the Common Shares to
be purchased by AnorMED will be acquired for investment for AnorMED’s own account, not as a nominee or agent, and not with
a view to the resale or distribution of any part thereof. AnorMED has no present intention of selling, granting any participation
in or otherwise distributing the same. By executing this Agreement, AnorMED further represents that AnorMED does not presently
have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person
or to any third person, with respect to any of the Common Shares and AnorMED has not been formed for the specific purpose of acquiring
the Common Shares.

 

		(d)	Restricted Securities. AnorMED understands that the Common Shares have not been, and will not be,
registered under the Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act,
which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of AnorMED’s representations
as expressed in Section 17.1(c). AnorMED understands that the Common Shares are “restricted securities” under applicable
U.S. federal and state securities laws and that, pursuant to these laws, AnorMED must hold the Common Shares indefinitely unless
they are registered with the SEC and qualified by state authorities, or an exemption from such registration and qualification requirements
is available.

 

		(e)	Legends. AnorMED understands that the Common Shares shall bear the following legend:

 

		(i)	“THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SUCH ACT, OR
UNLESS NEORX HAS RECEIVED AN OPINION OF COUNSEL OR OTHER EVIDENCE, SATISFACTORY TO NEORX AND ITS COUNSEL, THAT SUCH REGISTRATION
IS NOT REQUIRED.”

 

		(f)	Accredited Investor. AnorMED is an “accredited investor” in:

 

		(i)	the United States pursuant to Rule 501(a) of Regulation D promulgated under the Securities Act;
and

 

		(ii)	Canada pursuant to subsection 1.1 (m) of the definition of “accredited investor”
                                                                set forth in Multilateral Instrument 45-103 – Capital
                                                                Raising Exemptions.

 

		(g)	Reliance. AnorMED has, in connection with its decision to purchase the number of Common Shares
set forth herein, relied solely upon the SEC Reports and the representations and warranties of NeoRx contained in this Agreement.

 

		(h)	Investment Experience. AnorMED has such knowledge and experience in financial and
                                                                             business matters that AnorMED is capable of evaluating the merits and risks of the investment in the Common Shares.

 

    	 	- 33 -	 

     

    

 

Article
18 REGISTRATION RIGHTS.

 

NeoRx
shall use all commercially reasonable efforts to file a registration statement with the Securities and Exchange Commission covering
resale of those shares of unregistered Common Stock issued pursuant to Section 6.2(b) within 60 days after the date of this Agreement
and use all commercially reasonable efforts to cause such registration statement to become effective within 90 days after such
filing date (or 150 days after the filing date if the registration statement is reviewed by the SEC). NeoRx shall use all commercially
reasonable efforts to file a registration statement with the Securities and Exchange Commission covering resale of those shares
of unregistered Common Stock issued pursuant to Section 6.3(a) within 60 days after the achievement of the milestone set forth
in Section 6.3(a) and use all commercially reasonable efforts to cause such registration statement to become effective within 90
days after such filing date (or 150 days after the filing date if the registration statement is reviewed by the SEC). NeoRx, shall
use all commercially reasonable efforts to file a registration statement, post-effective amendment or prospectus supplement, as
applicable, with the Securities and Exchange Commission covering resale of those shares of unregistered Common Stock issued pursuant
to Section 6.3(b) within 60 days of achievement of the milestone set forth in Section 6.3(b) and use all commercially reasonable
efforts to cause such registration statement to become effective within 90 days after such filing date (or 150 days after the filing
date if the registration statement is reviewed by the SEC). If a requested registration statement is not filed within the applicable
60-day period set forth above or if such registration statement is not declared effective by the SEC within 90 days (or 150 days,
as applicable) thereafter, then AnorMED shall, at AnorMED’s sole option and election, have the right at any time within the
subsequent 15 days after the expiration of such 60-, 90- or 150-day period to tender the previously-issued shares of NeoRx Common
Stock received pursuant to Sections 6.2(b), 6.3(a) and 6.3(b), as applicable, by written notice to NeoRx and in lieu shares of
NeoRx Common Stock receive the amount specified in Sections 6.2(b), 6.3(a) or 6.3(b), as applicable, in cash. Notwithstanding the
foregoing, AnorMED shall not be entitled to registration rights under this Agreement and shall not be entitled to the right to
tender shares to NeoRx if all of the shares of NeoRx Common Stock held by AnorMED may be sold by AnorMED pursuant to Rule 144 of
the Securities Act during any ninety (90) day period as determined by counsel to NeoRx pursuant to a written opinion letter, reasonably
satisfactory in form and substance to AnorMED, addressed to NeoRx’s transfer agent to such effect; provided, further, that
if any of the shares of NeoRx Common Stock held by AnorMED may be sold by AnorMED pursuant to Rule 144(k) of the Securities Act,
then the opinion of NeoRx’s counsel shall also state that the restrictive legends on the stock certificates representing
such shares be removed pursuant to Rule 144(k).

 

Article
19 MISCELLANEOUS.

 

		19.1	Assignment; Inurement.

 

Neither
this Agreement nor any interest under this Agreement shall be assignable by either party without the prior written consent of the
other party. Assignment in contravention of this Section 19.1 shall be considered a material breach of this Agreement pursuant
to Section 14.4. Subject to other provisions of this Section 19.1, all rights and obligations under this Agreement and the licenses
granted in this Agreement shall be binding upon and inure to the benefit of the successors in interest of the respective parties.
Any assignment in violation of the foregoing shall be null and void. In the event that NeoRx assigns its rights and obligations
under this Agreement to a Third Party in accordance with the terms of this Section 19.1, all payments due and payable to AnorMED
under this Agreement by such Third Party after the effective date of assignment shall be made in cash including, in particular,
payments due and payable to AnorMED pursuant to Article 6.

 

		19.2	Dispute Resolution.

 

		(a)	Prior to engaging in any formal dispute
                                         resolution with respect to any dispute, controversy or claim arising out of or in relation
                                         to this Agreement or the breach, termination or invalidity of this Agreement (each, a
                                         “Dispute”), the Chief Executive Officers of the parties shall attempt
                                         for a period not less than 60 days to resolve the Dispute.

 

		(b)	Except as otherwise set out in this
                                         Section 19.2, any Dispute that cannot be settled amicably by agreement of the parties
                                         pursuant to Subsection 19.2(a) shall be finally settled by arbitration in accordance
                                         with the arbitration rules (the “Rules”) of the American Arbitration
                                         Association then in force, by three arbitrators. Each party shall select one arbitrator
                                         and the selected party arbitrators shall select the third arbitrator. Each such arbitrator
                                         shall have appropriate experience in the biopharmaceutical industry. Arbitration proceedings
                                         may not be instituted until the party alleging breach of this Agreement by the other
                                         party has given the other party the 60 days notice to remedy any alleged breach (as more
                                         specifically set out in other parts of this Agreement) and the other party has failed
                                         to do so.

 

    	 	- 34 -	 

     

    

  

		(c)	The place of arbitration shall be Seattle, Washington if
initiated by AnorMED and Vancouver, British Columbia if initiated by NeoRx.

 

		(d)	The award rendered in any arbitration shall be final and
binding upon both parties. The judgment rendered by the arbitrators shall include costs of arbitration, reasonable attorneys’
fees and reasonable costs for any expert and other witnesses.

 

		(e)	Nothing in this Agreement shall be deemed as preventing
either party from seeking injunctive relief (or any other provisional remedy) from any court having jurisdiction over the parties
and the subject matter of the Dispute as necessary to protect either party’s name, Confidential Information or Intellectual
Property.

 

		(f)	Judgment upon the award may be entered in any court having jurisdiction, or application may
                                                                                                     be made to such court for judicial acceptance of the award and/or an order of enforcement as the case may be.

 

		(g)	Notwithstanding the provisions of Subsections 19.2(b) through
19.2(f), inclusive, in the event of a Dispute relating to the compliance by NeoRx (or its marketing partner or sublicensee, as
the case may be) with the development requirements under Section 2.1 or the commercialization requirements under Section 4.1,
the evaluation process set out in Exhibit C shall apply.

 

		(h)	Notwithstanding the provisions of Subsections 19.2(b)
through 19.2(f), inclusive, either party shall be free to submit any Dispute relating to Intellectual Property to any court having
jurisdiction over the parties and the subject matter of the Dispute and to seek such relief and remedies as are available in that
court.

 

		19.3	Entire Agreement.

 

This Agreement and all Exhibits attached
to this Agreement (which shall form an integral part of this Agreement), entered into as of the date first written above, constitute
the entire agreement between the parties relating to the subject matter hereof and supersede all previous writings and understandings.
No terms or provisions of this Agreement shall be varied or modified by any prior or subsequent statement, conduct or act of either
of the parties, except that the parties may mutually amend this Agreement by written instruments specifically referring to and
executed in the same manner as this Agreement. In the event of conflict between the terms and conditions of this Agreement and
those of any Exhibit attached to this Agreement or any other agreement executed by the parties, the terms and conditions of this
Agreement shall govern, unless the parties expressly provide that the conflicting term or condition of such Exhibit or agreement
shall supersede the corresponding term or condition of this Agreement.

 

		19.4	Force Majeure.

 

If the performance of any part of this
Agreement by either party, or of any obligation under this Agreement, is prevented, restricted, interfered with or delayed by reason
of any cause beyond the reasonable control of the party liable to perform, unless conclusive evidence to the contrary is provided,
the party so affected shall, upon giving written notice to the other party, be excused from such performance to the extent of such
prevention, restriction, interference or delay, provided that the affected party shall use its reasonable commercial efforts to
avoid or remove such causes of non-performance and shall continue performance with the utmost dispatch whenever the causes are
removed. When such circumstances arise, the parties shall discuss what, if any, modification of the terms of this Agreement may
be required in order to arrive at an equitable solution.

 

		19.5	Further Assurances.

 

The parties shall both execute and deliver
such further instruments and do such further acts as may be required to implement the intent of this Agreement.

 

		19.6	Governing Law.

 

This Agreement shall be governed by the
laws of the State of Washington and the United States of America applicable without regard to conflict of law provisions contained
therein.

 

    	 	- 35 -	 

     

    

 

		19.7	Insurance.

 

Commencing at the time of NeoRx’
initial clinical testing of a Licensed Product, NeoRx shall maintain liability insurance with respect to its activities under the
Development Program and any other development activities at commercially reasonable and appropriate levels. NeoRx currently maintains,
with respect to clinical development-related activities, insurance coverage in an amount equal to US$10,000,000 per occurrence.
NeoRx shall maintain such insurance for so long as it conducts activities under the Development Program or any other development
activities. NeoRx’ general liability insurance shall name AnorMED as an additional insured. Upon request, NeoRx shall provide
AnorMED with evidence of such insurance coverage.

 

		19.8	Notices.

 

All notices in connection with this Agreement
shall be in writing and shall be:

 

		(a)	delivered personally; or

 

		(b)	mailed by registered or certified mail (return receipt
requested and postage prepaid); or

 

		(c)	sent by express courier service (receipt verified); or

 

		(d)	sent by facsimile transmission (with confirmation notice
sent as described above);

 

to the following addresses of the parties:

 

	If to AnorMED:	 	If to NeoRx:
	 	 	 	 
	 	AnorMED Inc.	 	 	NeoRx Corporation.
	 	#200 - 20353 64th Ave	 	 	300 Elliott Avenue West, Suite 500
	 	Langley, British Columbia	 	 	Seattle, Washington
	 	Canada V2Y 1N5 	 	 	USA 98119-4114
	 	 	 	 	 
	 	Attention:	President and	 	 	Attention:	Chief Executive Officer
	 	 	Chief Executive Officer	 	 	 	 
	 	 	 	 	 	Facsimile:	(206) 286-2537
	 	Facsimile:	(604)530-0976	 	 	 	 
	 	 	 	 	With a copy to the NeoRx Legal Department.

 

Any notice shall be deemed to have been
received:

 

		(e)	on the date of delivery, if delivered personally or by
express courier; or

 

		(f)	on the fifth Business Day following the date of mailing if sent by registered or certified
                                                                             mail; or

 

		(g)	on the next Business Day following the date of transmission
if sent by facsimile transmission.

 

		19.9	Change of Address.

 

Either party may, at any time, give notice
of any change of address to the other and the address specified in the notice shall be that party’s address for the purpose
of receiving notices.

 

		19.10	Rights and Remedies.

 

The rights and remedies available under
this Agreement shall be cumulative and not alternative and shall be in addition to and not a limitation of any rights and remedies
otherwise available to the parties at law or in equity.

 

		19.11	Severability.

 

In the event any portion of this Agreement
shall be held illegal, void or ineffective, the remaining portions of this Agreement shall remain in full force and effect. If
any of the terms or provisions of this Agreement are in conflict with any applicable statute or rule of law, then such terms or
provisions shall be deemed inoperative to the extent that they may conflict therewith and shall be deemed to be modified to conform
with such statute or rule of law.

 

    	 	- 36 -	 

     

    

 

		19.12	Counterparts; Facsimile.

 

This Agreement may be executed in any number
of counterparts (either originally or by facsimile), each of which shall be deemed to be an original and all of which taken together
shall be deemed to constitute one and the same instrument.

 

IN WITNESS WHEREOF, each of the parties
hereto has caused this Agreement to be executed by its duly authorized officer as of the date first written above.

  

	ANORMED INC.	 	NEORX CORPORATION
	by its authorized signatory:	 	by its authorized signatory:
	 	 	 
	/s/ Michael J. Abrams	 	/s/ Jack  L. Bowman
	Name:	Michael J. Abrams	 	Name: 	Jack  L. Bowman
	Title:	President & CEO	 	Title:	Chairman and CEO

 

    	 	- 37 -	 

     

    

 

EXHIBIT A

ANORMED PATENTS

 

The Patents set out on the following tables comprise the AnorMED
Patents:

 

	
        TABLE I:

        Patent Family: AnorMED Reference No.
        20010 Portfolio

        Title: PLATINUM COMPLEXES

         

	Reference No.	 	Filing Date	 	Application No.	 	Issue Date	 	
        Expiration

        Date
	 	Issued Patent No.
	20010.00 (United States)	 	7-Feb-96	 	597,953	 	9-Sep-97	 	7-Feb-2016	 	5,665,771
	20010.40 (Australia)	 	31-Jan-96	 	42258/96	 	4-Nov-99	 	31-Jan-2016	 	707814
	20010.41 (Canada)	 	7-Feb-96	 	2,169,019	 	4-Feb-03	 	7-Feb-2016	 	2,169,019
	20010.42 (EPC)	 	29-Jan~96	 	96300601	 	13-Jun-01	 	29-Jan-2016	 	0727430
	20010.43 (Finland)	 	14-Feb-96	 	96/0660	 	 	 	 	 	 
	20010.44 (Japan)	 	14-Feb-96	 	8-26935	 	10-Aug-01	 	24-Feb-2016	 	03219235
	20010.45 (S Korea)	 	12-Feb-96	 	96-3292	 	25-May-02	 	12-Feb-2016	 	339866
	20010.46 (Mexico)	 	13-Feb-96	 	96.0589	 	22-Nov-99	 	13-Feb-2016	 	194214
	20010.47 (New Zealand)	 	7-Feb-96	 	280946	 	6-Oct-97	 	7-Feb-2016	 	280946
	20010.48 (Norway)	 	13-Feb-96	 	1996.0569	 	25-Apr-00	 	13-Feb-2016	 	307.569
	20010.49 (S Africa)	 	5-Feb-96	 	96/0885	 	30-0ct-96	 	5-Feb-2016	 	96/0885
	20010.50 (Taiwan)	 	7-Feb-96	 	85101525	 	26-Sep-01	 	6-Feb-2016	 	NI-133176
	20010.51 (Hong Kong)	 	29-Jan-96	 	98113066.5	 	S-Feb-02	 	29-Jan-2016	 	HK1011997
	20010.52 (Austria)	 	29-Jan-96	 	96300601	 	13-Jun-01	 	29-Jan-2016	 	0727430
	20010.53 (Belgium)	 	29-Jan-96	 	96300601	 	13-Jun-01	 	29-Jan-2016	 	0727430
	20010.54 (Denmark)	 	29-Jan-96	 	96300601	 	13-Jun-01	 	29-Jan-2016	 	0727430
	20010.55 (France)	 	29-Jan-96	 	96300601	 	13-Jun-01	 	29-Jan-2016	 	0727430
	20010.56 (Germany)	 	29-Jan-96	 	96300601	 	13-Jun-01	 	29-Jan-2016	 	P 696 13 254.0-08
	20010.57 (Greece)	 	29-Jan-96	 	96300601	 	13-Jun-01	 	29-Jan-2016	 	20010401373
	20010.58 (Ireland)	 	29-Jan-96	 	96300601	 	13-Jun-01	 	29-Jan-2016	 	0727430
	20010.59 (Italy)	 	29-Jan-96	 	96300601	 	13-Jun-01	 	29-Jan-2016	 	0727430
	20010.60 (Luxembourg)	 	29-Jan-9 6	 	96300601	 	13-Jun-01	 	29-Jan-2016	 	0727430
	20010.61 (Netherlands)	 	29-Jan-96	 	96300601	 	13-Jun-01	 	29-Jan-2016	 	0727430
	20010.62 (Portugal)	 	29-Jan-96	 	96300601	 	13-Jun-01	 	2 9-Jan-2016	 	0727430
	20010.63 (Spain)	 	29-Jan-96	 	96300601	 	13-Jun-01	 	29-Jan-2016	 	0727430
	20010.64 (Sweden)	 	29-Jan-9 6	 	96300601	 	13-Jun-01	 	29-Jan-2016	 	0727430
	20010.65 (Switzerland)	 	29-Jan-96	 	96300601	 	13-Jun-01	 	29-Jan-2016	 	0727430
	20010.66 (Great Britain)	 	29-Jan-96	 	96300601	 	13-Jun-01	 	29-Jan-2016	 	0727430

 

     

     

    

 

	
        TABLE II:

        Patent Family: AnorMED Reference No.
        20036 Portfolio

        Title: PROCESS FOR PREPARING AMINE PLATINUM
        COMPLEXES

         

	Reference No.	 	Filing Date	 	Application No.	 	Issue Date	 	
        Expiration

        Date
	 	Issued Patent No.
	30036.00 (U.S. Provisional)	 	13-Apr-99	 	60/128,939	 	 	 	 	 	 
	20036.00 (United States)	 	11-Apr-00	 	09/547,074	 	11-Feb-03	 	11-Apr-2020	 	6,518,428
	20036.20 (United States)	 	4-Oct-00	 	09/679,952	 	2-Jul-02	 	11-Apr-2020	 	6,413,953
	20036.40 (PCT)	 	1 1-Apr-00	 	PCT/CA00/00385	 	 	 	 	 	 
	20036.41 (Argentina)	 	12-Apr-00	 	P 00 01 01 696	 	 	 	 	 	 
	20036.42 (Bangladesh)	 	12-Apr-00	 	81/2000	 	23 Aug 02	 	13-Apr-2015	 	1003443
	20036.43 (Malaysia)	 	12-Apr-00	 	PI 20001537	 	 	 	 	 	 
	20036.44 (Pakistan)	 	12-Apr-00	 	320/2000	 	 	 	 	 	 
	20036.45 (Philippines)	 	12-Apr-00	 	1-2000-00898	 	 	 	 	 	 
	20036.46 (Taiwan)	 	23-Jun-00	 	89112556	 	 	 	 	 	 
	20036.47 (Thailand)	 	11-Apr-00	 	56822	 	 	 	 	 	 
	* 20036.49 (Taiwan)	 	12-Dec-00	 	89126493	 	 	 	 	 	 
	* 20036.50 (Argentine)	 	11-Apr-01	 	P 01 01 01 742	 	 	 	 	 	 
	* 20036.51 (Bangladesh)	 	8-Apr-01	 	110/2001	 	 	 	 	 	 
	* 20036.52 (Malaysia)	 	11-Apr-00	 	PI 20011740	 	 	 	 	 	 
	* 20036.53 (Pakistan)	 	11-Apr-01	 	340/2001	 	 	 	 	 	 
	* 20036.54 (Philippines)	 	11-Apr-01	 	1-2001-00909	 	 	 	 	 	 
	* 20036.55 (Thailand)	 	11-Apr-01	 	64949	 	 	 	 	 	 
	* 20036.56 (Venezuela)	 	11-Apr-01	 	781-2001	 	 	 	 	 	 
	* 20036.57 PCT	 	11-Apr-01	 	PCT/CA01/00518	 	 	 	 	 	 
	20036.58 (Australia)	 	11 -Apr-00	 	39510/00	 	 	 	 	 	 
	20036.59 (Bulgaria)	 	11 -Apr-00	 	106 090	 	 	 	 	 	 
	20036.60 (Brazil)	 	11 -Apr-00	 	PI0009780-2	 	 	 	 	 	 
	20036.61 (Canada)	 	11-Apr-00	 	2,368,849	 	 	 	 	 	 
	20036.62 (China)	 	11 -Apr-00	 	807635.9	 	 	 	 	 	 
	20036.63 (Czech republic)	 	11-Apr-00	 	PV 2001-3648	 	 	 	 	 	 
	20036.64 (Estonia)	 	11-Apr-00	 	0536/01PC	 	 	 	 	 	 
	20036.65 (EPC)	 	11-Apr-00	 	EP 00918620.6	 	 	 	 	 	 
	20036.66 (Hungary)	 	11-Apr-00	 	P0200748	 	 	 	 	 	 
	20036.67 (Indonesia)	 	11-Apr-00	 	W00200102330	 	 	 	 	 	 
	20036.68 (Israel)	 	11-Apr-00	 	145671	 	 	 	 	 	 

 

    	 	- 2 -	 

     

    

 

	
        TABLE II:

        Patent Family: AnorMED Reference No.
        20036 Portfolio

        Title: PROCESS FOR PREPARING AMINE PLATINUM
        COMPLEXES

         

	Reference No.	 	Filing Date	 	Application No.	 	Issue Date	 	
        Expiration 

        Date
	 	Issued Patent No.
	20036.69 (India)	 	11-Apr-00	 	IN/PCT/2001/01005	 	 	 	 	 	 
	20036.70 (Iceland)	 	11-Apr-00	 	6092	 	 	 	 	 	 
	20036.71 (Japan)	 	11-Apr-00	 	2000-610861	 	 	 	 	 	 
	20036.72 (South Korea)	 	11-Apr-00	 	10-2001-7013049	 	 	 	 	 	 
	20036.73 (Mexico)	 	11-Apr-00	 	PA/A/2001/010430	 	 	 	 	 	 
	20036.74 (Norway)	 	11-Apr-00	 	2001 4957	 	 	 	 	 	 
	20036.75 (New Zealand)	 	11-Apr-00	 	514736	 	 	 	 	 	 
	20036.76 (Poland)	 	11-Apr-00	 	P351612	 	 	 	 	 	 
	20036.77 (Russian Fed.)	 	11-Apr-00	 	2001130457	 	 	 	 	 	 
	20036.78 (Singapore)	 	11-Apr-00	 	200105839-5	 	 	 	 	 	 
	20036.79 (Slovakia)	 	11-Apr-00	 	PV 1468-2001	 	 	 	 	 	 
	20036.80 (Ukraine)	 	11-Apr-00	 	2001117756	 	 	 	 	 	 
	20036.81 (South Africa)	 	11-Apr-00	 	20017965	 	 	 	 	 	 
	20036.82 (Hong Kong)	 	4-Feb-02	 	02100835.7	 	 	 	 	 	 

 

* Note: 20036.49 – 20036.57 Applications are either abandoned
or lapsed.

 

	
        TABLE III:

        Patent Family: AnorMED Reference No.
        20043 Portfolio

        Title: Platinum Compounds as Antitumor
        Agents

         

	Reference No.	 	Filing Date	 	Application No.	 	Issue Date	 	
        Expiration

        Date
	 	Issued Patent No.
	20043.00 (United States)	 	4-Oct-00	 	09/678,595	 	 	 	 	 	 
	20043.40 (PCT)	 	2-Oct-0l	 	PCT/US01/30838	 	 	 	 	 	 
	* 20043.41 (Taiwan)	 	12-Dec-00	 	89126491	 	 	 	 	 	 
	* 20043.42 (Argentina)	 	3-Oct-0l	 	P 010104672	 	 	 	 	 	 
	* 20043.43 (Bangladesh)	 	4-Oct-00	 	236/01	 	 	 	 	 	 
	*20043.44 (Malaysia)	 	4-Oct-00	 	PI 20014645	 	 	 	 	 	 
	* 20043.45 (Pakistan)	 	3-Oct-0l	 	937/2001	 	 	 	 	 	 
	*20043.46 (Thailand)	 	2-Oct-0l	 	68750	 	 	 	 	 	 
	* 20043.47 (Venezuela)	 	2-Oct-0l	 	2079-2001	 	 	 	 	 	 
	20043.48 (EPC)	 	2-Oct-0l	 	01975671.7	 	 	 	 	 	 
	20043.49 (Japan)	 	2-Oct-0l	 	2002-532453	 	 	 	 	 	 
	20043.50 (South Korea)	 	2-Oct-0l	 	10-2003-7004780	 	 	 	 	 	 

 

* Note: 20043.41-20043.47 are either abandoned or lapsed.

 

    	 	- 3 -	 

     

    

 

	
        TABLE IV:

        Patent Family: AnorMED Reference No.
        20062 Portfolio

        Title: Combination Chemotherapy

         

	Reference No.	 	Filing Date	 	Application No.	 	Issue Date	 	
        Expiration

        Date
	 	Issued Patent No.
	20062.00 (United States)	 	10-May-2001	 	10/276,503	 	 	 	 	 	 
	20062.41 (PCT)	 	10-May-01	 	PCT/GB01/02060	 	 	 	 	 	 
	20062.42 (Argentina)	 	10-May-01	 	01 01 02214	 	 	 	 	 	 
	20062.43 (Malaysia)	 	3-May-01	 	PI 2001 2142	 	 	 	 	 	 
	20062.45 (Pakistan)	 	10-May-01	 	0424/2001	 	 	 	 	 	 
	20062.46 (Thailand)	 	9-May-01	 	65376	 	 	 	 	 	 
	20062.47 (Taiwan)	 	21-May-01	 	90112094	 	 	 	 	 	 
	20062.48 (Venezuela)	 	10-May-01	 	982-2001	 	 	 	 	 	 
	20062.49 (Bangladesh)	 	8-May-01	 	128/2001	 	 	 	 	 	 
	20062.50 (EPC)	 	10-May-01	 	01925764.1	 	 	 	 	 	 
	20062.51 (Australia)	 	10-May-01	 	2001252442	 	 	 	 	 	 
	20062.52 (Bulgaria)	 	10-May-01	 	107281	 	 	 	 	 	 
	20062.53 (Brazil)	 	10-May-01	 	PI0110837-9	 	 	 	 	 	 
	20062.54 (Canada)	 	10-May-01	 	2,410,067	 	 	 	 	 	 
	20062.55 (China)	 	10-May-01	 	01809337.X	 	 	 	 	 	 
	20062.56 (Czech Republic)	 	10-May-01	 	PV2002-3766	 	 	 	 	 	 
	20062.57 (Estonia)	 	10-May-01	 	P200200648	 	 	 	 	 	 
	20062.58 (Hong Kong)	 	5-Mar-03	 	03101630.1	 	 	 	 	 	 
	20062.59 (Hungary)	 	10-May-01	 	P 0302130	 	 	 	 	 	 
	20062.60 (Indonesia)	 	10-May-01	 	W00200202607	 	 	 	 	 	 
	20062.61 (Israel)	 	10-May-01	 	151959	 	 	 	 	 	 
	20062.62 (India)	 	10-May-01	 	IN/PCT/2002/01241	 	 	 	 	 	 
	20062.63 (Iceland)	 	10-May-01	 	6571	 	 	 	 	 	 
	20062.64 (Japan)	 	10-May-01	 	2001-583780	 	 	 	 	 	 
	20062.65 (South Korea)	 	10-May-01	 	10-2002-7015404	 	 	 	 	 	 
	20062.66 (Mexico)	 	10-May-01	 	PA/A/2002/011247	 	 	 	 	 	 
	20062.67 (Norway)	 	10-May-01	 	20025502	 	 	 	 	 	 
	20062.68 (New Zealand)	 	10-May-01	 	521632	 	 	 	 	 	 
	20062.69 (Poland)	 	10-May-01	 	151959	 	 	 	 	 	 
	20062.70 (Russian Fed.)	 	10-May-01	 	2002133963	 	 	 	 	 	 
	20062.71 (Singapore)	 	10-May-01	 	200206341-0	 	 	 	 	 	 

 

    	 	- 4 -	 

     

    

 

	
        TABLE IV:

        Patent Family: AnorMED Reference No.
        20062 Portfolio

        Title: Combination Chemotherapy

	Reference No.	 	Filing Date	 	Application No.	 	Issue Date	 	
        Expiration

        Date
	 	Issued Patent No.
	20062.72 (Slovakia)	 	10-May-01	 	PP-1639-2002	 	 	 	 	 	 
	20062.73 (Ukraine)	 	10-May-01	 	20021210043/M	 	 	 	 	 	 
	20062.74 (South Africa)	 	10-May-01	 	2002/9279	 	 	 	 	 	 

 

    	 	- 5 -	 

     

    

 

EXHIBIT
B

DEVELOPMENT
PROGRAM

 

The Development Program shall include the
following clinical studies:

 

		1.	A Phase I safety and pharmacology study with an oral formulation
of AMD473; and

 

		2.	A Phase II study to confirm and/or demonstrate activity
in a cancer indication with an intravenous formulation of AMD473.

 

     

     

    

 

EXHIBIT
C

EVALUATION
PROCESS

 

Evaluation of Commercialization Activities.

 

		1.	Each party shall select
                                         a mutually acceptable person as an independent evaluator (each an “Evaluator”)
                                         and the two selected Evaluators shall select a mutually acceptable third Evaluator, to
                                         conduct the evaluation set forth in Section 2 of this Exhibit C. If the parties
                                         cannot agree on the choice of Evaluators, the selecting authority shall be the British
                                         Columbia International Commercial Arbitration Centre.

 

		2.	Unless the parties mutually agree otherwise, the following
rules and procedures shall govern the conduct of the parties and the Evaluators before and during the investigation by the Evaluators:

 

		(a)	within 30 days after the selection of the Evaluators, NeoRx
shall provide to the Evaluators and AnorMED a written summary of its position. Upon receipt of NeoRx’ summary, AnorMED shall
have 15 days to prepare and submit to NeoRx and the Evaluators its own summary in reply to the summary submitted by NeoRx; and

 

		(b)	on receipt of the summaries and any other documents,
statements or records submitted by the parties, the Evaluators shall have 30 days within which to conduct such further inquiries
as the Evaluators may deem necessary for the purpose of reviewing the efforts made by NeoRx with respect to:

 

		(i)	the development of the Licensed Products in compliance
with the requirements of Section 2.1; or

 

		(ii)	the promotion, marketing, sale or other commercialization
of the Licensed Products in compliance with the requirements of Section 4.1.

 

For the purpose of conducting such an inquiry,
the Evaluators shall have the right to:

 

		(iii)	require either party to disclose any further documents
or records which the Evaluators consider to be relevant;

 

		(iv)	interview or question either orally (or by way of written
questions) one or more representatives of either party on issues deemed to be relevant by the Evaluators;

 

		(v)	make an "on site" inspection of NeoRx’
facilities; and

 

		(vi)	obtain if necessary, the assistance of an independent expert
to provide technical information with respect to any area in which the Evaluators do not have a specific expertise.

 

		3.	The Evaluators shall within 30 days after starting the
inquiry, prepare a report setting out the Evaluators’ findings and conclusions as to whether or not NeoRx is in breach of
Section 2.1 or Section 4.1, as the case may be. If the Evaluators determine that NeoRx is in breach, then the Evaluators shall
specify in the report the Evaluators’ conclusions as to what additional measures may be required to achieve compliance with
Section 2.1 or Section 4.1, as the case may be, and NeoRx shall thereafter make the efforts so specified. If NeoRx fails to make
such efforts, after notice of termination for breach provided in accordance with the terms of Section 14.4, then AnorMED’s
sole remedy for NeoRx’ failure to make the efforts specified in Section 2.1 or Section 4.1, as the case may be, shall be
that this Agreement may be terminated in accordance with Section 14.4.

 

		4.	The report and conclusions of the Evaluators shall be delivered
to NeoRx and AnorMED, and shall be accepted by both parties as final and binding.

 

     

     

    

 

		5.	AnorMED may not call for more than one evaluation pursuant
hereto in any two (2) calendar year period. The cost of an evaluation hereunder shall be borne 50% by NeoRx and 50% by AnorMED.

 

    	 	- 2 -	 

     

    

 

EXHIBIT D

PRESS RELEASE

 

     

     

    

 

		
        AnorMED Inc.

        200 - 20353 64th Ave

        Langley, British Columbia

        Canada V2Y 1N5
	
         

        TEL (604) 530-1057

        FAX (604) 530-0976

        www.anormed.com

 

PRESS RELEASE

 

ANORMED LICENSES CANCER COMPOUND TO NEORX

 

	For Immediate Release:	April 5, 2004

 

Vancouver, British Columbia - AnorMED Inc. (TSX:AOM)
today announced that it has licensed its platinum based anti-cancer agent, AMD473, to NeoRx Corporation (NASDAQ: NERX). Under the
terms of the agreement, NeoRx was granted exclusive global rights, excluding Japan, to develop, manufacture and commercialize the
drug candidate for treatment of any human disease. NeoRx plans to initiate clinical studies for AMD473 in one or more cancer indications
in the second half of 2004.

 

Under the terms of the agreement, AnorMED received a one-time
upfront milestone payment of US$1 million cash and US$1 million in NeoRx common stock. In addition, AnorMED is eligible to receive
additional milestone payments of up to US$13 million, payable in cash or a combination of cash and NeoRx common stock. Upon an
approval AnorMED would receive royalty payments of up to 15% on product sales.

 

“Our partnership with NeoRx is an important milestone
for us. NeoRx has both the clinical capabilities and resources to advance the development of this drug candidate for its potential
to become an important new platinum chemotherapeutic. We look forward to working with the NeoRx team,” stated Dr. Michael
J. Abrams, President and CEO of AnorMED.

 

AMD473 is a platinum based chemotherapeutic agent with a proven
mechanism of action that has demonstrated clinical activity in hormone resistant prostate cancer, among other solid tumor cancers.
In addition, AMD473 has the potential to be developed as both intravenously and orally administerable chemotherapy.

 

NeoRx is a cancer therapeutics development company with headquarters
in Seattle, WA and pharmaceutical manufacturing facilities in Denton, TX. In March 2004 NeoRx began a phase III pivotal trial of
its lead therapeutic candidate, STRTM (Skeletal Targeted Radiotherapy), in patients with multiple myeloma, a cancer of the
bone marrow. NeoRx is developing STR for use with high-dose chemotherapy and autologous stem cell transplantation to treat multiple
myeloma and other cancers where stem cell transplantation is indicated.

 

AnorMED is a chemistry-based biopharmaceutical company focused
on the discovery and development of new small molecule therapeutics for the treatment of cancer and HIV, among others. The Company
has four clinical products in development and a research program focused on a novel class of compounds that target specific chemokine
receptors known to be involved in a variety of diseases.

 

-more-

 

     

     

    

 

AMD473
NeoRx 04/05/04

 

Over the course of 2004, AnorMED plans to complete Phase II
trials in AMD3100 for stem cell transplantation and hold an end of Phase II meeting with the FDA. AnorMED will also initiate further
trials for AMD070 in HIV patients. In addition, the Company expects to file an Investigational New Drug application to begin human
clinical trials for AMD3100 in heart attack patients. Information on AnorMED Inc. is available on the Company’s website:
www.anormed.com.

 

Note: Certain of the statements contained in this press release
contain forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance
or achievements expressed or implied by such forward-looking statements. The Company does not expect to update forward-looking
statements continually as conditions change. Investors are referred to the full discussion of risk factors associated with the
Company‘s business contained in the Company's Short Form Prospectus filed with securities regulatory authorities dated December
17, 2003.

 

For further information:

Elisabeth Whiting, M.Sc.

Senior Director, Corporate Development

& Communications

Office : (604) 532-4667

Direct: (604) 763-4682

e-mail: ewhiting@anormed.com

 

     

     

    

 

 

 

For Immediate Release

 

NEORX ACQUIRES CANCER COMPOUND FROM ANORMED

 

Acquisition broadens product pipeline
and complements

STRTM development program

 

Seattle, April 5, 2004 — NeoRx Corporation (NASDAQ:
NERX) today announced that it has acquired from AnorMED Inc. (TSX: AOM) the worldwide exclusive rights, excluding Japan, to develop,
manufacture and commercialize AMD473, a platinum-based anti-cancer agent. AMD473 has been administered to more than 500 cancer
patients in phase I and phase II clinical trials, demonstrating anti-cancer activity in a wide range of tumors and a manageable
safety profile. NeoRx expects to initiate clinical studies of AMD473 in one or more cancer indications in the second half of this
year.

 

“The acquisition of AMD473 fits our strategic focus on
broadening our drug development pipeline with a compound that has already proven effective in early stage trials,” said Jack
L. Bowman, Chairman and CEO of NeoRx. “Furthermore, we believe that the AMD473 development program is highly complementary
to our STRTM program and we have the clinical staff and financial resources to move forward with AMD473 clinical development,
while conducting our phase III trial with STR. We are also very satisfied with this transaction’s terms, which allow us to
reserve our financial resources for product development. All-in-all, we believe that the acquisition of AMD473 will prove to be
beneficial for our Company and our shareholders”

 

Under the terms of the agreement, NeoRx paid AnorMED a one-time
upfront milestone payment of $1 million in NeoRx common stock and $1 million in cash. The agreement also provides for additional
milestone payments to AnorMED of up to $13 million, payable in cash or a combination of cash and NeoRx common stock. Upon regulatory
approval, AnorMED would receive royalty payments of up to 15% on product sales.

 

Under the agreement, NeoRx has acquired an exclusive license,
under a portfolio of issued patents and patent applications, to develop, manufacture and commercialize AMD473. The patent portfolio
relates to composition of matter, formulations and methods of use of AMD473 and related analogs and compounds, and includes issued
patents and patent applications in ail major countries. The agreement also transfers to NeoRx certain know-how pertaining to AMD473,
including clinical and manufacturing data, regulatory submissions, and related information. Also under the agreement, AnorMED will
transfer to NeoRx an inventory of finished AMD473 suitable for use in clinical studies.

 

     

     

    

 

Philip S. Schein, MD, Chairman of NeoRx's Scientific Advisory
Board, said, "In clinical studies to date, AMD473 appears to have a broader spectrum of activity than currently available
platinum-based drugs, and also shows anti-tumor activity in some platinum- resistant tumors in laboratory studies. Clinical studies
also have indicated that AMD473 has an acceptable safety profile, and reduced toxicity to the kidney and peripheral nervous system
associated with the widely used platinum drug cisplatin. AMD473 also is noteworthy for its potential, based on preclinical data,
to address the growing need for oral chemotherapeutics for out-patient treatment."

 

In phase I clinical studies of AMD473 as a single agent and
in combination with other cancer therapeutics, anti-tumor activity was observed in a broad range of cancers. In phase II monotherapy
studies of AMD473, objective responses were observed in hormone-resistant prostate cancer, and in second-line ovarian, breast,
and lung cancers, including platinum-resistant and platinum-sensitive cancers. Existing platinum agents such as cisplatin and oxaliplatin
exhibit nephrotoxicity and/or neurotoxicity. No clinically significant nephrotoxicity or neurotoxicity has been observed with AMD473
to date. Moreover, AMD473 has shown oral bioavailability and anti-tumor activity with oral administration in preclinical studies,
and has the potential to be the first platinum agent with both intravenous and oral formulations.

 

Platinum-based cancer drugs have gained broad use since their
introduction nearly 20 years ago. The platinum drugs cisplatin, carboplatin and oxaliplatin are widely used in combination therapies
for numerous tumor types. The worldwide market for platinum-based cancer drugs is estimated to be over $1 billion. However, available
platinum drugs have undesirable side effects and toxicities, which limit their use. There also remain a number of cancer indications
that are not well treated with existing platinum agents, and all currently approved platinum agents are administered intravenously.
There is a need to expand the spectrum of activities of platinum anti-tumor agents to other cancer types. An orally administered
platinum agent also could be of significant benefit in the chemotherapeutic setting.

 

About AnorMED

AnorMED is a chemistry-based biopharmaceutical company focused
on the discovery and development of new small molecule therapeutics for the treatment of cancer and HIV, among others. The company
has four clinical products in development and a research program focused on a novel class of compounds that target specific chemokine
receptors known to be involved in a variety of diseases.

 

About NeoRx

NeoRx is a cancer therapeutics development company with headquarters
in Seattle and pharmaceutical manufacturing facilities in Denton, Tex. In March 2004, the Company opened enrollment in a phase
III pivotal trial of its lead therapeutic candidate, STRTM (Skeletal Targeted Radiotherapy), in patients with multiple myeloma,
a cancer of the bone marrow. NeoRx is developing STR for use with high-dose chemotherapy and autologous stem cell transplantation
to treat multiple myeloma and other cancers where stem cell transplantation is indicated.

 

     

     

    

 

This release contains forward-looking statements relating
to the development of the Company's products, future operating results and strategic goals that are subject to certain risks and
uncertainties which could cause actual results to differ materially from those projected. The words “believe,” "expect,”
“intend,” "anticipate,” variations of such words, and similar expressions identify forward-looking statements,
but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance
and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause the Company’s
actual results to differ include early stage of AMD473’s development, whether results of later-stage clinical trials of AMD473
will further validate and support the safety and efficacy of any AMD473 product, uncertainties related to the timing and costs
of completing clinical trials, and the timing of regulatory approvals, ability of AMD473 to demonstrate greater benefits than currently
available platinum-based drugs, expected growth in demand for oral chemotherapeutics and ability of AMD473 to address that need,
NeoRx's ability to develop and commercialize AMD473 in a timely and cost-effective manner and other risks and uncertainties described
in NeoRx's current and periodic reports filed with the Securities and Exchange Commission, including NeoRx's Annual Report on Form
10-K for the year ended December 31, 2003. Readers are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement
to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated
events.

 

NeoRx and STR are trademarks or registered trademarks of NeoRx
Corporation in the United States and/or foreign countries.

 

© 2004 NeoRx Corporation. All Rights Reserved.

 

For Further Information:

 

	NeoRx Corporation	Lippert/Heilshorn & Associates, Inc.
	Melinda G. Kile	Jody Cain (jcain@lhai.com)
	Vice President, Finance	Bruce Voss (bvoss@lhai.com)
	206-286-2501	310-691-7100

 

###

 

     

     

    

 

Exhibit 1

 

AMENDMENT NO. 1 TO

LICENSE AGREEMENT

 

THIS AMENDMENT NO. 1 TO LICENSE AGREEMENT (this “Amendment”),
effective as of September 18, 2006 (the “Amendment Date”), is entered into between ANORMED INC, (“AnorMED”),
a corporation organized and existing under the laws of Canada and having an office at #200 - 20353 64th Ave, Langley,
BC Canada V2Y IN5, and PONIARD PHARMACEUTICALS, INC. (“Poniard”), a corporation organized and existing under
the laws of the State of Washington end having an office at 300 Elliott Avenue West, Suite 500, Seattle, WA 98119, with respect
to the following facts:

 

WHEREAS, AnorMED and Poniard (previously NeoRx
Corporation) entered into that License Agreement dated as of April 2, 2004 (the “License Agreement”).

 

WHEREAS, AnorMED and Poniard desire to amend
the License Agreement in certain respects, all on the terms and conditions set forth below.

 

NOW, THEREFORE, in consideration of the foregoing
premises and the mutual covenants set forth below, the parties hereby amend the License Agreement and otherwise agree as follows:

 

1.     Payments.
In consideration of the rights granted hereunder, Poniard shall pay to AnorMED the following amounts at the times ramified:

 

		1.1.	On or before October 16, 2006, Poniard shall pay to AnorMED
the sum of five million U.S. dollars (US$5,000,000).

 

		1.2.	On or before March 31, 2007, Poniard shall pay to AnorMED
an additional sum of five million U.S. dollars (US$5,000.000).

 

2.     Territory.
In connection with the expansion of the Territory pursuant to Section 3.5 of this Amendment, the parties acknowledge and agree
that the provisions in the License Agreement regarding providing information or rights to AnorMED’s licensees outside of
the Territory, shall only apply with respect to any countries if and when excluded from the Territory in accordance with Section
4.2 (Decision Not to Commercialize) of the License Agreement.

 

3.     Amendments

 

		3.1.	The License Agreement is hereby amended by replacing all
uses of “NeoRx Corporation” with “Poniard Pharmaceuticals, Inc.”, and replacing all uses of the defined
term “NeoRx” with “Poniard.”

 

		3.2.	Section 1.1(v) of the License Agreement is hereby amended
by adding the following new sentence immediately following the end of Section 1.1(v):

 

     

     

    

 

As used in this Agreement, “end user”
shall mean, with respect to a Licensed Product, the first Person, that has not obtained from Poniard any license rights under Section
3.1 other than the right to use, to which such Licensed Product is sold or otherwise transferred in an arm’s-length, good
faith transaction.

 

		3.3.	Section 1.1(dd) of the License Agreement is hereby amended
and replaced in its entirety with the following;

 

(dd) “Sublicensee” shall
mean any Person who has obtained license rights from Poniard under the license granted to Poniard under Section 3.1, including,
without limitation, sublicensees of Poniard and its Affiliates, sublicensees of such sublicensees (i.e. subsublicensees), distributors
and any other Person who may sell or otherwise transfer Licensed Product to end users (as defined in Section 1.1(v)) of the Licensed
Product, in each case under such license rights;

 

and each occurrence of the term “sublicensee” and “sublicensees”
set out in the License Agreement is hereby replaced with the defined terms “Sublicensee” and “Sublicensees”,
respectively.

 

		3.4.	Section 1.1(ee) of the License Agreement is hereby amended
and replaced in its entirety with the following:

 

		(ee)	(intentionally omitted);

 

		3.5.	Section 1.1(gg) of the License Agreement is hereby amended
and restated in its entirety as follows:

 

		(gg)	“Territory” shall mean world-wide;

 

		3.6.	Section 6.3 of the License Agreement is hereby amended
and restated in its entirety as follows:

 

		6.3	Milestone Payments

 

In consideration of the license granted under Article 3,
Poniard shall pay to AnorMED the following milestone payments upon the first occurrence of each of the commercialization milestones
set forth below:

 

		(a)	[intentionally omitted];

 

		(b)	[intentionally omitted];

 

		(c)	[intentionally omitted];

 

		(d)	US$2,000,000 upon achieving Net Sales by Poniard and its
Affiliates of US$50,000,000 in the United States for any or all Licensed Products; and

 

     

     

    

 

		(e)	US$3,000,000 upon achieving Net Sales by Poniard and its
Affiliates of US$100,000,000 in the United States for any or all Licensed Products.

 

For purposes of this Section 6.3, “control”
in the definition of Affiliate shall mean direct or indirect beneficial ownership of 35% or greater interest in the income of a
Person or such other relationship as, in fact, constitutes actual control.

 

		3.7.	Section 6.4, subsection (a) of the License Agreement is
hereby amended and restated in its entirety as follows:

 

[intentionally omitted];

 

		3.8.	3.8 Section 6.4, subsection (b) of the License Agreement
is hereby emended and restated in its entirety as follows;

 

Each milestone payment to be made by Poniard under Subsections 6_3(d)
and 6.3(e) shall be made in cash, by certified cheque payable to the order of Marisa], or by bank transfer to the co-ordinates
given by AnorMED to Poniard.

 

		3.9.	Section 7.2 of the License Agreement is hereby amended
and restated in its entirety as follows:

 

		7.2	Basic Royalty.

 

In consideration of the license granted under Article 3,
Poniard shall pay to AnorMED, without duplication, in respect of each Licensed Product:

 

		(a)	for all Patent Pending Counties where no Competition exists
and all Issued Patent Countries, a royalty on Net Sales of such Licensed Product by Poniard and its Affiliates and any Sublicenses
in each calendar year as follows:

 

		i.	five percent (5%) of the first one hundred million dollars
(US$100,000,000) of such Net Sales in the calendar year, calculated cumulatively among all Patent Pending Counties where no Competition
exists and all Issued Patent Countries, world-wide;

 

		ii.	six percent (6%) of such Net Sales in excess of the first
one hundred million dollars (US$100,000.000) but less than four hundred million dollars (US$400,000,000) in the calendar year,
where such amounts are calculated cumulatively among all Patent Pending Countries where no Competition exists and all Issued Patent
Counties, world-wide:

 

		iii.	eight Percent (8%) of such Net Sales in excess of the first
four hundred million dollars (US$400,000,000) but less than one billion dollars (US$ 1,000,000,000) in the calendar year, where
such amounts are calculated cumulatively among all Patent Pending Counties where no Competition exists and all Issued Patent Countries,
world-wide; and

 

		iv.	nine percent (9%) of such Net Sales in excess of one billion
dollars (USS1,000,000,000) in the calendar year, calculated cumulatively among all Patent Pending Counties where no Competition
exists and all Issued Patent Counties, world-wide; and

 

     

     

    

 

		(b)	for all Patent Pending Countries where Competition exists
and all Know-How Counties, a royalty on Net Sales of such Licensed Product by Poniard and its Affiliates and any Sublicensees
in each calendar year as follows

 

		i.	two and ono-half percent (2 1/2%) of the first one hundred
million dollars (US$100,000,000) of such Net Sales in the calendar year, calculated cumulatively among all Patent Pending Counties
where Competition exists and all Know-How Countries, world-wide;

 

		ii.	three percent (3%) of such Net Sales in excess of the
first one hundred million dollars (US$ 100,000,000) but less than four hundred million dollars (US$400,000,00) in the calendar
year, where such amounts are calculated cumulatively among all Patent Pending Countries where Competition exists and all Know-How
Countries, world-wide;

 

		iii.	four percent (4%) of such Net Sales in excess of the
first four hundred million dollars (US$400,000,000) but less than one billion dollars (US$1,000,000,000) in the calendar year,
where such amounts are calculated cumulatively among all Patent Pending Countries where Competition exists and all Know-How Countries,
world-wide; and

 

		iv.	four and one-half percent (4 1/2%) of such Net Sales
in excess alone billion dollars (US$1,000,000,000) in the calendar year, calculated cumulatively among all Patent Pending Counties
where Competition exists and all Know-How Counties, worldwide;

 

in each of Subsections 7.2(a) and 7.2(b), until, the later
of either:

 

		(c)	the date of expiration of the last Valid Claim within the
AnorMED Patents covering the Licensed Product in the country of manufacture or sale, as applicable; or

 

		(d)	the expiration of 10 years after First Commercial Sale
of such Licensed Product in the country of sale.

 

For the purposes of this Section 7.2:

 

		(e)	“Issued Patent Countries” shall mean any or
all countries in the Territory where the Licensed Product sold is covered by one or more Valid Claims within the AnorMED Patents
described in Paragraph 1.1(ii)(ii) of the definition of Valid Claim, either in the country of manufacture or in the county of
sale;

 

     

     

    

 

		(f)	“Patent Pending Countries” shall mean any or
all countries in the Territory where the Licensed Product sold is covered by one or more Valid Claims within the AnorMED Patents
described in Paragraph 1.1(ii)(i) of the definition of Valid Claim, but not a Valid Claim within the AnorMED Patents described
in Paragraph 1.1(ii)(ii) of the definition of Valid Claim either in the county of manufacture or in the country of sale; and

 

		(g)	“Know-How Countries” shall mean any or all
counties in the Territory where there is no Valid Claim either in the country of manufacture or in the country of sale, but AnorMED
Know How is necessary to make, have made, use, sell, offer for sale or import the Licensed Product, either in the country of manufacture
or in the country of sale; and

 

		(h)	“control” in the definition of Affiliate shall
mean direct and indirect beneficial ownership of 35% or greater interest in the income of a Person or such other relationship
as, in fact, constitutes actual control.

 

For purposes of clarification, no multiple royalties shall
be due or payable under this Section 7.2 because the sale or manufacture of any Licensed Product is or shall be covered by more
than one Valid Claim within the AnorMED Patents in the country of manufacture and/or the country of sale.

 

		3.10.	Section 73 of the License Agreement is hereby amended
and restated in its entirety as follows:

 

		7.3	Sublicensing Royalty

 

		(a)	In this Section 7.3:

 

(i)          “Development
Milestone Payments” shall mean all revenues, receipts, monies, milestone payments and research and development fees (in respect
of research and development fees. only to the extent that same are in excess of reimbursement for the direct costs and Indirect
Costs of research and development or pursuit of Regulatory Approval undertaken by Poniard or its Affiliates pursuant to a written
research or development plan), payments (including amounts received from the sale of shares in the capital stock of Poniard in
excess of the Current Market Nee for such shares), license fees and the fair market value of all other consideration, collected
or received by Poniard or its Affiliates whether by way of cash, equity, credit or any barter, benefit, advantage, or concession,
that are contingent upon the achievement of an event or objective pursuant to a written research or development plan, and not merely
the passage of time, and shall exclude amounts collected or received by Poniard or its Affiliates on account of Net Sales of Licensed
Products;

 

     

     

    

 

(ii)         “Indirect
Costs” shall mean costs incurred for the benefit of the Development Program or the commercialization of a Licensed Product,
excluding directly identified costs (direct costs), and including facility rental costs; utilities costs; laboratory and manufacturing
equipment depreciation; and salaries, vacation pay, sick leave pay, health insurance premiums, FICA taxes (or their equivalent)
and pension costs for employees, but only to the extent that such employees work benefits the Development Program or the commercialization
of a Licensed Product; and

 

(iii)        “Upfront
Cash Payments” shall mean all revenues, receipts, monies and research and development fees (in respect of research and development
fees, only to the extent that same are in excess of reimbursement for the direct costs and Indirect Costs of research and development
or pursuit of Regulatory Approval undertaken by Poniard or its Affiliates pursuant to a written research . or development plan),
payments (including amounts received from the sale of shares in the capital stock of Poniard in excess of the Current Market Price
for such shares), license fees and the fair market value of all other consideration, collected or received by Poniard or its Affiliates
whether by way of cash, equity, credit or any barter, benefit, advantage, or concession, and shall exclude Development Milestone
Payments and amounts collected or received by Poniard or its Affiliates on account of Net Sales of Licensed Products.

 

		(b)	In consideration of the license granted under Article 3,
Poniard shall pay to AnorMED:

 

(i)          in
respect of any agreement entered into by Poniard or its Affiliates prior to March 18, 2007 for the sublicensing to a Third Party
of any of its rights granted under Section 31, a royalty of ten percent (10%) of all Upfront Cash Payments and Development Milestone
Payments received by Poniard under such agreement; and

 

(ii)         in
respect of any agreement entered into by Poniard or its Affiliates during the period following March 18, 2007 but prior to September
18, 2007 for the sublicensing to a Third Party of any of its rights granted under Section 3.1, a royalty of five percent (5%) of
all Upfront Cash Payments received by Poniard under such agreement.

 

		3.11.	Section 8.7(a)(i) of the License Agreement is hereby
4mended and restated in its entirety as follows:

 

(i)          in
the ease of Poniard, records of all sales of Licensed Products in the Territory, which shall show the manufacturing, sales, use
and other disposition of Licensed Products in sufficient detail to determine the royalties payable to AnorMED pursuant to Section
7.2 and 7.3, if any and

 

     

     

    

 

		3.12.	Section 10.1(6) of the License Agreement is hereby amended
by replacing the words ‘Subsections 7.2(a), 7.2(b) and 7.2(c)” on the sixth line thereof with the words “Subsections
7.2(a) and 7.2(b)”, and replacing the words “Subsection 7.2(d)” on the tenth line thereof with the words “Subsection
7.2(b)”, so as to read

 

		(b)	At any time during the Term, Poniard, in Poniard's sole
discretion, may determine that any particular Patent within the AnorMED Patents in any particular country in the Territory should
not be prosecuted or maintained for legal or commercial reasons and in such emit, shall so notify Anent/MD. Upon receipt of such
notice, any Patents identified in such notice shall remain or he deemed to remain within the AnorMED Patents for the purposes
of the grant of rights by AnorMED to Poniard pursuant to Article3 of this Agreement and Poniard's obligations pursuant to Subsections
7.2(a) and 7.2(h) for the payment of royalties for any such Patents shall remain unchanged and continue at the royalty rate for
such Patent as of the date of Poniard's notice to AnorMED, provided that where the discontinuance of the prosecution or maintenance
of the Patent is due to reasons of lack of patentability, invalidity or unenforceability of the Patent, Poniard's obligations
pursuant to Subsection 7.1(3) for the payment of royalties for AnorMED Know-How shall apply. AnorMED, at AnorMED's cost and expense
and in AnorMED's sole discretion, may continue prosecution and/or maintenance of any particular Patent i4unti.6ed in such notice.

 

		4.	Miscellaneous. All terms used, bat not &fined,
herein shall have the respective meanings set forth in the License Agreement Except as otherwise expressly modified by this Amendment,
the License Agreement shall remain in full force and effect in accordance with its terms. This Amendment shall be governed by
the laws of the State of Washington and the United States of America applicable without regard to conflict of law provisions contained
therein. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument

 

IN WITNESS WHEREOF, the parties have executed this Amendment effective
as of the Amendment Date.Exhibit 10.15

 

SECURITIES PURCHASE AGREEMENT

 

This Securities Purchase
Agreement (this “Agreement”) is dated as of [_______], 2016, between Accelerated Phanna, Inc., a Delaware corporation
(the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors
and permitted assigns, a “Purchaser” and collectively, the “Purchasers”).

 

WHEREAS, subject to the
terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the
“Securities Act”), and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser,
and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described
in this Agreement.

 

NOW, THEREFORE, IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of
which are hereby acknowledged, the Company and each Purchaser agree as follows:

 

ARTICLE I.

DEFINITIONS

 

1.1           Definitions.
In addition to the terms defined elsewhere in this Agreement: (a) capitalized terms that are not otherwise defined herein have
the meanings given to such terms in the Articles of Incorporation (as defined herein), and (b) the following terms have the meanings
set forth in this Section 1.1.

 

“Acquiring Person” shall have the meaning
ascribed to such term in Section 4.15.

 

“Action” shall have the meaning ascribed to such term in Section 3.1(j).

 

“Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under
common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Board of Directors” means
the board of directors of the Company.

 

“Business Day”
means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which
banking institutions in the State of New York are authorized or required by law or other governmental action to close.

 

“Closing” means a Closing
of the purchase and sale of the Securities pursuant to Section 2.1.

 

“Closing Date”
means the Business Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto,
and all conditions precedent to (i) the Purchasers’ obligation to pay the Subscription Amount at such Closing, and (ii) the
Company’s obligations to deliver the Securities to be issued and sold at such Closing, in each case, have been satisfied
or waived.

 

“Commission” means the United
States Securities and Exchange Commission.

 

“Common Stock” means the
common stock of the Company, $0.00001 par value per share, and any other class of securities into which such securities may hereafter
be reclassified or changed.

 

     1

     

    

 

“Common Stock
Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common
Stock.

 

“Company Counsel” means
Randy Saluck, Esq., c/o Accelerated Pharma, Inc., 15W155 81’ Street, Burr Ridge, IL 60527, fax: (630) 325-4179.

 

“Conversion Price” shall
have the meaning ascribed to such term in the Note.

 

“Conversion Shares” means
shares of the Company’s Common Stock issuable upon conversion of the Note and interest in accordance with the terms of the
Note.

 

“Disclosure Schedules” means
the Disclosure Schedules of the Company delivered concurrently herewith.

 

“End Date” shall have the
meaning ascribed to such term in Section 4.9.

 

“Equity Line of Credit” shall
have the meaning ascribed to such term in Section 4.9.

 

“Escrow Agreement” means
the escrow agreement to be employed in connection with the sale of the Securities, a copy of which is annexed hereto as Exhibit
C.

 

“Exchange Act” means the
Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Exempt Issuance” means the issuance of (a) shares of Common Stock and options to officers, directors, employees, or consultants of the Company
prior to and after the Closing Date in the amounts and on the terms set forth on Schedule 3.1(k), (b) securities upon the
exercise or exchange of or conversion of Securities issued hereunder (subject to adjustment for forward and reverse stock splits
and the like that occur after the date hereof) and/or other securities exercisable or exchangeable for or convertible into shares
of Common Stock issued and outstanding on the date of this Agreement, provided that such securities and any term thereof have not
been amended since the date of this Agreement to increase the number of such securities or to decrease the issue price, exercise
price, exchange price or conversion price of such securities and which securities and the principal terms thereof are set forth
on Schedule 3.1(g), (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested
directors of the Company, provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which
is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business
of the Company and shall be intended to provide to the Company substantial additional benefits in addition to the investment of
funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital
or to an entity whose primary business is investing in securities, and (d) securities issued or issuable pursuant to this Agreement,
the Note or the Warrants, or upon exercise or conversion of any such securities.

 

“FCPA” means the Foreign
Corrupt Practices Act of 1977, as amended.

 

“FDA” shall have the meaning ascribed
to such term in Section 3.1(11).

 

“FDCA” shall have the meaning
ascribed to such term in Section 3.1(11).

 

“Financial Statements” 
means the financial information annexed hereto as Schedule 3.1(h).

 

     2

     

    

 

“Fully-Diluted
Basis” means the assumption that all options, warrants or other convertible securities or instruments or other rights
to acquire Common Stock or any other existing or future classes of capital stock have been exercised or converted, as applicable,
in full, regardless of whether any such options, warrants, convertible securities or instruments or other rights are then vested
or exercisable or convertible in accordance with their terms.

 

“GAAP” shall
mean United States generally accepted accounting principals applied on a consistent basis.

 

“Going Public Event” shall
have the meaning ascribed to such term in Section 4.13.

 

“Indebtedness” shall have the meaning ascribed to such
term in Section 3.1(w).

 

“Intellectual Property Rights” shall Have the meaning ascribed to such term in Section 3.1(o).

 

“Liens” means a lien, charge,
pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction,

 

“Maioritv in Interest” shah
have the meaning ascribed to such ten;; in •Section 5.5

 

“Material Adverse Effect” shall
have the meaning assigned to such term in Section 3: (b).

 

“Material Permits” shall have the meaning ascribed
to such term in Section 3.1(m).

 

“Maximum Rate” shall have the meaning ascribed to such tern: in Section 5.17.

 

“Money Laundering. Laws” 
shall have the meaning ascribed to such term in Section 3.1(aa).

 

“Notes” means the convertible notes, in the
form of Exhibit A hereto.

 

“OFAC” shall have the meaning
ascribed to such term in Section 3.1(bb).

 

“Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited
liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Prior Offerings” means the offering by the Company of convertible notes and common stock purchase warrants on substantially similar, but not
identical terms as this offering for which closings took place as of December 23, 2014 for gross proceeds to the Company of $750,000,
as of May 8, 20:5 for gross proceeds of 52,050,000, as of June 11, 2015 for gross proceeds of 550,000, and as of November 6, 2015
for gross proceeds of 5500,000.

 

“Prior Offering
Transaction Documents” means, collectively, the Prior Offering Securities Purchase Agreement, Prior Offering Note, Prior
Offering Warrant, and Prior Offering Security Agreement.

 

“Prior Offering Note” means
the convertible notes issued in connection with the Prior Offerings,

 

“Prior Offerina
Purchasers” rneans the purchasers to the Prior Offerings.

 

“Prior Offering Securities Purchase
Agreements” means the securities purchase agreements employed in connection with the Prior Offerings.

 

     3

     

    

 

“Prior Offering Security Agreement” 
means the Amended and Restated Security Agreement dated as of May 8, 20:5 employed in connection with the Prior Offerings.

 

“Prior Offering Warrants” 
means the common stock purchase warrants issued in connection with the Prior Offerings.

 

“Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition, whether commenced or threatened.

 

“Public Company Date” means
not later than the 150th day after the Qualified Offering has been consummated.

 

“Purchaser Counsel” shall
mean Crushko & Mittman, P.C., 515 Rockaway Avenue, Valley Stream, New York 11581, facsimile: (212) 697-3575.

 

“Purchaser Partv” shall have
the meaning ascribed to such term in Section 4.6.

 

“Oualified Offering” 
means the first occurrence of an offering of the Company’s Common Stock which closes in one or more closings in connection
with which the Company receives not less than 55,000,000 of gross cash proceeds from the sale of Common Stock on or before November
15, 2016 by Palladium Capital Advisors, LLC pursuant to the terms of an investment banking agreement between the Company and Palladium
Capita: Advisors, LLC, and thereafter by the Company or other placement agent until the Maturity Date (as defined in the Note)
accelerated or otherwise,

 

“Regulation D” means Regulation
D under the Securities Act.

 

“Required Aporovals” shall
have the meaning ascribed to such term in Section 3.1(e).

 

“Required Minimum” 
means, as of any date, the maximum aggregate number of shares of Common Stock then issued or potentially issuable in the future
pursuant to the Transaction Documents, including but not limited to any Underlying Shares issuable upon conversion in full of the
Notes and the interest that could accrue through the term thereof and the Warrant Shares issuable upon exercise of the Warrants,
ignoring any conversion or exercise limits set forth therein.

 

“Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from
time to time, or any similar rule or regulation hereafter adopted by the Commission having( substantially the same purpose and
effect as such Rule.

 

“Second Amended
and Restated Security Agreement” means the Second Amended and Restated Security Agreement dated as of the date of this
Agreement, a copy of which is annexed hereto as Exhibit D.

 

“Securities” means the Notes,
the Warrants, and the Underlying Shares.

 

“Securities Act” 
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Subscriction
Amount” means, as to each Purchaser, the aggregate amount to be paid for the Notes and Warrants purchased hereunder as
specified below such Purchaser’s name on the signature page of this Agreement and next to the heading “Subscription
Amount,” in United States dollars and in immediately available funds.

 

     4

     

    

 

“Subsidiary” means with respect to any entity at any date, any direct or indirect corporation, limited or general partnership, limited liability
company, trust, estate, association, joint venture or other business entity of which (A) more than 50% of (i) the outstanding capital
stock having (in the absence of contingencies) ordinary voting power to elect a majority of the board of directors or other managing
body of such entity, (H) in the case of a partnership or limited liability company, the interest in the capital or profits of such
partnership or limited liability company or (Hi) in the case of a trust, estate, association, joint venture or other entity, the
beneficial interest in such trust, estate, association or other entity business is, at the time of determination, owned or controlled
directly or indirectly through one or more intermediaries, by such entity, or (B) is under the actual control of the Company. Representations,
undertakings and obligations set forth in this Agreement shall be applicable only to Subsidiaries which exist or have existed at
the applicable and relevant time.

 

“Termination Date” shall
have the meaning ascribed to such term in Section 2.1.

 

“Third Waiver
and Consent” means the agreement entered into by the Company and the requisite Prior Offering Purchasers sufficient to
cause it to be binding on the Company and all of the Prior Purchasers in the form annexed hereto as Exhibit F.

 

“Trading Day” means a day
on which the principal Trading Market is open for trading.

 

“Trading Market”
 means any of the following markets or exchanges: the NYSE MKT LLC, the Nasdaq Capital Market, the Nasdaq Global Market,
the Nasdaq Global Select Market, the New York Stock Exchange, the OTC Bulletin Board, the OTCQB, or the OTCQX (or any successors
to any of the foregoing).

 

“Transaction Documents” means this Agreement, the Notes, the Warrants, the Escrow Agreement, the Prior Offering Security Agreement, all exhibits and schedules
thereto and hereto, the Second Waiver and Consent, and any other documents or agreements executed in connection with the transactions
contemplated hereunder.

 

“Transfer Agent” means the
transfer agent for the Common Stock, and any successor transfer agent of the Company. As of the Closing Date, the Company is the
Transfer Agent.

 

“Underlying Shares” 
means the shares of Common Stock issued and issuable upon conversion of the Notes and payment of interest on the Notes in accordance
with the terms of the Notes and upon exercise of the Warrants in accordance with the terms of the Warrants.

 

“Variable Priced Equity Linked Instruments” 
shall have the meaning ascribed to such term in Section 4.9.

 

“Variable Rate
Transaction” shall have the meaning ascribed to such term in Section 4.9.

 

“Warrants” means the Common
Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Article!! hereof, in the form of Exhibit
B attached hereto.

 

“Warrant Shares” means the
shares of Common Stock issuable upon exercise of the Warrants.

 

     5

     

    

 

ARTICLE II.

PURCHASE AND SALE

 

2.1         Closing.
On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution
and delivery of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly,
agree to purchase, an aggregate of up to 51,500.000 principal amount of Notes and Warrants as determined pursuant to Section 2.2(a)
(such purchase and sale being the “Closing”. Each Purchaser shall deliver to the Company such Purchaser’s
Subscription Amount, and the Company shall deliver to each Purchaser its respective Note and Warrants, as determined pursuant
to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the
Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices
of G&M or such other location as the parties shall mutually agree. Notwithstanding anything herein to the contrary, the initial
Closing must take place on or before May 2, 2016. The Closing Date for the final Closing shall occur on or before June 30, 2016
(the “Termination Date”). With respect to any Closing not held on or before the Termination Date, the Company
shall cause all subscription documents and funds, if any, to be returned, without interest or deduction to each prospective Purchaser.
Notwithstanding of the date of any Closing subsequent to the initial Closing, all time effective clauses in the Transaction Documents
shall commence on the initial Closing Date and Transaction Documents will be deemed modified Mutatis Mutandum in connection
with such subsequent Closings, if any, that take place after the initial Closing. The ‘Maturity Date of the Notes issued
at all Closing subsequent to the initial Closing and the exercise period of the Warrants issued at such Closings shall be the
same as the Maturity Date of the Notes issued at the initial Closing and be co-terminous with the exercise period of the Warrants
issued at the initial Closing.

 

2.2         Deliveries.

 

(a)          On
or prior to a Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:

 

(i)          this
Agreement duly executed by the Company with the schedules and exhibits thereto current as of each such Closing Date;

 

(ii)         the
Second Amended and Restated Security Agreement duly executed by the Company;

 

(iii)        a
Note with a principal amount equal to such Purchaser’s Subscription Amount registered in the name of such Purchaser;

 

(iv)        Warrants
registered in the names of such Purchaser with an aggregate exercise price equal to fifty percent (50%) of such Purchaser’s
Subscription Amount, subject to adj UStITICIlt as provided therein;

 

(vi)        the
Escrow Agreement duly executed by the Company; and

 

(vi)        the
Third Waiver and Consent signed by the Prior Offering Purchasers and

Company.

 

(b)          On
or prior to a Closing Date, each Purchaser shall deliver or cause to be delivered to the Escrow Agent the following:

 

(i)          this
Agreement duly executed by such Purchaser;

 

     6

     

    

 

(ii)         the
Second Amended and Restated Security Agreement duly executed by such Purchaser;

 

(iii)        such
Purchaser’s Subscription Amount by wire transfer or as otherwise permitted under the Escrow Agreement, to the Escrow Agent;
and

 

(iv)        the
Escrow Agreement duly executed by such Purchaser.

 

2.3         Closing
Conditions.

 

(a)          The
obligations of the Company hereunder to effect a Closing are subject to the following conditions being met:

 

(i)          the
accuracy in all material respects (determined without regard to any materiality, Material Adverse Effect or other similar qualifiers
therein) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific
date therein in which case they shall be accurate as of such date);

 

(ii)         all
obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and

 

(iii)        the
delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.

 

(b)          The
respective obligations of a Purchaser hereunder to effect a Closing, unless waived by such Purchaser, are subject to the following
conditions being met:

 

(i)          the
accuracy in all material respects (determined without regard to any materiality, Material Adverse Effect or other similar qualifiers
therein) on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date
therein in which case they shall be accurate as of such date);

 

(ii)         all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed,

 

(iii)        the
Escrow Agent shall have received executed signature pages to this Agreement and aggregate Subscription Amount of $500,000 with
respect to the initial Closing and not less than $250,000 with respect to subsequent Closings;

 

(iv)        the
delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;

 

(v)         there
shall have been no Material Adverse Effect with respect to the Company since the date hereof; and

 

(vi)        from
the date hereof to each respective Closing Date, trading in securities in the United States generally as reported by Bloomberg
L.P. shall not have been suspended or limited, nor shall a banking moratorium have been declared either by the United States or
New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national or
international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each
case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.

 

     7

     

    

 

ARTICLE III.

REPRESENTATIONS AND WARRANTIES

 

3.1         Representations
and Warranties of the Company. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed
a part hereof and shall qualify any representation made herein to which it refers and any other representation to the extent such
Disclosure Schedule reasonably relates thereto without a requirement of a cross-reference. The Company hereby makes the following
representations and warranties to each Purchaser as of the date hereof and each Closing Date unless as of a specific date therein
in which case they shall be accurate as of such date:

 

(a)          Subsidiaries.
All of the direct and indirect subsidiaries of the Company and the Company’s ownership interests therein as of the date
of this Agreement are set forth on Schedule 3.1(a). The Company owns, directly or indirectly, all of the capital stock or
other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital
stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe
for or purchase securities. If the Company has no Subsidiaries relevant to any component of this Agreement as of a particular date,
then such reference shall not be applicable.

 

(b)          Organization
and Oualification. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly
existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company
nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation,
bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business
and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted
or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as
the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity
or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business,
prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse
effect on the Company’s ability to perform in any material respect on a timely basis its obligations under any Transaction
Document (any of (i), (H) or (Hi), a “Material Adverse Effect”) and, no Proceeding has been instituted in any
such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.

 

(c)         Authorization;
Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by
it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company
and no further action is required by the Company, the Board of Directors or the Company’s stockholders and creditors in connection
herewith or therewith other than in connection with the Required Approvals except those filings requires to be made with the Commission
and state agencies after the Closing Date. This Agreement and each other Transaction Document to which it is a party has been (or
upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof,
will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except:
(i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws
of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability
of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions
may be limited by applicable law.

 

     8

     

    

 

(d)          No
Conflicts. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents, the
issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby to which it
is a party do not and will not: (i) conflict with or violate any provision of the Company’s or any Subsidiary’s certificate
or articles of incorporation, bylaws or other organizational or charter documents, (ii) conflict with, or constitute a default
(or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any
of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration
or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing
a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which
any property or asset of the Company or any Subsidiary is bound or affected, or (iii) conflict with or result in a violation of
any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which
the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property
or asset of the Company or a Subsidiary is bound or affected.

 

(e)          Filings,
Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice
to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i)
the filing of Form D with the Commission, and (ii) such filings as are required to be made under applicable state securities laws
(collectively, the “Required Approvals”).

 

(f)           Issuance
of the Securities. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction
Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The
Company has reserved from its duly authorized capital stock a number of shares of Common Stock for issuance of the Underlying Shares
at least equal to the Required Minimum on the date hereof.

 

(g)          Capitalization.
The capitalization of the Company is as set forth in Schedule 3.1(g). Except as disclosed on Schedule 3.1(g), no Person
has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions
contemplated by the Transaction Documents. Except as disclosed on Schedule 3.1(g), there are no outstanding options, employee
or incentive stock option plans warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating
to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to
subscribe for or acquire any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company
or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents. Except for the
stock option plan annexed to Schedule 3.1(g) hereto, there is no stock option plan in effect as of the Closing Date. Except as
set forth on Schedule 3.1 (g), the issuance and sale of the Securities will not obligate the Company to issue shares of
Common Stock or other securities to any Person (other than the Purchasers) and will not result in a right of any holder of Company
securities to adjust the exercise, conversion, exchange or reset price under any of such securities. All of the outstanding shares
of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in material
compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive
rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any stockholder, the
Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting
agreements or other similar agreements with respect to the Company’s capital stock to which the Company is a party or, to
the knowledge of the Company, between or among any of the Company’s stockholders.

 

     9

     

    

 

(h)          Financial
Statements. Annexed hereto as Schedule 3.1(h) is financial information of the Company (“Financial Statements”).
The Financial Statements have not been prepared in accordance with GAAP. The Financial Statements fairly present in all material
respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results
of operations and cash flows for the periods then ended, subject to normal, immaterial adjustments and inclusion of footnotes
which would be required pursuant to generally accepted accounting principles.

 

(i)           Material
Changes: Undisclosed Events, Liabilities or Developments. Since the date of the Financial Statements except as disclosed on
Schedule 3.161: (i) there has been no event, occurrence or development that has had or that could reasonably be expected
to result in a Material Adverse Effect, (ii) the Company has not incurred any material liabilities (contingent or otherwise) other
than trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice, (iii) the Company
has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other
property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock
and (v) the Company has not issued any equity securities to any officer, director or Affiliate.

 

(j)           Litigation.
There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company,
threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator,
governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an “Action”)
which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the
Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse
Effect. At no time, neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of
any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary
duty.

 

(k)          Labor
Relations. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of
the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its Subsidiaries’
employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or
any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure
or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant
in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of
its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance
with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and
conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.

 

     10

     

    

 

(l)          Compliance.
Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not
been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor
has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit aueement or any other agreement or instrument to which it is a party or by which it or any of its properties is
bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any
court, arbitrator or other governmental authority or (Hi) is or has been in violation of any statute, rule, ordinance or regulation
of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental
protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as
could not have or reasonably be expected to result in a Material Adverse Effect.

 

(m)        Regulatory
Permits. The Company and the Subsidiaries possess all certificates, authorizations and pennits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as presently conducted, and as
contemplated to be conducted, except where the failure to possess such permits could not reasonably be expected to result in a
Material Adverse Effect (“Material Permits”). and neither the Company nor any Subsidiary has received any notice
of proceedings relating to the revocation or modification of any Material Permit.

 

(n)         Title
to Assets. The Company and the Subsidiaries have good and marketable title in all personal property owned by them that is material
to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially
affect the value of such propeity and do not materially interfere with the use made and proposed to be made of such property by
the Company and the Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves
have been made and, the payment of which is neither delinquent nor subject to penalties. The Company and Subsidiaries do not own
any real property. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under
valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.

 

(0)          Intellectual
Property.

 

(i)           The
term “Intellectual Proper tv Rights” includes:

 

1.           the
name of the Company and each Subsidiary, all fictional business names, trading names, registered and unregistered trademarks,
service marks, and applications of the Company and each Subsidiary (collectively. “Marks”);

 

2.          all
patents, patent applications, and inventions and discoveries that ma” be patentable of the Company and each Subsidiary (collectively,
“Patents”):

 

3.          all
copyrights in both unpublished works and published works of the Company and each Subsidiary (collectively, “Coovrights”):

 

4.          all
rights in mask works of the Company and each Subsidiary (collectively, “Ric,Fhts in Mask Works”);

 

5.          all
know-how, trade secrets, confidential information, customer lists, software, technical information, data, process technology,
plans, drawings, and blue prints (collectively, “Trade Secrets”): owned, used, or licensed by the Company and
each Subsidiary as licensee or licensor; and

 

6.          the
license or right to directly or indirectly use any of the foregoing, whether perpetually or for a fixed term, whether or not subject
to defeasement, and whether or not reduced to writing or otherwise memorialized.

 

     11

     

    

 

(ii)        Agreements.   
Schedule 3.1(6) contains a complete and accurate list and description of all material Intellectual Property Rights and of all
contracts relating to the Intellectual Property Rights to which the Company is a party or by which the Company is bound, except
for any license implied by the sale of a product and perpetual, paid-up licenses for commonly available software programs with
a value of less than S10,000 under which the Company is the licensee. There are no outstanding and, to Company’s knowledge,
no threatened disputes or disagreements with respect to any such agreement.

 

(iii)        Know-How
Necessary for the Business. The Intellectual Property Rights are all those necessary for the operation of the Company’s
businesses as it is currently conducted or contemplated to be conducted. The Company is the owner of all right, title, and interest
in and to each of the Intellectual Property Rights, free and clear of all liens, security interests, charges, encumbrances, equities,
and other adverse claims, and has the right to use all of the Intellectual Property Rights. To the Company’s knowledge, no
employee of the Company has entered into any contract that restricts or limits in any way the scope or type of work in which the
employee ma” be engaged or requires the employee to transfer, assign, or disclose information concerning his work to anyone
other than of the Company.

 

(iv)        Patents.
The Company is the owner of or licensee of all right, title and interest in and to each of the Patents, free and clear of all
Liens and other adverse claims. All of the issued Patents are currently in compliance with formal legal requirements (including
payment of filing, examination, and maintenance fees and proofs of working or use), are valid and enforceable, and are not subject
to any maintenance fees or taxes or actions falling due within ninety days after the Closing Date. No Patent has been or is now
involved in any interference, reissue, reexamination, or opposition proceeding. To the Company’s knowledge: (1) there is
no potentially interfering patent or patent application of any third party, and (2) no Patent is infringed or has been challenged
or threatened in any way. To the Company’s knowledge, none of the products manufactured and sold, nor any process or know-how
used, by the Company infringes or is alleged to infringe any patent or other proprietary right of any other Person.

 

(v)         Trademarks.
The Company is the owner of all right, title, and interest in and to each of the Marks, free and clear of all Liens and other
adverse claims. All Marks that have been registered with the United States Patent and Trademark Office are currently in compliance
with all formal legal requirements (including the timely post-registration filing of affidavits of use and incontestability and
renewal applications), are valid and enforceable, and are not subject to any maintenance fees or taxes or actions falling due within
ninety days after the Closing Date. No Mark has been or is now involved in any opposition, invalidation, or cancellation and, to
the Company’s knowledge, no such action is threatened with respect to any of the Marks, To the Company’s knowledge:
(I) there is no potentially interfering trademark or trademark application of any third party, and (2) 710 Mark is infringed or
has been challenged or threatened in an)’ way. To the Company’s knowledge, none of the Marks used by the Company infringes
or is alleged to infringe any trade name, trademark, or service mark of any third party.

 

(vi)        Copyrights.
The Company is the owner of all right, title, and interest in and to each of the Copyrights, free and clear of all Liens and
other adverse claims. All the Copyrights have been registered and are currently in compliance with forrnal requirements, are valid
and enforceable, and are not subject to any maintenance fees or taxes or actions falling due within ninety days after the date
of the Closing. No Copyright is infringed or, to the Company’s knowledge, has been challenged or threatened in any way. To
the Company’s knowledge, none of the subject matter of any of the Copyrights infringes or is alleged to infringe any copyright
of any third party or is a derivative work based on the work of a third party. All works encompassed by the Copyrights have been
marked with the proper copyright notice.

 

     12

     

    

 

(vii)       Trade
Secrets. With respect to each Trade Secret, the documentation relating to such Trade Secret is current, accurate, and sufficient
in detail and content to identify and explain it and to allow its full and proper use without reliance on the knowledge or memory
of any individual. The Company has taken all reasonable precautions to protect the secrecy, confidentiality, and value of its Trade
Secrets. The Company has good title and an absolute (but not necessarily exclusive) right to use the Trade Secrets. The Trade Secrets
are not part of the public knowledge or literature, and, to the Company’s knowledge, have not been used, divulged, or appropriated
either for the benefit of any Person (other the Company) or to the detriment of the Company. No Trade Secret is subject to any
adverse claim or has been challenged or threatened in any way.

 

(P)         Insurance.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks
and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged. Neither
the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and
when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without
a situ:if-loam increase in cost.

 

(q)          Transactions
With Affiliates and Employees, Except as set forth in the Financial Statements and Transaction Documents, none of the officers
or directors of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any
Subsidiary is presently a partv to any transaction with the Company or any Subsidiary (other than for services as employees, officers
and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing
for rental of real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise
requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any
officer, director, or any such employee Has a substantial interest or is an officer, director, trustee, stockholder, member or
partner, in each case in excess of 5100,000 other than for: (i) payment of salary or consulting fees for services rendered, (ii)
reimbursement for expenses incurred on behalf of the Company and (iii) except as disclosed on Schedule 3.: (2). A copy of
all employment agreements to which the Company and any Subsidiary are parties is annexed as Schedule 3.: (cp.

 

(r)          Certain
Fees, Except as set forth on Schedule 3.1(r). no brokerage, finder’s fees, commissions or due diligence fees are
or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment
banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have
no obligation with respect to any such fees or with respect to any claims made by or on behalf of other Persons for fees of a type
contemplated in this Section 3.1(:) that may be due in connection with the transactions contemplated by the Transaction Documents.

 

(s)          Investment
Company. The Company is not, and is not an Affiliate of and immediately after receipt of payment for the Securities, will not
be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become an “investment company” subject to registration
under the Investment Company Act of 1940, as amended.

 

     13

     

    

 

(t)           Registration
Rights. No Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act
of any securities of the Company or any Subsidiary.

 

(u)          Application
of Takeover Protections. As of the Closing Date, the Company will have taken all necessary action, if any, in order to render
inapplicable as of the Closing Date and thereafter any control share acquisition, business combination, poison pill (including
any distribution under a rights agreement) or other similar anti-takeover provision under the Company’s certificate of incorporation
(or similar charter documents) or the laws of the State of Delaware that is or could become applicable to the Purchasers as a result
of the Purchasers and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including
without limitation as a result of the Company’s issuance of the Securities and the Purchasers’ ownership of the Securities.

 

(v)          Disclosure.
All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries,
their respective businesses and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, when
taken together as a whole, is true and correct in all material respects and does not contain any untrue statement of a material
fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under
which they were made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations
or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2.

 

(w)         Solvency.
Based on the consolidated financial condition of the Company as of the Closing Date, and the Company’s good faith estimate
of the fair market value of its assets, after giving effect to the receipt by the Company of the proceeds from the sale of the
Securities hereunder: (i) the fair saleable value of the Company’s assets exceeds the amount that will be required to be
paid on or in respect of the Company’s existing debts and other liabilities (including known contingent liabilities) as they
mature, (ii) the Company’s assets do not constitute unreasonably small capital to carry on its business as now conducted
and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the business
conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii) the current
cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking
into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when
such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature
(taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of
any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or
reorganization laws of any jurisdiction within one year from the Closing Date. The Company Financial Statements and Schedule
3.1 (i) set forth all outstanding liens secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the
Company or any Subsidiary has commitments. For the purposes of this Agreement, “Indebtedness” means (x) any
liabilities for borrowed money or amounts owed in excess of $100,000 other than (i) trade accounts payable incurred by the Company
and its Subsidiaries in the ordinary course of business or (ii) debt financing from a licensed United States bank regularly engaged
in such lending activity, and (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others,
whether or not the same are or should be reflected in the Company’s balance sheet (or the notes thereto), except guaranties
by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business,
but excluding trade accounts payable incurred by the Company and its Subsidiaries in the ordinary course of business; and (z) the
present value of any lease payments in excess of $100,000 due under leases required to be capitalized in accordance with generally
accepted accounting principles. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.

 

     14

     

    

 

(x)           Tax
Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local
income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject,
(ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due
on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of
all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid
taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or
of any Subsidiary know of no basis for any such claim.

 

(y)          Foreign
Corrupt Practices. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent
or other person acting on behalf of the Company or any Subsidiary, has: (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any
unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns
from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person
acting on its behalf of which the Company is aware) which is in violation of law or (iv) violated in any material respect any provision
of FCPA.

 

(z)          Acknowledgment
Regarding Purchasers’ Purchase of Securities. The Company acknowledges and agrees that each of the Purchasers is acting
solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in
any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given
by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions
contemplated thereby is merely incidental to the Purchasers’ purchase of the Securities. The Company further represents to
each Purchaser that the Company’s decision to enter into this Agreement and the other Transaction Documents has been based
solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.

 

(aa)        Money
Laundering. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the “Money
Laundering Laws”), and no action, suit or proceeding by or before any court or governmental agency, authority or body
or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge
of the Company or any Subsidiary, threatened.

 

(bb)        Office
of Foreign Assets Control. Neither the Company nor any Subsidiary nor, to the Company’s knowledge, any director, officer,
agent, employee or affiliate of the Company is currently subject to any U.S. sanctions administered by the Office of Foreign Assets
Control of the U.S. Treasury Department (“OFAC”).

 

(cc)        Private Placement.
Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2, no registration under
the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers as contemplated hereby.

 

(dd)        No General Solicitation
or Integration. To the best knowledge of the Company, neither the Company nor any person acting on behalf of the Company has
offered or sold any of the Securities by any form of general solicitation or general advertising. To the best knowledge of the
Company, the Company has offered the Securities for sale only to the Purchasers and certain ether “accredited investors”
within the meaning of Rule 501 under the Securities Act,

 

     15

     

    

 

(cc)        indebtedness
and Seniority. As of the date hereof, all Indebtedness and Liens are as set forth on the Company Financial Statements and Schedule
3.1(R. Except as set forth on the Company Financial Statements and Schedule 3.1(R. as of the Closing Date, no Indebtedness,
equity, Common Stock Equivalent is senior to the Notes in right of payment, whether with respect to interest or upon liquidation
or dissolution, or otherwise, and, capital lease obligations (which is senior only as to the property covered thereby).

 

(ff)         FDA.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the Federal
Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged, labeled,
tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product. a “Pharmaceutical
Product”), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by the Company in compliance with at: applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, :abeling, advertising, record keeping and filing of reports, except where the
failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company’s
knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge,
complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries
has received any notice, warning letter or other COMMunication from the FDA or any other govermnental entity, which (i) contests
the premarket clearance, licensure, registration, or approve: of, the uses of, the distribution of, the manufacturing or packaging
of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of,
requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials
relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of
its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to
enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any
violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the
aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being
conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA, The Company has not
been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed
to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing
any product being developed or proposed to be developed by the Company.

 

(gg)       No
Disqualification Events. With respect to the Securities to be offered and sold hereunder in reliance on Rule 506 under the
Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer
of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company’s outstanding
voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under
the Securities Act) connected with the Company in any capacity at the time of sale (each. an “Issuer Covered Person” and,
Together. “Issuer Covered Persons”) is subject to any of the “Bad Actor” disqualifications described
in Rule 506(d)(:)(i) to (viii) under the Securities Act (a “Disqualification Event”), except for a Disqualification
Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any issuer Covered Person
is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under
Rule 506(e), and has furnished to the Purchasers a copy of any disclosures provided thereunder.

 

     16

     

    

 

(hh)       Other Covered Persons.
The Company is not aware of any person (other than Palladium Capital Advisors LLC) that has been or will be paid (directly or indirectly)
remuneration for solicitation of purchasers in connection with the sale of any Regulation D Securities.

 

(ii)          Notice
of Disqualification Events. The Company will notify the Purchasers in writing, prior to the Closing Date of (i) any Disqualification
Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, become a Disqualification
Event relating to any Issuer Covered Person.

 

(jj)          Survival.
The foregoing representations and warranties shall survive the Closing Date.

 

3.2         Representations
and Warranties of the Purchasers. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants
as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein):

 

(a)          Organization:
Authority. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability
company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and
performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary
corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction
Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with
the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance
with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii) to the extent the indemnification
provisions contained in this Agreement may be limited by applicable law.

 

(b)          Understandings
or Arrangements. Such Purchaser understands that the Securities are “restricted securities” and have not been registered
under the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account
and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act
or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities
Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons to
distribute or regarding the distribution of such Securities in violation of the Securities Act or any applicable state securities
law (this representation and warranty not limiting such Purchaser’s right to sell the Securities pursuant to a registration
statement or otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities
hereunder in the ordinary course of its business.

 

     17

     

    

 

(c)          Purchaser
Status. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on
which it converts a Note or exercises any Warrants, it will be either: (i) an “accredited investor” as defined in
Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act or (ii) a “qualified institutional buyer”
as defined in Rule 144A(a) under the Securities Act. Such Purchaser is not required to be registered as a broker-dealer under
Section 15 of the Exchange Act. Such Purchaser has the authority and is duly and :egall)’ qua ified to purchase and own
the Securities. Such Purchaser is able to bear the risk of such investment for an indefinite period and to afford a complete loss
:hereof. Such Purchaser has provided the information in the Accredited Investor Questionnaire attached hereto as Exhibit E
(the “Investor Questionnaire”). The information set forth on the signature pages hereto and the lnvestor
Questionnaire regarding such Purchaser is true and complete in ad respects. Except as disclosed in the Investor Questionnaire,
such Purchaser has had no position, office or other materia; relationship within the pas: three years with the Company or Persons
(as defined below) known to such Purchaser to be affiliates of the Company, and is not a member of the Financial Industry Regulatory
Authority or an “associated person” (as such term is defined under the FINRA ivlembership and Registration Rides Section
:011).

 

(d)          Experience
of Such Purchaser. Such Purchaser, either alone or together with its representatives; has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Stich Purchaser is able to bear the economic risk
of an investmem in the Securities and, at the present time, is able to afford a complete loss of such investment.

 

(e)          lnformation
on Comoany. Purchasers are not deemed to have any knowledge of any information not Mc:tided in the Financia: Statements or
the Transaction Documents unless such information is delivered in the manner described in the next sentence. Each Purchaser was
afforded (i) the opportunity to ask such questions as such Purchaser deemed necessary of, and to receive answers front, representatives
of the Company concerning the merits and risks of acquiring the Securities; (ii) the right of access to information about the
Company a d its financial condition, results of operations; business, properties, management and prospects sufficient
to enable such Purchaser to eva:uate the Securities; and (iii) the opportunity to obtain such additional information that the
Company possesses or can acquire without on effort or expense that is necessary to make an informed investment decision with respect
to acquiring the Securities. In addition, such Purchaser may have received in writing from the Company such other information
concerning its operations, financial condition and other matters as such Purchaser has requested, identified thereon as OTHER
WRITTEN INFORMATION (such other information is codeetively, the “Other Writ-ten information”), and
considCled al: factors such Purchaser deems material in deciding on the advisability of investing in the Securies.

 

(f)           Compliance
with Securities Act: Reliance on Exemntions. Such Pwthaser understands and agrees that the Securities have not been registered
under the 1933 Act or any applicab:e state securities :aws, by reason of their issuance in a transaction that does not require
registration under the 933 Act, and that such Securities must be held indefinitely unless a subsequent disposition is registered
under the :933 Act or any applicable state securities laws or is exempt from such registration. Such Purchaser understands and
agrees:ha:the Securities are being offered and sold to such Purchaser in reliance on specific exemptions from the registration
requirements of United States federal and state securities laws and regulations and that the Company is relying in part upon the
truth and accuracy of, and such 2m -chaser’s compliance with, the representations, warranties, agreements, acknowledgments
and understandings of such Purchaser se: forth t herein in order to dete—ine the availability of such exemptions and the
&igibi:ity of such Purchaser to acquire the Securities.

 

(g)          Communication
of Offer. Such Purchaser is no: purchasing the Securities as a result of any “genera: solicitation” or “general
advertising,” as such terms are defined in Regulation D, which 11C.1.1 des, but is not limited to, any advertisement, article,
notice or other communication regarding the Securities published in any newspaper, magazine or similar media or on the internet
or broadcast over television, radio or the intemet or presented at any seminar or any other general solicitation or genera: advertiseme:it,

 

     18

     

    

 

(h)          No
Governmental Review. Such Purchaser understands that no United States federal or state agency or any other governmental or
state agency has passed on or made recommendations or endorsement of the Securities or the suitabiiity of the investment in the
Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

(i)           No
Conflicts. The execution, delivery and performance of this Agreement and performance under the other Transaction Documents
and the consummation by such Purchaser of the transactions contemplated hereby and thereby or relating hereto or thereto do not
and will not (i) result in a violation of such Purchaser’s charter documents, bylaws or other organizational documents, if
applicable, (ii) conflict with nor constitute a default (or an event which with notice or :apse of time or both would become a
default) under any agreement to which such Purchaser is a party, nor (iii) result in a violation of any law, rule, or regulation,
or any order, judgment or decree of any court or governmental agency applicable to such Purchaser or its properties ;except for
such conflicts, defaults and violations as would not, individually or in the aggregate, have a material adverse effect on such
Purchaser). Such Purchaser is not required to obtain any consent, authorization or order of, or make any tiling or registration
with, any court or governmental agency in order for it to execute, deliver or perform any of its obligations under this Agreement
or perform under the other Transaction Documents nor to purchase the Securities in accordance with the terms hereof, provided that
for purposes of the representation made in this sentence, such Purchaser is assuming: and relying upon the accuracy of the relevant
representations and agreements of the Company herein.

 

(j)           Tax
Liability. Such Purchaser has reviewed with its own tax advisors the federal, state, local and foreign tax consequences of
this investment and the transactions contemplated by this Agreement. Such Purchaser understands that it (and not the Company)
shall be responsible for its own tax liability that may arise as a result of this investment or the transactions contemplated
by this Agreement.

 

(k)          Survival.
The foregoing representations and warranties shall survive the Closing Date.

 

3.3         Reliance.
The Company acknowledges and agrees that the representations contained in Section 3.2 shall not modify, amend or affect such
Purchaser’s right to rely on the Company’s representations and warranties contained in this Agreement or any representations
and warranties contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection
with this Agreement or the consummation of the transaction contemplated hereby.

 

ARTICLE IV.

OTHER AGREEMENTS OF THE PARTIES

 

4.1         Transfer
Restrictions.

 

(a)          Disposition
of Securities. The Securities may only be disposed of in compliance with state and federal securities laws. In connection with
any transfer of Securities other than pursuant to an effective registration statement or Rule :44, to the Company or to an Affiliate
of a Purchaser or in connection with a pledge as contemplated in Section 4.1(b)„ the Company may require the transferor thereof
to provide to the Company at the Company’s expense, an opinion of counsel selected by the transferor and reasonably acceptable
to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such
transfer does not require registration of such transferred Securities under the Securities Act. As a condition of transfer, any
such transferee shall agree in writing to be bound by the terms of this Agreement and shall have the rights and obligations of
a Purchaser under this Agreement.

 

     19

     

    

 

(b)          Legend.
The Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Securities in
the following: form:

 

[NEITHER: THIS SECURITY
[NOR THE SECURITIES INTO WHICH THIS SECURITY IS [EXERCISABLE: [CONVERTIBLE:: HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF
1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REG:STRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL
OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS
SECURITY [AND THE SECURITIES ISSUABLE UPON :EXERCISE: [CONVERSION] OF THIS SECURITY] MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE
MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR”
AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

The Company acknowledges
and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer
or grant a security interest in some or al: of the Securities to a financial institution that is an “accredited investor”
as defined in Ru:e 501(a) under the Securities Act and who agrees to be bound by the provisions of this Agreement and, if required
under the terms of such arrangement, such Purchaser may transfer pledge or secure Securities to the pledgees or secured parties.
Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee,
secured party or pledger shah be required in connection therewith. At such Purchaser’s expense, the Company will execute
and deliver such reasonable documentation as a pledgee or secured party of Securities may reasonably request in connection with
a pledge or transfer of the Securities,

 

(c)          Legend
Removal. Certificates evidencing the Underlying Shares shall not contain any legend (including the legend set forth in Section
4.1(b) hereof): (i) while a registration statement covering the resale of such security is effective under the Securities Act,
(ii) following any sale of such Underlying Shares pursuant to Rule 144, or (iii) if such legend is not required under applicable
requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission).
The Company agrees that following such time as such legend is no longer required under this Section 4.1(c), it will, no later
than ten (1O) Business Days following the delivery by a Purchaser to the Company or the Transfer Agent of a certificate representing
Underlying Shares issued with a restrictive legend (such tenth Business Day. the “Legend Removal Dare”), together
with all representation letters, certificates and legal opinions required by the Transfer Agent, deliver or cause to be delivered
to such Purchaser a certificate representing such shares that is free from all restrictive and ether legends (ho’vever,
the Corporation shall use reasonable best efforts to deliver such shares within seven (7) Business Days). The Company may not
make any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth
in this Section 4.

 

(d)          Resale
Requirements. Each Purchaser, severally and not jointly with the ether Purchasers, agrees with the Company that such Purchaser
will sell the Securities pursuant to either the registration requirements of the Securities Act, including any applicable prospectus
delivery requirements, or an exemption therefrom, and that if Securities are sold pursuant to a registration statement, they vi
11 be sold in compliance with the plan of distribution set forth therein, and acknowledges that the removal of the restrictive
legend from certificates representing Securities as set forth in this Section 4.1 is predicated upon the Company’s reliance
upon this understanding.

 

     20

     

    

 

(e)          Remedies.
Commencing after the occurrence of a Going Public Event, in addition to such Purchaser’s other available rentedies, the
Company shall pay to a Purchaser, in cash, as partial liquidated damages and not as a penalty, for each $1,000 of Conversion Shares
or \Varrant Shares delivered for removal of the restrictive legend and Conversion Shares delivered for conversion into Shares,
$10 per Trading Day for each Trading Day following the Legend Removal Date or the date such Securities are to be delivered pursuant
to the Note until such Common Stock certificate is delivered without a legend pursuant to Section 4.1(c) or such Conversion Shares.
Nothing herein shall limit such Purchaser’s right to elect in lieu of the aforedescribed liquidated damages to pursue actual
damages for the Company’s failure to deliver certificates representing any Underlying Shares as required by the Transaction
Documents, and such Purchaser shall have the right to pursue all remedies available to it at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief

 

(f)           Injunction.
In the event a Purchaser shall request delivery of Securities as described in this Section 4.1 or Common Stock pursuant to the
Note and the Company is required to deliver such Securities, the Company may not refuse to deliver Securities based on any claim
that such Purchaser or anyone associated or affiliated with such Purchaser has not complied with Purchaser’s obligations
under the Transaction Documents, or for any other reason, unless, an injunction or temporary restraining order from a court, on
notice, restraining and or enjoining delivery of such unlegended shares shall have been sought and out by the Conmpany and the
Company has posted a surety bond for the benefit of such Purchaser in the amount of 120% of the amount of the aggregate purchase
price of the Securities intended to be subject to the injunction or temporary restraining order, which bond shall remain in effect
until the completion of arbitration/litigation of the dispute and the proceeds of which shall be payable to such Purchaser to the
extent Purchaser obtains judgment in Purchaser’s favor.

 

(g)          Buy-In.
In addition to any other rights available to Ptirchaser, if the Company fails to deliver to a Purchaser Securities as required
pursuant to this Agreement or the Note and after the Legend Removal Date or required delivery date pursuant to the Note the Purchaser,
or a broker on the Purchaser’s behalf, purchases (in an open market transaction or otherwise) shares of Common Stock to deliver
in satisfaction of a sale by such Purchaser of the shares of Common Stock which the Purchaser was entitled to receive in unlegended
form from the Company (a “Buy-In”), then the Company shall promptly pay in cash to the Purchaser (in addition
to any remedies available to or elected by the Purchaser) the amount, if any, by which (A) the Purchaser’s total purchase
price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (B) the aggregate purchase
price of the shares of Common Stock delivered to the Company for reissuance as unlegendcd Shares or as are required to be delivered
pursuant to the Note, as the case may be, together with interest thereon at a rate of’15% per annum accruing until such amount
and any accrued interest thereon is paid in full (which amount shall be paid as liquidated damages and not as a penalty). For example,
if a Purchaser purchases shares of Common Stock having a total purchase price of SI 1,000 to cover a Buy-In with respect to S 10,000
of purchase price of Shares - delivered to the Company for reissuance as unlegended shares, the Company shall be required to pay
the Purchaser $1,000, plus interest, if any. The Purchaser shall provide the Company written notice indicating the amounts payable
to the Purchaser in respect of the Buy-In.

 

4.2         Acknowledgment
of Dilution. The Company acknowledges that the issuance of the Securities may result in dilution of the outstanding
shares of Common Stock, which dilution [may be substantial under certain market conditions. The Company
further acknowledges that its obligations under the Transaction Documents, including, without limitation, its obligation to
issue the Underlying Shares pursuant to the Transaction Documents, are unconditional and absolute and not subject to any
right or set off, counterclaim, delay or reduction, regardless of the effect of any such dilution or any claim the Company
may have against any Purchaser and regardless of the dilutive effect that such issuance may have on the ownership of the
other stockholders of the Company.

 

     21

     

    

 

4.3         Furnishing
of Information.

 

(a)          The
Company covenants and agrees with the Purchaser that until the Going Public Event, the Company shall deliver to the Purchaser:
(i) for each of its first three fiscal quarters unaudited quarterly financial statements within 75 days after each quarter-end,
(ii) subject to Section 4.3(b), annual audited financial statements prepared according to GAAP within 120 days of year-end, and
(iii) copies of any documents or data furnished to the Company’s stockholders in their capacity as Company stockholders regarding
the Company or its affairs, simultaneously with the furnishing of such documents or data to such stockholders. The foregoing obligations
will be deemed satisfied if such financial statements have been filed with the Commission and are available on the EDGAR system.

 

(b)          Not
later than April 20, 2016, the Company will provide to the Purchasers audited financial statements prepared according to GAAP by
an auditing firm registered with the PCAOB, for the then most recent fiscal year and unaudited stub period financial statements
in form and substance sufficient to meet the minimum requirements for filing with the Commission pursuant to Regulation 5- X and
Form S-I or Form 10.

 

(c)          For
so long as the Notes and Prior Offering Notes remain outstanding the Company shall engage a consultant (the “Consultant”)
pursuant to the terms of a consulting agreement, the form of which is annexed hereto as Exhibit G. The Company will be
responsible to compensate Consultant pursuant to the terms of the consulting agreement.

 

4.4         Conversion
and Exercise Procedures. Each of the form of Notice of Conversion attached to the Note and form of Notice of Exercise included
in the Warrants sets forth the totality of the procedures required of the Purchasers in order to convert the Note or exercise the
Warrant. No additional legal opinion, other information or instructions shall be required of the Purchasers to convert their Note
or exercise their Warrants. The Company shall honor conversions of the Note and exercises of the Warrants and shall deliver Underlying
Shares in accordance with the terms, conditions and time periods set forth in the Transaction Documents.

 

4.5         Use
of Proceeds. The proceeds of the offering will be employed by the Company substantially for the purposes set forth on Schedule
4.5.

 

     22

     

    

 

4.6         Indemnification
of Purchasers. Subject to the provisions of this Section 4.6, the Company will indemnify and hold each Purchaser and its directors,
officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of
a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles
notwithstanding a lack of such title or any other title) of such controlling persons (each, a “Purchaser Party”)
harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all
judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such
Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants
or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against
Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not
an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless
such action is based upon a breach of such Purchaser Parry’s representations, warranties or covenants under the Transaction
Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations by such
Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which constitutes fraud, gross negligence,
willful misconduct or malfeasance). If any action shall be brought against any Purchaser Party in respect of which indemnity may
be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall
have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any
Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but
the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment
thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time
to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel, a material
conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the
Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will
not be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company’s
prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that
a loss, claim, damage or liability is attributable to any Purchaser Party’s breach of its representations, warranties or
covenants under the Transaction Documents. The indemnification required by this Section 4.6 shall be made by periodic payments
of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity
agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company
or others and any liabilities the Company may be subject to pursuant to law.

 

4.7         Reservation
and Listing of Securities.

 

(a)          The
Company shall maintain a reserve from its duly authorized shares of Common Stock for issuance pursuant to the Transaction Documents
in such amount as may then be required to fulfill its obligations in full under the Transaction Documents, but not less than the
Required Minimum.

 

(b)          If,
on any date, the number of authorized but unissued (and otherwise unreserved) shares of Common Stock is less than the Required
Minimum on such date, then the Board of Directors shall amend the Company’s certificate or articles of incorporation to increase
the number of authorized but unissued shares of Common Stock to at least the Required Minimum at such time, as soon as possible
and in any event not later than the 60’h day after such date. The Company may increase its authorized capital to 300,000,000
shares of Common Stock and 20,000,000 shares of blank check preferred stock; with no change in per share par value.

 

4.8           Form
D; Blue Sky Filings. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation
D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company shall
reasonably determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to the Purchasers
at the Closing under applicable securities or “Blue Sky” laws of the states of the United States, and shall provide
evidence of such actions promptly upon request of any Purchaser.

 

     23

     

    

 

4.9         Subsequent
Equity Sales. Except in connection with the Securities offered in this Agreement or a Qualified Offering, without prior written
approval of a Majority in Interest, until the later to occur of: (i) a Going Public Event, and (ii) December 31, 2017 (“End
Date”), from the date hereof until the End Date, the Company will not, without the consent of a Majority in Interest,
enter into any Equity Line of Credit or similar agreement, nor issue nor agree to issue any common stock, floating or Variable
Priced Equity Linked Instruments nor any of the foregoing or equity with price reset rights (subject to adjustment for stock splits,
distributions, dividends, recapitalizations and the like) (collectively, the “Variable Rate Transaction”). For
purposes hereof, “Equity Line of Credit” shall include any transaction involviiw a written agreement between
the Company and an investor or underwriter ‘vhereby 111C Corn pan)’ has the right to “put” its securities
to the investor or underwriter over all agreed period of time and at an agreed price or price formula, and “Variable Priced
Equity Linked Instruments” shall include: (A) any debt Or equity securities which are convertible into, exercisable
or exchangeable for, or carry the right to receive additional shares of -Common Stock either (1) at any conversion,
exercise or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for Common Stock
at any time after the initial issuance of such debt or equity security, or (2) with a fixed conversion, exercise or exchange price
that is subject to being reset at sonic future date at any time afler the initial issuance or such debt or equity security clue
to a change in the market price of the Company’s Common Stock since date of initial issuance, and (13) any amortizing convertible
security which amortizes prior to its maturity date, where the Company is required or has the option to (or any investor in such
transaction has the option to require the Company to) make stlell alhodization payments in Shares or COMIllon Stock which are valued
at a price that is based upon and/or varies with the trading prices of or quotations for Common Stock at any time after the in
issuance or such debt or equity security (whether or not such payments in stock are subject to certain equity conditions). For
purposes of determining the total consideration for a convertible instrument (including a right to purchase equity of-
the Company) issued, subject to an original issue or similar discount or which principal amount is directly or indirectly increased
after issuance, the consideration will be deemed to be the actual cash amount received by the Company in consideration of the original
issuance of such convertible instrument.

 

4.10       Equal
Treatment of Purchasers. No consideration (including any modification of any Transaction Document) shall be offered or paid
to any Person to amend or consent to a waiver or modification of ally provision or any of the Transaction Documents or Prior Offering
Transaction Documents unless the same Or substantially similar consideration is also offered, nutiods mutandis, on a ratable
basis to all of the parties to this Agreement and the Prior Offering Securities Purchase Agreement. For clarification purposes,
this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Pin-chaser,
and is intended for the COITipaay to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting
in concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise.

 

4.11       Integration.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined
in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require
the registration under the Securities Act of the sale or the Securities.

 

4.12       Maintenance
of Property and Insurance. Until the End Date, the Company shall keep all of its property, which is necessary or useful
to the conduct of its business, in good working order and condition, ordinary wear and tear excepted. Until the End Date, the Company
will maintain insurance coverage or the type and not less than the ainount in effect as or the Closing Date.

 

4.13       Going
Public Event. On or before the Public Company Date, the Company (i) will, subject to the approval or a Majority in Interest,
consummate a merger or business combination with a company that has a class of equity subject to I he reporting requirements or
Section 13 or 15(d) under the Exchange Act, or (ii) file a registration statement on Form S-1 or Form I 0, for the purpose of having
the class or Common Stock comprising the Underlying Shares subject to the reporting requirements of Section III or 15(d) under
the Exchange Act. The Company having the same class of equity as the Underlying Shares subject to the reporting requirements of
Section 13 or 15(d) is referred to herein as the “Going Public Event”. The Company will cause the Going Public
Event to occur on or before the Public Company Date.

 

     24

     

    

 

4.14       Preservation
of Corporate Existence. Until the End Date, the Company shall preserve and maintain its corporate existence, rights, privileges
and franchises in the jurisdiction of its incorporation, and qualify and remain qualified, as a foreign corporation in each jurisdiction
in which such qualification is necessary in view of its business or operations and where the failure to qualify or remain qualified
might reasonably have a Material Adverse Effect upon the financial condition, business or operations of the Company taken as a
whole.

 

4.15       Shareholder
Rights Plan. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any
Purchaser is an “Acquiring Person” under any control share acquisition, business combination, poison pill (including
any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company,
or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities
under the Transaction Documents.

 

4.16       Reimbursement.
If any Purchaser becomes involved in any capacity in any Proceeding by or against any Person who is a stockholder of the Company
(except as a result of sales, pledges, margin sales and similar transactions by such Purchaser to or with any current stockholder),
solely as a result of such Purchaser’s acquisition of the Securities under this Agreement, the Company will reimburse such
Purchaser for its reasonable legal and other expenses (including the cost of any investigation preparation and travel in connection
therewith) incurred in connection therewith, as such expenses are incurred. The reimbursement obligations of the Company under
this paragraph shall be in addition to any liability which the Company may otherwise have, shall extend upon the same terms and
conditions to any Affiliates of the Purchasers who are actually named in such action, proceeding or investigation, and partners,
directors, agents, employees and controlling persons (if any), as the case may be, of the Purchasers and any such Affiliate, and
shall be binding upon and inure to the benefit of any successors, assigns, heirs and personal representatives of the Company, the
Purchasers and any such Affiliate and any such Person. The Company also agrees that neither the Purchasers nor any such Affiliates,
partners, directors, agents, employees or controlling persons shall have any liability to the Company or any Person asserting claims
on behalf of or in right of the Company solely as a result of acquiring the Securities under this Agreement.

 

4.17       Security
Interest. The Prior Offering Purchasers were granted a security interest in assets of the Company pursuant to the Amended and
Restated Security Agreement. The Amended and Restated Security Agreement is hereby amended to include the Purchasers and the Company
agrees that the Purchasers are hereby made parties to the Amended and Restated Security Agreement as Secured Parties therein, the
Purchasers Notes and all amounts owing to them at any time derived from the Notes in the same manner as Obligations arising under
the Prior Notes are included in the definition “Obligations under the Amended and Restated Security Agreement, and their
interests in the Obligations are pad pasu in proportion to their specific Obligation amounts and of equal priority with the other
components of the Obligations. The Company will execute such other agreements, documents and financing statements reasonably requested
by the Purchasers and Collateral Agent under the Amended and Restated Security Agreement to memorialize and further protect the
security interest described herein, which will be filed at the Company’s expense with the jurisdictions, states and counties
designated by the Purchasers. The Company will also execute all such documents reasonably necessary in the opinion of Collateral
Agent to memorialize and further protect the security interest described herein. The Purchaser’s execution of this Agreement
shall be deemed to be such Purchaser’s execution, entry into an agreement to be bound by the Amended and Restated Security
Agreement as if such Purchaser executed the signature page thereto as of the date such Purchaser executed the signature page to
this Agreement.

 

     25

     

    

 

ARTICLE V.

MISCELLANEOUS

 

5.1         Ter:nation.
This Agreement may be terminated by any Purchaser, as to such Purchaser’s obligations hereunder only and without any
effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the
initial Closing has not been consummated on or before May 2, 2016, Cr any subsequent Closing prior to June 30, 2016; orovided,
however. that such termination will not affect the right of any party to sue for any breach by any other party (or parties).

 

5.2         Fees
and Exoenses. Except as expressly set forth on Schedule 3.1(r), each party shall pay the fees and expenses of its advisers,
counsel, accountants and other experts, if any, and all ether expenses incurred bv such parry incident to the negotiation;
preparation, execution, delivei-y and performance of this Agreement. The Company shall pay all Transfer Agent
fees, stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers. The Company
agrees to pay pursuant to the Escrow Agreement reasonable legal and Escrow Agent fees of O&M, counsel to some of the Purchasers,
in the amount of S:0,000, incurred in connection with the negotiation, preparation, execution and delivery of the Transaction
Documents and initial Closing.

 

5.3         Entire
AEreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of
the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or
written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.

 

5.4         Notices.
All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing
and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return
receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted
by hand delivery, telegram; or facsimile, addressed as set forth below or to such other address as such party shall
have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall
be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile
machine, at the address or number designated below (if delivered on a business day during normal business hours where such notice
is to be received), or the first business day following. such delivery (if delivered other than on a business day during normal
business hours where such notice is to be received) or (b) on the second business clay following the date of mailing by express
courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur.
The addresses for such communications shall be: (i) if to the Company, to: Accelerated Pharma, Inc., 15W:55 SY’ Street, Burr
Ridge, IL 60527, Attn: Michael Fonstein, Chief Executive Officer, facsimile: (630)325-4179, with a copy by fax only to (which shall
not constitute notice): Randy Sahick, Esq., c/o Accelerated Pharma, Inc., :5W15.5 S ls’ Street, Burr Ridge, IL 60527, facsimile:
(630) 325-4:79; and (ii) if to the Purchasers, to: the addresses and fax numbers indicated on the signature pages hereto;
with an additional copy by fax only to (which shall not constitute notice): Crushiko & Mittman, P.C., 515 Rockaway Avenue,
Valley Stream, New York 1158: Attn: Edward NI. Grushko, Esq., facsimile: (212) 697-3575,

 

5.5         Amendments:
Waivers. Except with respect to the Prior Offering Security Agreement, no provision of this Agreement nor ar.),
other Transaction Document may be waived, modified, supplemented or amended nor consent obtained or approval deemed granted except
in a written instrument signed, in the case of an amendment, by the Company and the Purchasers holding at least a majority in interest
(“Mai oritv in interest”) of the component of the affected Securities then outstanding or, in the case of a
waiver, by the party against whont enforcement of any such waived provision is sought. No waiver of any default With respect to
any provision, condition or requirement of this Agreement nor any other Transaction Document shall be deemed to be a continuing
waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement thereof;
nor shall any delay or omission of any party to exercise an’ right thereunder in any manner impair the exercise of any such
right. For purposes of determ’riing a Majority in Interest with respect to the Notes and Prior Offering Notes issued as of
May 8, 2015, June :1, 20:5 and November 6, 2015, the holders of the Notes and the Prior Notes issued as of Mav 3, 2015, June 11,
20:5 and November 6, 2015 shall be aggregated. A Majority in Interest with respect to the Prior Offering Security Agreement shall
mean a majority based on the Purchasers and Prior Offering Purchasers, in the aggregate.

 

     26

     

    

 

5.6         Headings.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or
affect any of the provisions hereof,

 

5.7         Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and :sermined
assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of
each Purchaser (other than by merger). Following the Closing, any Purchaser may assign, on ten (10) Business Day prior notice any
or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided that
such transferee agrees in writing to be bound with respect to the transferred Securities by the provisions of the Transaction Documents
that apply to the “Purchasers” and is able to make each and every representation made by Purchasers in this Agreement.
No assignment by a Purchaser will be allowed if the result would be an increase in the number of actual or beneficial owners of
the assigned securities.

 

5.3         No
Third-Pary Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise
set forth in Section 4.10.

 

5.9         Coverning
Law. All questions concernin:a the construction, validity, enforcement and interpretation offite Transaction Documents shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof except as to these matters which are required by the laws of the State of Delaware to be
governed by the laws of the State of Delaware. Each party agrees that all legal proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party
hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts siring in the City of New York, Borough of Manhattan for the adjudication of any dispute
hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to
the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any action, suit
or proceeding, any claim that it is not personally subject to thejurisdiction of any such court, that such suit, action or proceeding
is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail
or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement
and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence
an action or proceeCii:17. to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the
Company under Section 4.10, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for
its reasonable anorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of
such action or proceeding.

 

5.10       Survival.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.

 

     27

     

    

 

5.11       Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the
same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it
being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile
transmission or by e-mail delivery of a “.pdr format data file, such signature shall create a valid and binding obligation
of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf’
signature page were an original thereof.

 

5.12       Severability.
If any term, provision, covenant or restriction of any Transaction Document is held by a court of competent jurisdiction to
be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein
shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use
their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result
as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention
of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any
of such that may be hereafter declared invalid, illegal, void or unenforceable.

 

5.13       Rescission
and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of)
any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser
may, at any time prior to the Company’s performance of such obligations, rescind or withdraw, in its sole discretion from
time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice
to its future actions and rights; provided however, that in the case of a rescission of a conversion of a Note or exercise
of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded conversion
or exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such
shares and the restoration of such Purchaser’s right to acquire such shares pursuant to such Purchaser’s Note or Warrant
(including, issuance of a replacement warrant certificate evidencing such restored right).

 

5.14       Replacement
of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or
in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory
to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall
also pay any reasonable costs (including customary indemnity) associated with the issuance of such replacement Securities.

 

5.15       Remedies.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each
of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the
Transaction Documents and hereby agree to waive and not to assert in any action for specific performance of any such obligation
the defense that a remedy at law would be adequate.

 

5.16       Payment
Set Aside. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or
exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from,
disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person
under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action),
then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived
and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.

 

     28

     

    

 

5.17       Usury.
To the extent it may lawfully do so, the Company hereby agrees not to insist upon or plead or in any manner whatsoever claim,
and will resist any and all efforts to be compelled to take the benefit or advantage of, usury laws wherever enacted, now or at
any time hereafter in force, in connection with any claim, action or proceeding that may be brought by any Purchaser in order to
enforce any right or remedy under any Transaction Document Notwithstanding any provision to the contrary contained in any Transaction
Document, it is expressly agreed and provided that the total liability of the Company under the Transaction Documents for payments
in the nature of interest shall not exceed the maximum lawful rate authorized under applicable law (the “Maximum Rate”),
and, without limiting the foregoing, in no event shall any rate of interest or default interest, or both of them, when aggregated
with any other sums in the nature of interest that the Company may be obligated to pay under the Transaction Documents exceed such
Maximum Rate. It is agreed that if the maximum contract rate of interest allowed by law and applicable to the Transaction Documents
is increased or decreased by statute or any official governmental action subsequent to the date hereof, the new maximum contract
rate of interest allowed by law will be the Maximum Rate applicable to the Transaction Documents from the effective date thereof
forward, unless such application is precluded by applicable law. If under any circumstances whatsoever, interest in excess of the
Maximum Rate is paid by the Company to any Purchaser with respect to indebtedness evidenced by the Transaction Documents, such
excess shall be applied by such Purchaser to the unpaid principal balance of any such indebtedness or be refunded to the Company,
the manner of handling such excess to be at such Purchaser’s election.

 

5.18       Independent
Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any
other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the
Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers
are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Purchaser shall be entitled to independently protect and enforce its rights, including, without limitation, the
rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser
to be joined as an additional party in any proceeding for such purpose. Each Purchaser has been represented by its own separate
legal counsel in its review and negotiation of the Transaction Documents. The Company has elected to provide all Purchasers with
the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do
so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each
other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively
and not between and among the Purchasers.

 

5.19       Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding
Business Day.

 

5.20       Construction.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction
Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting
party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and
every reference to share prices and shares of Common Stock in any Transaction Document snail be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after
the date of this Agreement.

 

     29

     

    

 

5.21       WAIVER
OF :WRY TRULL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES
EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.

 

5.22       Ecuitable
Ad I usztnent. Trading volume amounts, price/volume amounts and similar figures in the Transaction Documents shall be equitably
adjusted (but without duplication) to offset the effect of stock splits, similar events and as otherwise described in this Agreement
and Warrants.

 

(Signature Pages Icollalt)

 

     30

     

    

  

IN WITNESS WHEREOF, the parties hereto have
caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.

 

	ACCELERATED PHARMA, INC.	Address for Notice:
	 	 
	 	15W155 81st Street
	 	Burr Ridge, IL 60527
	 	Fax: (630) 325-4179

 

	By:	/s/ Michael Fonstein	 	 
	 	Name: Michael Fonstein	 	 
	 	Title: Chief Executive Officer	 	 

 

With a copy to (which shall not constitute notice):

 

Randy Saluck, Esq.

c/o Mortar Rock Capital

767 Third Avenue, 11th Floor

New York, NY 10017

Fax: (212) 308-3625

 

[REMAINDER OF PAGE INTENTIONALLY LEFT
BLANK

SIGNATURE PAGE FOR PURCHASER FOLLOWS]

 

     31

     

    

  

EXHIBITS AND SCHEDULES

 

	Exhibit A	Form of Note
	Exhibit B	Form of Warrant
	Exhibit C	Escrow Agreement
	Exhiblt D	Security Agreement
	Exhibit E	Form of Investor Questionnaire
	Exhibit F	Third Waiver and Consent
	 	 
	Sclr.edn.e 3.1(a)	 
	Schedule 3.1(g)	 
	Schedule 3.1(h)	 
	Schedule 3.1(1)	 
	Schedule 3.1 (o)	 
	Schedule 3.1(q)	 
	Schedule 3.1(r)	 
	Schedule 4.5	 

 

     32

     

    

 

Exhibit A

 

Form of Note

 

[see exhibit 10.16 to the Company’s registration
statement on Form S-1, as amended (file no. 333-214048) (the “Form S-1”)]

 

    A-1

     

    

 

Exhibit B

 

Form of Warrant

 

[see exhibit 4.5 to the Company’s registration
statement on Form S-1]

 

    B-1

     

    

 

Exhibit C

  

ESCROW AGREEMENT

 

This Agreement is dated as of [___________]
among Accelerated Pharma, Inc., a Delaware corporation (the "Company"), the parties identified on Schedule A hereto each
a "Purchasers", and collectively "Purchasers"), and Grushko & Mitnan, P.C. (the "Escrow' Agent'');

 

WITNESSETH:

 

WHEREAS, the Company and Purchasers have entered
into a Securities Purchase Agreement calling for the sale by the Company to the Purchasers of secured Notes and Warrants for an
aggregate purchase price of up to [__________]; and

 

WHEREAS, the parties hereto require the Company
to deliver the Notes against payment therefor, with such Notes, Warrants and the Escrowed Funds to be delivered to the Escrow Agent,
along With the other documents, instruments and payments hereinafter described, to be held in escrow and released by the Escrow
Agent in accordance with the terms and conditions of this Agreement; and

 

WHEREAS, the Escrow Agent is willing to serve
as escrow agent pursuant to the terms and conditions of this Agreement;

 

NOW THEREFORE, the parties agree as follows:

 

ARTICLE I

 

INTERPRETATION

 

1.1.          Definitions.
Capitalized terms used and not otherwise defined herein that are defined in the Securities Purchase Agreement shall have the meanings
given to such terms in the Securities Purchase Agreement, whenever used in this Agreement, the following terms shall have the following
respective meanings:

 

		·	"Agreement" means this Agreement and all amendments made hereto and thereto by written agreement between the parties;

 

		·	"Collateral Agent" shall mean Patricia Watkins;

 

		·	"Escrowed Payment" means an aggregate cash payment of up to [________], which is the Subscription Amount;

 

		·	"Fees" shall have the meaning set forth in Section 3.1(r) and on Schedule 3.: (r) to the Securities Purchase Agreement;

 

		·	"Initial Closing Date" shall have the meaning se; forth in Section 1 of the Securities Purchase Agreement;

 

		·	"Notes" means the notes due eighteen months after the Closing Date, in the form of Exhibit A TO the Securities Purchase
Agreement;

 

		·	"Security Agreement" means the Security Agreement entered into or to be entered into by the parties in reference
to the security interest granted pursuant to the Notes;

 

		·	"Securities Purchase Agreement" means the Securities Purchase Agreement (and the exhibits thereto) entered into or
to be entered into by the parties in reference to the sale and purchase of Notes;

 

		·	"Warrants" shall have the meaning set forth in Section 1.1 of the Securities

 

    C-1

     

    

 

Purchase Agreement;

 

		·	Collectively, the Company executed Securities Purchase Agreement Security Agreement, Notes, and Warrants are referred to as
"Company Documents"; and

 

		·	Collectively, the Escrowed Payment, and the Purchasers executed Securities Purchase Agreement, and Security Agreement are referred
to as "Purchasers Documents'.

 

1.2           Entire
Agreement. This Agreement along with the Company Documents and the Purchasers Documents to which the Purchasers and the Company
or Subsidiary are a par' constitute the entire agreement between the panics hereto pertaining to the Company Documents and Purchasers
Documents and supersedes all prior agreements, understandings, negotiations and discussions, whether oral or written, of the parties.
There are no warranties, representations and other agreements made by the parties in connection with the subject matter hereof,
except as specifically set forth in this Agreement, the Company Documents and the Purchasers Documents.

 

1.3.          Extended
Meanings. In this Agreement words importing the singular number include the plural and vice versa; words importing the masculine
gender include the feminine and neuter genders. The word "person" includes an individual, body corporate, partnership,
trustee or trust or unincorporated association, executor, administrator or legal representative.

 

1.4.          Waivers
and Amendments. This Agreement may be amended, modified, superseded, cancelled, renewed or extended, and the terms and conditions
hereof may be waived, only by a written instrument signed by all parties, or, in the case of a waiver, by the party waiving compliance.
Except as expressly stated herein, no delay on the par: of any party in exercising any right, power or privilege hereunder shall
operate as a waiver thereof, nor shall any waiver on the part of any party of any right, power or privilege hereunder preclude
any other or future exercise of any other right, power or privilege hereunder.

 

1.5           Headings.
The division of this Agreement into articles, sections, subsections and paragraphs and the insertion of headings are for convenience
of reference only and shall not affect the construction or interpretation of this Agreement.

 

1.6.          Law
Governing this Agreement. This Agreement shall be governed by and construed in accordance with the laws of the State of New York
without regard to conflicts of laws principles that would result in the application of the substantive laws of another jurisdiction.
Any action brought by either party against the other concerning the transactions contemplated by this Agreement shall bc brought
only in the state courts of New York or in the federal courts located in the state of New York. Both parties and the individuals
executing this Agreement and other agreements on behalf of the Company agree to submit to the jurisdiction of such courts and waive
trial by jury. The prevailing party (which shall be the party which receives an award most closely resembling the remedy or action
sought) shall be entitled to recover From the other party its reasonable attorney's fees and costs. In the event that any provision
of this Agreement or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute
or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed
modified to conform with such statute or rule of' law. Any such provision which may prove invalid or unenforceable under any law
shall not affect the validity or enforceability of any other provision of any agreement.

 

    C-2

     

    

 

1.7.          Specific
Enforcement Consent to Jurisdiction. The Company and Purchasers acknowledge and agree that irreparable damage would occur in the
event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise
breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent or cure breaches
of the provisions of this Agreement and to enforce specifically the terms and provisions hereof or thereof, this being in addition
to any other remedy to which any of them may be entitled by law or equity. Subject to Section 1.6 hereof, each of the Company and
Purchasers hereby waives, and agrees not to assert in any such suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of such court, that the suit, action or proceeding is brought in an inconvenient forum or that the
venue of the suit, action or proceeding is improper. Nothing in this Section shall affect or limit any right to serve process in
any other manner permitted by law.

 

ARTICLE II

DELIVERIES TO THE ESCROW AGENT

 

2.1.          Company
Deliveries. On or before the Initial Closing Date, the Company shall execute and deliver the Company Documents to the Escrow Agent.

 

2.2.          Purchasers
Deliveries. On or before the Initial Closing Date, Purchasers shall execute and deliver the Securities Purchase Agreements, and
Security Agreement, shall cause the Collateral Agent to execute and deliver the Security Agreement, and shall deliver the Escrowed
Payment in cash, to the Escrow Agent. The Escrowed Payment will be delivered pursuant to the following wire transfer instructions:

 

[____]

 

2.3.          Intention
to Create Escrow Over Company Documents and Purchasers Documents. The Purchasers and Company intend that the Company Documents
and Purchasers Documents shall be held in escrow by the Escrow Agent pursuant to this Agreement for their benefit as set forth
herein.

 

2.4.          Escrow
Agent to Deliver Company Documents and Purchasers Documents. The Escrow Agent shall hold and release the Company Documents and
Purchasers Documents only in accordance with the terms and conditions of this Agreement.

 

ARTICLE III

RELEASE OF COMPANY DOCUMENTS AND PURCHASERS
DOCUMENTS

 

3.1.          Release
of Escrow. Subject to the provisions of Section 4.2, the Escrow Agent shall release the Company Documents and Purchasers Documents
as follows:

 

On the Initial Closing Date, the Escrow Agent will simuitaneousiy
release the Company Documents to the Purchasers and release the Purchasers Documents to the Company, except that the Security Agreement,
and Subsidiary Guaranty, if any, will be released to the Collateral Agent.

 

Notwithstanding the above, upon receipt by the Escrow Agent of joint
written instructions ("joint Instructions") signed by the Company and the Purchasers, it shall deliver the Company Documents
and Purchasers Documents in accordance with the terms of the Joint Instructions.

 

    C-3

     

    

 

(e)          Anything
herein to the contrary notwithstanding, upon receipt by the Escrow

 

Agent of a final and non-appealable judgment, order, decree or award
of a court of competent jurisdiction (a "Court Order"), the Escrow Agent shall deliver the Company Documents and Purchasers
Documents in accordance with the Court Order. Any Court Order shall be accompanied by an opinion of counsel for the party presenting
the Court Order to the Escrow Agent (which opinion shall be satisfactory to the Escrow Agent) to the effect that the court issuing
the Court Order has competent jurisdiction and that the Court Order is final and non-appealable.

 

3.2.          The
Initial Closing may take place on or before [_________]. After [_______], the Escrow Agent will promptly return the applicable
Company Documents to the Company and return the Purchasers Documents to the Purchasers.

 

3.3.          Acknowledgement
of Company and Purchasers: Disputes. The Company and the

 

Purchasers acknowledge that the only terms and conditions upon which
the Company Documents and Purchasers Documents are to be released are set forth in Sections 3 and 4 of this Agreement. The Company
and the Purchasers reaffirm their agreement to abide by the terms and conditions of this Agreement with respect to the release
of the Company Documents and Purchasers Documents. Any dispute with respect to the release of the Company Documents and Purchasers
Documents shall be resolved pursuant to Section 4.2 or by agreement between the Company and Purchasers.

 

ARTICLE IV

CONCER-NENG THE ESCROW AGENT

 

4.1.          Duties
and Responsibilities of the Escrow Anent The Escrow Agent's duties and responsibilities shall be subject to the following terms
and conditions:

 

(a)          The
Purchasers and Company acknowledge and agree that the Escrow Agent (i) shall not be responsible for or bound by, and shall not
be required to inquire into whether either the Purchasers or Company is entitled to receipt of the Company Documents and Purchasers
Documents pursuant to any other agreement or otherwise; (ii) shall be obligated only for the performance of such duties as are
specifically assumed by the Escrow Agent pursuant to this Agreement; (Hi) may rely on and shall be protected in acting or refraining
from acting upon any written notice, instruction, instrument, statement, request or document furnished to it hereunder and believed
by the Escrow Agent in good faith to be genuine and to have been signed or presented by the proper person or party, without being
required to determine the authenticity or correctness of any fact stated therein or the propriety or validity' or the service thereof;
(iv) may assume that any person believed by the Escrow Agent in good faith to be authorized to give notice or make any statement
or execute any document in connection with the provisions hereof is so authorized; (v) shall not be under any duty to give the
property held by Escrow Agent hereunder any greater degree of care than Escrow Agent gives its own similar property; and (vi) may
consult counsel satisfactory to Escrow Agent, the opinion of such counsel to be full and complete authorization and protection
in respect of any action taken, suffered or omitted by Escrow Agent hereunder in good faith and in accordance with the opinion
of such counsel.

 

    C-4

     

    

 

(b)          The
Purchasers and Company acknowledge that the Escrow Agent is acting solely as a stakeholder at their request and that the Escrow
Agent shall not be liable for any action taken by Escrow Agent in good faith and believed by Escrow Agent to be authorized or within
the rights or powers conferred upon Escrow Agent by this Agreement. The Purchasers and Company, jointly and severally, agree to
indemnify and hold harmless the Escrow Agent and any of Escrow Agent's partners, employees, agents and representatives for any
action taken or omitted to be taken by Escrow Agent or any of them hereunder, including the fees of outside counsel and other costs
and expenses of defending itself against any claim or liability under this Agreement, except in the case of gross negligence or
willful misconduct on Escrow Agent's part committed in its capacity as Escrow Agent under this Agreement, The Escrow Agent shall
owe a duty only to the Purchasers and Company under this Agreement and to no other person.

 

(c)          The
Purchasers and Company jointly and severally agree to reimburse the Escrow Agent for reasonable outside counsel fees, to the extent
authorized hereunder and incurred in connection with the performance of its duties and responsibilities hereunder.

 

(d)          The
Escrow Agent may at any time resign as Escrow Agent hereunder by giving five (5) days prior written notice of resignation to the
Purchasers and the Company. Prior to the effective date of the resignation as specified in such notice, the Purchasers and Company
will issue to the Escrow Agent a Joint Instruction authorizing delivery of the Company Documents and Purchasers Documents to a
substitute Escrow Agent selected by the Purchasers and Company. If no successor Escrow Agent is named by the Purchasers and Company,
the Escrow Agent may apply to a court of competent jurisdiction in the State of New York for appointment of a successor Escrow
Agent, and to deposit the Company Documents and Purchasers Documents with the clerk of any such court.

 

(e)          The
Escrow Agent does not have and will not have any interest in the Company Documents and Purchasers Documents, but is serving only
as escrow agent, having only possession thereof The Escrow Agent shall not be liable for any loss resulting from the making or
retention of any investment in accordance with this Escrow Agreement.

 

(f)          This
Agreement sets forth exclusively the duties of the Escrow Agent with respect to any and all matters pertinent thereto and no implied
duties or obligations shall be read into this Agreement.

 

(g)          The
Escrow Agent shall be permitted to act as counsel for the Purchasers in any dispute as to the disposition of the Company Documents
and Purchasers Documents, in any other dispute between the Purchasers and Company, whether or not the Escrow Agent is then holding
the Company Documents and Purchasers Documents and continues to act as the Escrow Agent hereunder.

 

(h)          The
provisions of this Section 4.1 shall survive the resignation of the Escrow Agent or the termination of this Agreement.

 

    C-5

     

    

 

4.2.          Dispute
Resolution: Judgments. Resolution of disputes arising under this Agreement shall be subject to the following terms and conditions:

 

(a)          If
any dispute shall arise with respect to the delivery, ownership, right of possession or disposition of the Company Documents and
Purchasers Documents, or if the Escrow Agent shall in good faith be uncertain as to its duties or rights hereunder, the Escrow
Agent shall be authorized, without liability to anyone, to (i) refrain from taking any action other than to continue to hold the
Company Documents and Purchasers Documents pending receipt of a Joint Instruction from the Purchasers and Company, or (ii) deposit
the Company Documents and Purchasers Documents with any court of competent jurisdiction in the State of New York, in which event
the ESCFONV Agent shall give written notice thereof to the Purchasers and the Company and shah thereupon be relieved and discharged
from al: further obligations pursuant to this Agreement. The Escrow Agent may, but shall be under no duty to, institute or defend
any legal proceedings which relate to the Company Documents and Purchasers Documents. The Escrow Agent shah have the right to retain
counsel if it becomes involved in any disagreement, dispute or litigation on account of this Agreement or otherwise determines
that it is necessary to consul: counsel.

 

(b)          The
Escrow Agent is hereby expressly authorized to comply with and obey any Court Order. In case the Escrow Agent obeys or complies
with a Court Order, the Escrow Agent shah not be liable to the Purchasers and Company or to any other person, firm, corporation
or entity by reason of such compliance.

 

ARTICLE V

GENERAL MATTERS

 

5.1           Termination.
This escrow shall terminate upon the release of al: of the Company Documents and Purchasers Documents or at any time upon the agreement
in writing of the Purchasers and Company.

 

5.2.          Notices.
All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing
and, unless othenvise specified herein, shah be (i) personal:), served, (ii) deposited in the mail, registered or certified, return
receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted
by hand delivery, telegram, or facsimile, addressed as set forth beiow or to such other address as such party shall have specified
most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed
effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine,
at the address or number designated below (if delivered on a business day during normal business hours where such notice is to
be received), or the first business day foilowing such delivery (if delivered other than on a business day during normal business
hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service,
fully prepaid, addressed to such address, or upon actua: receipt of such mailing, whichever shall firs: occur. The addresses for
such communications shall be:

 

	(a)	If to the Company, to:
	 	Accelerated Pharrna,
	 	15 W l55 81st Street
	 	Burr Ridge, FL 60527
	 	Attn: Michael Fonstein, CEO
	 	Fax: (630) 325-4:79

 

With a copy by fax only to (which shall not constitute notice):

 

	 	Polsinelli PC
	 	161 N. Clark Avenue, Suite 4200
	 	Chicago, IL 6060:
	 	Arm: Teddy C. Scott, Jr., Ph.D.
	 	Fax: (312) 873-2913

 

		(b)	If to the Purchasers: to: the addresses and fax numbers
listed on Schedule A hereto.

 

With a copy by facsimile only to (which shall not constitute notice):

 

	 	Grushko & Mittman, P.C.
	 	515 Rockaway Avenue
	 	Valley Stream, New York 11581
	 	Attn: Edward M. Grushko, Esq.
	 	Fax: (212) 697-3575

 

		(c)	If to the Escrow Agent, to:

 

	 	Grushko & Mittman, P.C.
	 	515 Rockaway Avenue
	 	Valley Stream, New York 11581
	 	Fax: (2 I 2) 697-3575

 

or to such other address as any of them shall give to the others
by notice made pursuant to this Section 5.2.

 

5.3.          Interest.
The Escrowed Payment shall not be held in an interest bearing account nor will interest be payable in connection therewith. In
the event the Escrowed Payment is deposited in an interest bearing account, any interest earned on the Escrowed Payment will be
paid in the New York State Client Protection Fund or for a similar purpose.

 

5.4.          Assignment;
Binding Agreement. Neither this Agreement nor any right or obligation hereunder shall be assignable by any party without the prior
written consent of the other parties hereto. This Agreement shall entire to the benefit of and be binding upon the parties hereto
and their respective legal representatives, successors and assigns.

 

5.5.          Invalidity.
In the event that any one or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid,
illegal, or unenforceable in any respect for any reason, the validity, legality and enforceability of any such provision in every
other respect and of the remaining provisions contained herein shall not be in any way impaired thereby, it being intended that
all of the rights and privileges of the parties hereto shall be enforceable to the fullest extent permitted by law.

 

5.6.          Counterparts/Execution.
This Agreement may be executed in any number of counterparts and by different signatories hereto on separate counterparts, each
of which, when so executed, shall be deemed an original, but all such counterparts shall constitute but one and the same instrument.
This Agreement may be executed by facsimile transmission and delivered by facsimile transmission.

 

5.7.          Agreement.
Each of the undersigned states that he has read the foregoing Escrow Agreement and understands and agrees to it.

 

[THIS SPACE INTENTIONALLY LEFT BLANK]

 

    C-6

     

    

 

IN WITNESS WHEREOF, the undersigned have executed and delivered
this Escrow Agreement, as of the date first written above.

 

	COMPANY:
	 
	ACCELERATED PHARMA, INC. A Delaware corporation
	 
	ESCROW AGENT:
	 
	"PURCHASERS": 

  

    C-7

     

    

 

Exhibit D

 

SECURITY AGREEMENT

 

This SECURITY AGREEMENT, dated as of [_______]
(this “Agreement”), is among Accelerated Pharma, Inc, a Delaware corporation (the “Company”). each Subsidiary
of the Company which shah become a party to this Agreement by execution and delivery of the form annexed hereto as Annex A and
the Subsidiary Guaranty annexed thereto (each such Subsidiary, a “Guarantor” and together with the Company, the “Debtors”).
Patricia Watkins, as collateral agent (the “Collateral Anent”) for and the holders of the Company’s Secured Convertible
Notes due [_________], in the original aggregate principal amount of up to $[_________] (collectively, the “Notes”)
(collectively, the “Secured Parties”).

 

WITNESSETH:

 

WHEREAS, pursuant to the Securities Purchase
Agreement (as defined in the Notes), the Secured Parties have severally agreed to extend the loans to the Company evidenced by
the Notes;

 

WHEREAS, pursuant to a certain Subsidiary
Guaranty (“Guaranty”) to be dated as of the date of the Additional Debtor Joinder, forms of which are annexed hereto
as Annex A, the Guarantor agrees to guarantee and act as surety for payment of such Notes, and other obligations of the Company;

 

WHEREAS, in order to induce the Secured
Parties to extend the loans evidenced by the Notes, each Debtor has agreed to execute and deliver to the Collateral Agent this
Agreement and to grant Collateral Agent, for the ratable benefit of the Secured Parties, a security interest in certain property
of such Debtor to secure the prompt payment, performance and discharge in full of all of the Debtors’ obligations under the
Notes and Transaction Documents.

 

NOW, THEREFORE, in consideration of the
agreements herein contained and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
the parties hereto hereby agree as follows:

 

1            Certain Definitions. As used in this Agreement, the following
terms shall have the meanings set forth in this Section 1. Terms used but not otherwise defined in this Agreement that are defined
in Article S or 9 of the t:CC (such as “account,” “chattel paper,” “commercial tort claim,”
“deposit account,” “document,” “equipment,” “fixtures,” “general intangibles,”
“goods,” “instruments,” “inventory,” “investment property,” “letter-of-credit
rights,” “proceeds” and ‘‘supporting obligations”) shall have the respective meanings Riven
such terms in Article S or 9 of the UCC, as applicable. Upper case terms shall have the meanings attributed to them in the Securities
Purchase Agreement.

 

(a)          “Collateral”
means the collateral in which the Collateral Agent is granted a security interest by this Agreement and which shall include the
following personal property of the Debtors, whether presently owned or existing or hereafter acquired or coming into existence,
wherever situated, and all additions and accessions thereto and all substitutions and replacements thereof, and all proceeds, products
and accounts thereof, including, without limitation, all proceeds from the disposition, sale or transfer of the Collateral and
of insurance covering the same and of any tort claims in connection therewith, and all dividends, interest, cash, notes, securities,
equity interest or other property at any time and from time to time acquired, receivable or otherwise distributed in respect of,
or in exchange for, any or all of the Pledged Securities (as defined below):

 

    D-1

     

    

 

(i)          All
goods, including, without limitation, (A) all machinery, equipment, computers, motor vehicles, trucks, tanks, boats, ships, appliances,
furniture, special and general tools, fixtures, test and quality control devices and other equipment of every kind and nature and
wherever situated, together with all documents of title and documents representing the same, all additions and accessions thereto,
replacements therefor, all parts therefor, and all substitutes for any of the foregoing and all other items used and useful in
connection with any Debtor’s businesses and al: improvements thereto; and (B) all inventory;

 

(ii)         All
contract rights and other general intangibles, including, without limitation, all partnership interests, membership interests,
stock or other securities, rights under any of the Organizational Documents (as defined herein), agreements related to the Pledged
Securities (as defined herein), licenses, distribution and other agreements, computer software (whether “off-theshelf;”
licensed from any third party or developed by any Debtor), computer software development rights, leases, franchises, customer lists,
qua:ity control procedures, grants and rights, goodwill, trademarks, service marks, trade styles, trade names, patents, patent
applications, copvriallts, and income tax refunds;

 

(iii)        All
accounts, together with all instruments, all documents of title representing any of the foregoing, all rights in any merchandising,
goods, raw materials, timber cut or to be cut, oil, gas, hydrocarbons, and minerals extracted or to be extracted, equipment, motor
vehicles and trucks which any of the same may represent, and all right, title, security and guaranties with respect to each account,
including any right of stoppage in transit;

 

(iv)        All
documents, letter-of-credit rights, instruments and chattel taper;

 

(v)         All
commercial tort claims;

 

(vi)        All
deposit accounts and all cash (whether or not deposited in such deposit accounts);

 

(vii)       All
investment property;

 

(viii)      All supporting
obligations;

 

(ix)         All
files, records, books of account, business papers, and computer programs; and

 

(x)          the
products and proceeds of all of the foregoing Collateral set forth in clauses (i)-(ix) above.

 

    D-2

     

    

 

Without limiting the generality of the
foregoing, the “Collateral” shall include all investment property and general intangibles respecting ownership and/or
other equity interests in Guarantor, including, without limitation, the shares of capital stock and the other equity interests
listed on Schedule H hereto (as the same may be modified from time to time pursuant to the terms hereof), and any other shares
of capital stock and/or other equity interests of any other direct or indirect Subsidiary of any Debtor obtained in the future,
and, in each case, all certificates representing such shares and/or equity interests and, in each case, all rights, options, warrants,
stock, other securities and/or equity interests that may hereafter be received, receivable or distributed in respect of, or exchanged
for, any of the foregoing and all rights arising under or in connection with the Pledged Securities, including, but not limited
to, all dividends, interest and cash.

 

Notwithstanding the foregoing, nothing
herein shall be deemed to constitute an assignment of any asset which, in the event of an assignment, becomes void by operation
of applicable law or the assignment of which is otherwise prohibited by applicable law (in each case to the extent that such applicable
law is not overridden by Sections 9-406, 9-407 and/or 9-408 of the UCC or other similar applicable law); provided however, that
to the extent permitted by applicable law, this Agreement shall create a valid security interest in such asset and, to the extent
permitted by applicable law, this Agreement shall create a valid security interest in the proceeds of such asset.

 

(b)          “Intellectual
Property” means the collective reference to all rights, priorities and privileges relating to intellectual property, whether
arising under United States, multinational or foreign laws or othenvise, including, without limitation, (i) all copyrights arising
under the laws of the United States, any other country or any political subdivision thereof, whether registered or unregistered
and whether published or unpublished, all registrations and recordings thereof, and all applications in connection therewith, including,
without limitation, all registrations, recordings and applications in the United States Copyright Office, (ii) all patents of the
United States, any other country or any political subdivision thereof, all reissues and extensions thereof, and all applications
for letters patent of the United States or any other country and all divisions, continuations and continuations-in-part thereof,
(iii) all trademarks, trade names, corporate names, company names, business names, fictitious business names, trade dress, service
marks, logos, domain names and other source or business identifiers, and all goodwill associated therewith, now existing or hereafter
adopted or acquired, all registrations and recordings thereof, and all applications in connection therewith, whether in the United
States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country
or any political subdivision thereof, or otherwise, and all common law rights related thereto, (iv) all trade secrets arising under
the laws of the United States, any other country or any political subdivision thereof, (v) all rights to obtain any reissues, renewals
or extensions of the foregoing, (vi) all licenses for any of the foregoing, (vii) any items included in the definition of Intellectual
Property Rights as defined in the Securities Purchase Agreement and not set forth above, and (viii) all causes of action for infringement
of the foregoing.

 

(c)          “Majority
in Interest” means, at any time of determination, the holders of more than fifty percent (50%) (based on then-outstanding
principal amounts and accrued interest of Notes at the time of such determination) of the Notes.

 

(d)          “Necessary
Endorsement” means undated stock powers endorsed in blank and other proper instruments of assignment duly executed and such
other instruments or documents as the Collateral Agent (as that term is defined below) may reasonably request.

 

    D-3

     

    

 

(e)          “Obligations”
means all of the liabilities and obligations (primary, secondary, direct, contingent, sole, joint or several) due or to become
due, or that are now or may be hereafter contracted or acquired, or owing to, of any Debtor to the Secured Parties, including,
without limitation, all obligations under this Agreement, the Notes, the Guaranty and obligations under any other Transaction Document,
instrument, agreement or other document executed and/or delivered in connection herewith or therewith in each case, whether now
or hereafter existing, voluntary or involuntary, direct or indirect, absolute or contingent, liquidated or unliquidated, whether
or not jointly owed with others, and whether or not from time to time decreased or extinguished and later increased, created or
incurred, and all or any portion of such obligations or liabilities that are paid, to the extent all or any part of such payment
is avoided or recovered directly or indirectly from any of the Secured Parties as a preference, fraudulent transfer or otherwise
as such obligations may be amended, supplemented, converted, extended or modified from time to time. Without limiting the generality
of the foregoing, the term “Obligations” shall include, without limitation: (i) principal of, and interest on the Notes
and the loans extended pursuant thereto; (ii) any and all other fees, indemnities, costs, obligations and liabilities of the Debtors
from time to time under or in connection with this Agreement, the Notes and any other Transaction Documents, instruments, agreements
or other documents executed and/or delivered in connection herewith or therewith; and (iii)all amounts (including but not limited
to post-petition interest) in respect of the foregoing that would be payable but for the fact that the obligations to pay such
amounts are unenforceable or not allowable due to the existence of a bankruptcy, reorganization or similar proceeding involving
any Debtor.

 

(f)          “Organizational
Documents” means with respect to any Debtor, the documents by which such Debtor was organized (such as a certificate of incorporation,
certificate of limited partnership or articles of organization, and including, without limitation, any certificates of designation
for preferred stock or other forms of preferred equity) and which relate to the internal governance of such Debtor (such as bylaws,
a partnership agreement or an operating, limited liability or members agreement).

 

(g)          “Pledged
Securities” shall have the meaning ascribed to such term in Section 4(i).

 

(h)          “UCC”
means the Uniform Commercial Code of the State of New York and or any other applicable law of any state or states which has jurisdiction
with respect to all, or any portion of, the Collateral or this Agreement, from time to time. It is the intent of the parties that
defined terms in the UCC should be construed in their broadest sense so that the term “Collateral” will be construed
in its broadest sense. Accordingly if there are, from time to time, changes to defined terms in the UCC that broaden the definitions,
they are incorporated herein and if existing definitions in the UCC are broader than the amended definitions, the existing ones
shall be controlling.

 

2            Grant of Security Interest in Collateral. As an inducement
for the Secured Parties to extend the loans as evidenced by the Notes and to secure the complete and timely payment, performance
and discharge in full, as the case may be, of all of the Obligations, each Debtor hereby unconditionally and irrevocably pledges,
grants and hypothecates to the Secured Parties a security interest in and to, a lien upon and a right of set-off against all of
their respective right, title and interest of whatsoever kind and nature in and to, the Collateral (a “Security Interest”
and, collectively, the “Security Interests”).

 

    D-4

     

    

 

3            Delivery of Certain Collateral. At any time at the request
of the Collateral Agent, each Debtor shall deliver or cause to be delivered to the Collateral Agent, any and all certificates and
other instruments or documents representing any of the Collateral, in each case, together with all Necessary Endorsements.

 

4            Representations, Warranties, Covenants and Agreements of
the Debtors. Except as set forth under the corresponding section of the disclosure schedules delivered to the Secured Parties and
Collateral Agent concurrently herewith (the “Disclosure Schedules”), which Disclosure Schedules shall be deemed a part
hereof. As of the date hereof, each Debtor represents and warrants to the Secured Parties as follows and, until the repayment in
full of the Obligations, covenants and agrees with, the Secured Parties as follows:

 

(a)          Each
Debtor has the requisite corporate, partnership, limited liability company or other power and authority to enter into this Agreement
and otherwise to carry out its obligations hereunder. The execution, delivery and performance by each Debtor of this Agreement
and the filings contemplated herein have been duly authorized by all necessary action on the part of such Debtor and no further
action is required by such Debtor. This Agreement, when executed and delivered, will constitute the legal, valid and binding obligation
of each Debtor, enforceable against each Debtor in accordance with its terms except as such enforceability may be limited by applicable
bankruptcy, insolvency, reorganization and similar laws of general application relating to or affecting the rights and remedies
of creditors and by general principles of equity.

 

(b)          The
Debtors have no place of business or offices where their respective books of account and records are kept (other than temporarily
at the offices of its attorneys or accountants) or places where Collateral is stored or located, except as set forth on Schedule
A attached hereto. Except as specifically set forth on Schedule A, each Debtor is the record owner of the real property where such
Collateral is located, and there exist no mortgages or other liens or. any such real property or on the Collateral except for Permitted
Liens (as defined in the Securities Purchase Agreement), which are identified on Schedule B hereto. Except as disclosed on Schedule
A and except for Collateral to be held by the Collateral Agent, none of such Collateral is in the possession of any consignee,
bailee, warehouseman, agent or processor.

 

(c)          Except
for Permitted Liens and except as set forth on Schedule B attached hereto, the Debtors are the sole owner of the Collateral (except
for non-exclusive licenses granted by any Debtor in the ordinary course of business), free and clear of any liens, security interests,
encumbrances, rights or claims, and are fully authorized to grant the Security Interests. Except as set forth on Schedule B attached
hereto, there is not on file in any governmental or regulatory authority, agency or recording office an effective financing statement,
security agreement, license or transfer or any notice of any of the foregoing (other than those that will be filed in favor of
the Secured Parties pursuant to this Agreement) covering or affecting any of the Collateral.

 

(d)          No
written claim has been received that any Collateral or any Debtor’s use of any Collateral violates the rights of any third
party. There has been no adverse decision to any Debtor’s claim of ownership rights in or exclusive rights to use the Collateral
in any jurisdiction or to any Debtor’s right to keep and maintain such Collateral in full force and effect, and there is
no proceeding involving said :”rights pending or, to the best knowledge of any Debtor, threatened before any court, judicial
body, administrative or regulator)’ agency, arbitrator or other governmental authority,

 

    D-5

     

    

 

(e)          Each
Debtor shall at all times maintain its books of account and records relating to the Collateral at its principal place of business
and its Collateral at the locations set forth on Schedule A attached hereto and may not relocate such books of account and records
or tangible Collateral except in the ordinary course of sales unless it delivers to the Secured Parties at :east 15 days prior
to such relocation (i) written notice of such relocation and the new location thereof (which must be within the United States)
and (ii) evidence that appropriate financing statements under the UCC and other necessary documents have been fled and recorded
and other steps have been taken to perfect the Security Interests to create in favor of the Secured Parties a valid, perfected
and continuing perfected first priority lien in the Collateral, except as otherwise permitted hereby.

 

(f)          This
Agreement creates in favor of the Secured Parties a valid security interest in the Collateral, subject only to Permitted Liens
securing the payment and performance of the Obligations. Upon making the filings described in the immediately following paragraph,
all security interests created hereunder in any Collateral that may be perfected by filing Uniform Commercial Code financing statements
shall have been duly perfected. Except for the filing of the Uniform Commercial Code financing statements referred to in the immediately
following paragraph, the recordation of the Intellectual Property Security Agreement (as defined below) with respect to copyrights
and copyright applications in the United States Copyright Office referred to in paragraph (m), the execution and delivery of deposit
account control agreements satisfying the requirements of Section 9-:04(a)(2) of the LICC with respect to each deposit account
of the Debtors, and the delivery of the certificates and other instruments provided in Section 3, no action is necessary :o create,
perfect or protect the security interests created hereunder. Without limiting the generality of the foregoing, except for the tiling
of said financing statements, the recordation of said Intellectual Property Security Agreement, and the execution and delivery
of said deposit account control agreements, no consent of any third parties and no authorization, approval or other action by,
and no notice to or filing with, any governmental authority or regulatory body is required for (i) the execution, delivery and
performance of this Agreement, (ii) the creation or perfection of the Security Interests created hereunder in the Collateral or
(iii) the enforcement of the rights of the Collateral Agent and the Secured Parties hereunder,

 

(g)          Each
Debtor hereby authorizes the Collateral Agent to file one or more financing statements under the UCC, with respect to the Security
Interests, with the proper filing and recording agencies in any jurisdiction deemed proper by it and authorizes Collateral Agent
to take any other action in Collateral Agent’s absolute discretion to effectuate, memorialize and protect Secured Parties’
interest and rights under this Agreement.

 

(h)          The
execution, delivery and performance of this Agreement by the Debtors does not (i) violate any of the provisions of any Organizational
Documents of any Debtor or, to the knowledge of any Debtor, any judgment, decree, order or award of any court, governmental body
or arbitrator or any applicable law, rule or regulation applicable to any Debtor or (ii) to the knowledge of each Debtor, conflict
with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give to
others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any
agreement, credit facility, debt or other instrument (evidencing any Debtor’s debt or otherwise) or other understanding to
which such Debtor is a party or by which any property or asset of any Debtor is bound or affected. If any, all required consents
(including, without limitation, from stockholders or creditors of any Debtor) necessary for any Debtor to enter into and perform
its obligations hereunder have been obtained.

 

    D-6

     

    

 

(i)          The
capital stock and other equity interests listed on Schedule H hereto (the “Pledged Securities”) represent all of the
capital stock and other equity interests of the Guarantor, and other Subsidiaries, if any, and represent all capital stock and
other equity interests owned, directly or indirectly, by the Company. All of the Pledged Securities, if applicable, are validly
issued, fully paid and nonassessable, and the Company is the legal and beneficial owner of the Pledged Securities, free and clear
of any lien, security interest or other encumbrance except for the security interests created by this Agreement and other Permitted
Liens.

 

(j)          The
ownership and other equity interests in partnerships and limited liability companies (if any) included in the Collateral (the “Pledged
Interests”) by their express terms do not provide that they are securities governed by Article 8 of the UOC and are not held
in a securities account or by any financial intermediary.

 

(k)          Except
for Permitted Liens, each Debtor shall at all times maintain the liens and Security Interests provided for hereunder as valid and
perfected first priority liens and security interests in the Collateral in favor of the Secured Parties until this Agreement and
the Security Interest hereunder shall be terminated pursuant to Section 14 hereof. Each Debtor hereby agrees to defend the same
against the claims of any and all persons and entities. Each Debtor shall safeguard and protect all Collateral for the account
of the Secured Parties. Upon request of the Collateral Agent, each Debtor will sign and deliver to the Collateral Agent on behalf
of the Secured Parties at any time or from time to time one or more financing statements pursuant to the UCC in form reasonably
satisfactory to the Collateral Agent and will pay the cost of filing the same in all public offices wherever filing is, or is deemed
by the Collateral Agent to be, necessary or desirable to effect the rights and obligations provided for herein. Without limiting
the generality of the foregoing, each Debtor shall pay all fees, taxes and other amounts necessary to maintain the Collateral and
the Security Interest hereunder, and each Debtor shall obtain and furnish to the Collateral Agent from time to time, upon demand,
such releases and/or subordinations of claims and liens (other than Permitted Liens) that may be required to maintain the priority
of the Security Interest hereunder.

 

(l)          Other
than with respect to Permitted Liens, no Debtor will transfer, pledge, hypothecate, encumber, license, sell or otherwise dispose
of any of the Collateral (except for non-exclusive licenses granted by a Debtor in its ordinary course of business, sales of inventory
by a Debtor in its ordinary course of business and disposition of obsolete equipment) without the prior written consent of the
Collateral Agent. The foregoing notwithstanding, Debtor may replace noncash components of the Collateral with a cash or Cash Equivalent
deposit made at an institution subject to a cash account control agreement acceptable to the Secured Parties, provided the amount
of cash deposited subject to such agreement is not less than the highest amount of the Obligations that may be outstanding pursuant
to the Transaction Documents. Cash Equivalent shall mean U.S. government Treasury bills, bank certificates of deposit, bankers
acceptances, corporate commercial paper and other money market instruments.

 

(m)          Each
Debtor shall keep and preserve its equipment, inventory and other tangible Collateral in good condition, repair and order and shall
not operate or locate any such Collateral (or cause to be operated or located) in any area excluded from insurance coverage.

 

    D-7

     

    

 

(n)          Each
Debtor shall maintain with financially sound and reputable insurers, insurance with respect to the Collateral, including Collateral
hereafter acquired, against loss or damage of the kinds and in the amounts customarily insured against by entities of established
reputation having similar properties similarly situated and in such amounts as are customarily carried under similar circumstances
by other such entities and otherwise as is prudent for entities engaged in similar businesses but in any event sufficient to cover
the full replacement cost thereof. Each Debtor shall cause each insurance policy issued in connection herewith to provide, and
the insurer issuing such policy to certify to the Collateral Agent, that (a) the Collateral Agent will be named as lender loss
payee and additional insured under each such insurance policy; and (b) if such insurance is proposed to be cancelled or materially
changed for any reason whatsoever, such insurer or the Company will promptly notify the Collateral Agent. In addition, the Collateral
Agent will have the right (but no obligation) at its election to remedy any default in the payment of premiums within thirty (30)
days of notice from the Company or the insurer of any such default. If no Event of Default (as defined in the Notes) exists and
if the proceeds arising out of any claim or series of related claims do not exceed $100,000, loss payments in each instance will
be applied by the applicable Debtor to the repair and/or replacement of property with respect to which the loss was incurred to
the extent reasonably feasible, and any loss payments or the balance thereof remaining, to the extent not so applied, shall be
payable to the applicable Debtor; provided , however that payments received by any Debtor after an Event of Default occurs and
is continuing or in excess of $100,000 for any occurrence or series of related occurrences shall be paid to the Collateral Agent
on behalf of the Secured Parties and, if received by such Debtor, shall be held in trust for the Secured Parties and immediately
paid over to the Collateral Agent unless otherwise directed in writing by the Collateral Agent. Copies of such policies or the
related certificates, in each case, naming the Collateral Agent as lender loss payee and additional insured shall be delivered
to the Collateral Agent at least annually and at the time any new policy of insurance is issued.

 

(o)          Each
Debtor shall, within ten (10) days of obtaining knowledge thereof, advise Collateral Agent promptly, in sufficient detail, of any
material adverse change in the Collateral, and of the occurrence of any event which would have a material adverse effect on the
value of the Collateral or on the Secured Parties’ security interest.

 

(p)          (p)          Each
Debtor shall promptly execute and deliver to the Collateral Agent such further deeds, mortgages, assignments, security agreements,
financing statements or other instruments, documents, certificates and assurances and take such further action as the Collateral
Agent may from time to time request and may in its sole discretion deem necessary to perfect, protect or enforce the Secured Parties’
security interest in the Collateral including, without limitation, one or more deposit account control agreements, and if applicable,
the execution and delivery of a separate security agreement with respect to each Debtor’s Intellectual Property (“Intellectual
Property Security Agreement”) in which the Secured Parties have been granted a security interest hereunder, all substantially
in forms reasonably acceptable to the Collateral Agent, which Intellectual Property Security Agreement, and other such documents
and agreements other than as stated therein, shall be subject to all of the terms and conditions hereof.

 

    D-8

     

    

 

(q)          Each
Debtor shall permit the Collateral Agent and its representatives and agents to inspect the Collateral during normal business hours
and upon reasonable prior notice, and to make copies of records pertaining to the Collateral as may be reasonably requested by
the Collateral Agent from time to time.

 

(r)          Each
Debtor shall take commercially reasonable steps necessary to diligently pursue and seek to preserve, enforce and collect any rights,
claims, causes of action and accounts receivable in respect of the Collateral.

 

(s)          Each
Debtor shall promptly notify the Secured Parties in sufficient detail upon becoming aware of any attachment, garnishment, execution
or other legal process levied against any Collateral and of any other information received by such Debtor that may materially affect
the value of the Collateral, the Security Interest or the rights and remedies of the Secured Parties hereunder.

 

(t)          All
information heretofore, herein or hereafter supplied to the Secured Parties by or on behalf of any Debtor wit:: respect to the
Collateral is accurate and complete in all material respects as of the date furnished and in light of the circumstances under which
such statements were made.

 

(u)          Each
Debtor shall at all times preserve and keep in full force and effect its existence and good standing and any rights and franchises
material to its business.

 

(v)         No
Debtor will change its name, type of organization, jurisdiction of organization, organizational identification number (if it has
one), legal or corporate structure, or add any new fictitious name unless it provides at least 15 days prior written notice to
the Collateral Agent of such change and, at the time of such written notification, such Debtor provides any financing statements
or fixture Minas necessary to perfect and continue the perfection of the Security Interests granted and evidenced by this Agreement.

 

(w)          Except
in the ordinary course of business, no Debtor may consign any of its inventory or sell any of its inventory on bill and hold; sale
or return, sale on approval, or other conditional terms of sale without the consent of the Collateral Agent which shall not be
unreasonably withheld.

 

(x)          No
Debtor may relocate its chief executive office to a new location without providing 15 days prior written notification thereof to
the Secured Parties and provided that at the time of such written notification, such Debtor provides any financing statements necessary
to perfect and continue the perfection of the Security Interests granted and evidenced by this Agreement.

 

(y)          Each
Debtor was organized and remains organized solely under the laws of the state set forth next to such Debtor’s name in Schedule
D attached hereto, which Schedule D sets forth each Debtor’s organizational identification number or, if any Debtor does
not have one, states that one does not exist.

 

(z)          

 

(i)          The
actual name of each Debtor is the name set forth in Schedule D attached hereto;

 

    D-9

     

    

 

(ii)         no
Debtor has any trade names except as set forth on Schedule E attached hereto;

 

(iii)        no
Debtor has used any name other than that stated in the preamble hereto or as set forth on Schedule E For the preceding five years;
and

 

(iv)        no
entity has merged into any Debtor or been acquired by any Debtor within the past five years except as set forth on Schedule E.

 

(aa)         At
any time that any Collateral consists of instruments, certificated securities or other items that require or permit possession
by a secured party to perfect the security interest created hereby, the applicable Debtor shall deliver such Collateral to the
Collateral Agent.

 

(bb)         During
the continuance of an Event of Default, each Debtor, in its capacity as issuer, hereby agrees to comply with any and all orders
and instructions of Collateral Agent regarding the Pledged Securities consistent with the terms of this Agreement without the further
consent of any Debtor as contemplated by Section 8-106 (or any successor section) of the UCC. Further, each Debtor agrees, solely
with respect to the Pledged Securities, that it shall not enter into a similar agreement (or one that would confer “control”
within the meaning of Article S of the UCC) with any other person or entity.

 

(cc)         each
Debtor shall cause all tangible chattel paper constituting Collateral to be delivered to the Collateral Agent or if such delivery
is not possible; then to cause such tangible chattel paper to contain a legend noting that it is subject to the security interest
created by this Agreement. To the extent that any Collateral consists of electronic chattel paper, the applicable Debtor shall
cause the underlying chattel paper to be “marked” within the meaning of Section 9-105 of the UCC (or successor section:
hereto).

 

(dd)         If
there is any investment property or deposit account included as Collateral that can be perfected by “control” through
an account control agreement, the applicable Debtor shall at the request of the Collateral Agent cause such an account control
agreement, in form and substance in each case satisfactory to the Collateral Agent, to be entered into and delivered to the Collateral
Agent for the benefit of the Secured Parties.

 

(ee)         To
the extent that any Collateral consists of letter-of-credit rights, the applicable Debtor shall cause the issuer of each underlying
letter of credit to consent to an assignment of the proceeds thereof to the Secured Parties.

 

(ff)           To
the extent that any Collateral is in the possession of any third party, the applicable Debtor shall join with the Collateral Agent
in notify). ‘in:: such third par’ of the Secured Parties’ security interest in such Collateral and shall use
commercially reasonable efforts to obtain an acknowledgement and agreement from such third party with respect to the Collateral,
in form and substance reasonably satisfactory to the Collateral Agent.

 

(gg)         If
any Debtor shall at any time hold or acquire a commercial tort claim; such Debtor shall promptly notify the Secured Parties in
a writing signed by such Debtor of the particulars thereof and grant to the Secured Parties in such writing a security interest
therein and in the proceeds thereof, all upon the terms of this Agreement, with such writing to be in form and substance satisfactory
to the Collateral Agent.

 

    D-10

     

    

 

(hh)         Each
Debtor shall promptly provide written notice to the Collateral Agent of any and all accounts which arise out of contracts with
any governmental authority and, to the extent necessary to perfect or continue the perfected status of the Security Interests in
such accounts and proceeds thereof, shall execute and deliver to the Collateral Agent an assignment of claims for such accounts
and cooperate with the Collateral Agent in taking any ether steps required, in its judgment, under the Federal Assignment of Claims
Act or any similar federal, state or local statute or rule to perfect or continue the perfected status of the Security Interests
in such accounts and proceeds thereof

 

(ii)           The
Company shah cause each subsidiary of the Company to promptly become a party hereto (an “Additional Debtor”), by executing
and delivering an Additional Debtor joinder substantially in the form of Annex A attached hereto and comply with the provisions
hereof applicable to the Debtors. Concurrent therewith; the Additional Debtor shall deliver replacement schedules for; or supplements
to all other Disclosure Schedules to (or referred to in) this Agreement, as applicable, which replacement schedules shall supersede,
or supplements shall modify; the Schedules then in effect. The Additional Debtor shah also deliver such opinions of counsel, authorizing
resolutions, good standing certificates, • incumbency certificates, organizational documents, financing statements and other
information and documentation as the Collateral Agent may reasonably request. Upon delivery of the foregoing to the Collateral
Agent, the Additional Debtor shall be and become a party to this Agreement with the same rights and obligations as the Debtors,
for all purposes hereof as fully and to the same extent as if it were an original signatory hereto and shall be deemed to have
made the representations; warranties and covenants set forth herein as of the date of execution and delivery of such Additional
Debtor Joinder (other than representations and warranties that specifically refer to an earlier date), and all references herein
to the “Debtors” shall be deemed to include each Additional Debtor.

 

(jj)           Each
Debtor shall vote the Fledged Securities to comply with the covenants and agreements set forth herein and in the Notes.

 

(kk)         Each
Debtor shall register the pledge of the applicable Pledged Securities cr. the books of such Debtor. Each Debtor shall notify each
issuer of Pledged Securities to register the pledge of the applicable Pledged Securities in the name of the Collateral Agent on
the books of such issuer. Further, except with respect to certificated securities delivered to the Collateral Agent, the applicable
Debtor shall deliver to Collateral Agent an acknowledgement of pledge (which, where appropriate, shall comply with the requirements
of the relevant UCC with respect to perfection by registration) signed by the issuer of the applicable Pledged Securities, which
acknowledgement shall confirm that: (a) it has registered the pledge on its books and records; and (b) at any time directed by
Collateral Agent during the continuation of an Event of Default, such issuer will transfer the record ownership of such Pledged
Securities into the name of any designee of the Collateral Agent, will take such steps as may be necessary to effect the transfer,
and will comply with all other instructions of the Collateral Agent regarding such Pledged Securities without the further consent
of the applicable Debtor.

 

(l1)          In the event that, upon an occurrence
of an Event of Default, Collateral Agent shall sell all or any of the Pledged Securities to another party or parties (herein called
the “Transferee”) or shall purchase or retain all or any of the Pledged Securities, each Debtor shall, to the extent
applicable: (i) deliver to Collateral Agent or the Transferee; as the case may be, the articles of incorporation; bylaws; minute
books, stock certificate books, corporate seals, deeds, leases, indentures, agreements, evidences of indebtedness, books of account,
financial records and all other Organizational Documents and records of the Debtors and their direct and indirect subsidiaries;
(ii) use its commercially reasonable efforts to obtain resignations of the persons then Sent iF.SZ as officers and directors of
the Debtors and their direct and indirect subsidiaries; if so requested; and (iii) use its commercially reasonable efforts to obtain
any approvals that are required by any governmental or regulatory body in order to permit the sale of the Pledged Securities to
the Transferee or the purchase or retention of the Pledged Securities by Collateral Agent and allow the Transferee or Collateral
Agent to continue the business of the Debtors and their direct and indirect subsidiaries.

 

    D-11

     

    

 

(mm)        Without
limiting the generality of thee other obligations of the Debtor hereunder, each Debtor shall (i) cause to be registered at the
United States Copyright Office all of its material copyrights, (ii) cause the security interest contemplated hereby with respect
to all Intellectual Property registered at the United States Copyright Office or United States Patent and Trademark Office to be
duly recorded at the applicable office, and (iii) give the Collateral Agent notice whenever it acquires (whether absolutely or
by license) or creates any additional material Intellectual Property.

 

(nn)         Each
Debtor will from time to time, at the joint and several expense of the Debtors, promptly execute and deliver all such further instruments
and documents, and take all such further action as may be reasonably necessary or desirable, or as the Collateral Agent may reasonably
request, in order to perfect and protect any security interest granted or purported to be granted hereby or to enable the Collateral
Agent to exercise and enforce Collateral Agent’s rights and remedies hereunder and with respect to any Collateral or to otherwise
carry out the purposes of this Agreement.

 

(oo)         Schedule
F attached hereto lists all of the patents, patent applications, trademarks, trademark applications, registered copyrights, and
domain names owned by any of the Debtors as of the date hereof. Schedule F lists all material licenses in favor of any Debtor for
the use of any patents, trademarks, copyrights and domain names as of the date hereof. All material patents and trademarks of the
Debtors have been duly recorded at the United States Patent and Trademark Office and all material copyrights of the Debtors have
been duly recorded at the United States Copyright Office.

 

(pp)         Except
as set forth on Schedule 0 attached hereto, none of the account debtors or other persons or entities obligated on any of the Collateral
is a governmental authority covered by the Federal Assignment of Claims Act or any similar federal, state or local statute or rule
in respect of such Collateral.

 

5             Effect of Pledge on Certain Rights. If any of the Collateral
subject to this Agreement consists of nonvoting equity or ownership interests (regardless of class, designation, preference or
rights) that may be converted into voting equity or ownership interests upon the occurrence of certain events (including, without
limitation, upon the transfer of all or any of the other stock or assets of the issuer), it is agreed that the pledge of such equity
or ownership interests pursuant to this Agreement or the enforcement of any of Collateral Agent’s rights hereunder shall
not be deemed to be the type of event which would trigger such conversion rights notwithstanding any provisions in the Organizational
Documents or agreements to which any Debtor is subject or to which any Debtor is party.

 

    D-12

     

    

 

6              Defaults. The following events shall be “Events of
Default”:

 

(a)          The
occurrence of an Event of Default (as defined in the Notes) under the Notes;

 

(b)          Any
representation or warranty of any Debtor in this Agreement shall prove to have been incorrect in any material respect when made;

 

(c)          The
failure by any Debtor to observe or perform any of its obligations hereunder for five (5) days after delivery to such Debtor of
notice of such failure by or on behalf of a Secured Party unless such default is capable of cure but cannot be cured within such
time frame and such Debtor is using best efforts to cure same in a timely fashion; or

 

(d)          If
any material provision of this Agreement shall at any time for any reason be declared to be null and void, or the validity or enforceability
thereof shall be contested by any Debtor, or a proceeding shall be commenced by any Debtor, or by any governmental authority having
jurisdiction over any Debtor, seeking to establish the invalidity or unenforceability thereof, or any Debtor shall deny that any
Debtor has any liability or obligation purported to be created under this Agreement.

 

7              Duty to Hold In Trust.

 

(a)          During
the continuance of an Event of Default, each Debtor shall, upon receipt of any revenue, income, dividend, interest or other sums
subject to the Security Interests, whether payable pursuant to the Notes or otherwise, or of any check, draft, note, trade acceptance
or other instrument evidencing an obligation to pay any such sum, hold the same in trust for the Secured Parties and shall forthwith
endorse and transfer any such sums or instruments, or both, to the Collateral Agent for distribution to the Secured Parties, pro-rata
in proportion to their respective then-currently outstanding principal amount of Notes for application to the satisfaction of the
Obligations (and if any Note is not outstanding, pro-rata in proportion to the initial purchases of the remaining Notes).

 

(b)          If
any Debtor shall become entitled to receive or shall receive any securities or other property (including, without limitation, shares
of Pledged Securities or instruments representing Pledged Securities acquired after the date hereof, or any options, warrants,
rights or other similar property or certificates representing a dividend, or any distribution in connection with any recapitalization,
reclassification or increase or reduction of capital, or issued in connection with any reorganization of such Debtor or any of
its direct or indirect subsidiaries) in respect of the Pledged Securities (whether as an addition to, in substitution of, or in
exchange for, such Pledged Securities or otherwise), such Debtor agrees to (i) hold the same in trust on behalf of and for the
benefit of the Secured Parties; and (ii) to deliver any and all certificates or instruments evidencing the same to Collateral Agent
on or before the close of business on the fifth Business Day following the receipt thereof by such Debtor, in the exact form received
together with the Necessary Endorsements, to be held by Collateral Agent subject to the terms of this Agreement as Collateral.

 

8              Rights and Remedies Upon Default.

 

(a)          After
the occurrence and during the continuance of any Event of Default, the Collateral Agent shall have the right to exercise all of
the remedies conferred hereunder and under the Notes, and the Collateral Agent shall have all the rights and remedies of a secured
party under the UCC. Without limitation, the Collateral Agent, for the benefit of the Secured Parties, shall have the following
rights and powers:

 

    D-13

     

    

 

(i)          The
Collateral Agent shall have the right to take possession of the Collateral and, for that purpose, enter, with the aid and assistance
of any person, any premises where the Collateral, or any part thereof, is or may be placed and remove the same, so long as the
same can be accomplished without breach of the peace and otherwise in compliance with applicable law, and each Debtor shall assemble
the Collateral and make it available to the Collateral Agent at places which the Collateral Agent shall reasonably select, whether
at such Debtor’s premises or elsewhere, and make available to the Collateral Agent, without rent, all of such Debtor’s
respective premises and facilities for the purpose of the Collateral Agent taking possession of, removing or putting the Collateral
in saleable or disposable form.

 

(ii)         Upon
notice to the Debtors by Collateral Agent, all rights of each Debtor to exercise the voting and other consensual rights which it
would otherwise be entitled to exercise and all rights of each Debtor to receive the dividends and interest which it would otherwise
be authorized to receive and retain, shall cease. Upon such notice, Collateral Agent shall have the right to receive, for the benefit
of the Secured Parties, any interest, cash dividends or other payments on the Collateral and, at the option of Collateral Agent,
to exercise in such Collateral Agent’s discretion all voting rights pertaining thereto. Without limiting the generality of
the foregoing, Collateral Agent shall have the right (but not the obligation) to exercise all rights with respect to the Collateral
as if it were the sole and absolute owner thereof, including, without limitation, to vote and/or to exchange, at its sole discretion,
any or all of the Collateral in connection with a merger, reorganization, consolidation, recapitalization or other readjustment
concerning or involving the Collateral or any Debtor or any of its direct or indirect subsidiaries.

 

(iii)        The
Collateral Agent shall have the right to seek an Order from a court appointing a Trustee to operate the business of each Debtor
using the Collateral and shall have the right to assign, sell, lease or otherwise dispose of and deliver all or any part of the
Collateral, at public or private sale or otherwise, either with or without special conditions or stipulations, for cash or on credit
or for fumre delivery, in such parcel or parcels and at such time or times and at such place or places, and upon such terms and
conditions as are commercially reasonable. Upon each such sale, lease, assignment or other transfer or disposition of Collateral,
the Collateral Agent, for the benefit of the Secured Parties, may, unless prohibited by applicable law which cannot be waived,
purchase all or any part of the Collateral being sold, free from and discharged of all trusts, claims, right of redemption and
equities of any Debtor, which are hereby waived and released,

 

(iv)        The
Collateral Agent shall have the right (but not the obligation) to notify any account debtors and any obligors under instruments
or accounts to make payments directly to the Collateral Agent, on behalf of the Secured Parties, and to enforce the Debtors’
rights against such account debtors and obligors.

 

(v)         The
Collateral Agent, for the benefit of the Secured Parties, may (but is not obligated to) direct any financial Intermediary or any
other person or entity holding any investment property to transfer the same to the Collateral Agent, on behalf of the Secured Parties,
or its designee.

 

    D-14

     

    

 

(vi)         The
Collateral Agent may (but is not obligated to) transfer any or all Intellectual Property registered in the name of any Debtor at
the United States Patent and Trademark Office and/or Copyright Office into the name of the Collateral Agent or any purchaser of
any Collateral.

 

(b)          The
Collateral Agent shall comply with any applicable law in connection with a disposition of Collateral and such compliance will not
be considered adversely to affect the commercial reasonableness of any sale of the Collateral, The Collateral Agent may sell the
Collateral without giving any wan-antics and may specifically disclaim such warranties. If the Collateral Agent sells any of the
Collateral On credit, the Debtors will only be credited with payments actually made by the purchaser. In addition, each Debtor
waives any and all rights that it may have to a judicial hearing in advance of the enforcement of any of the Collateral Agent’s
rights and remedies hereunder, including, without limitation, its right following an Event of Default to take immediate possession
of the Collateral and to exercise its rights and remedies with respect thereto.

 

(c)          If
any notice to Debtor of the sale or other disposition of Collateral is required by then applicable law, five (5) business days
prior written notice (which Debtor agree is reasonable notice within the meaning of Section 9,612(a) of the Uniform Commercial
Code) shah be given to Debtor of the time and place of any sale of Collateral. The rights granted in this Section are in addition
to any and all rights available to Collateral Agent under the Uniform Commercial Code.

 

(d)          For
the purpose of enabling the Collateral Agent to further exercise rights and remedies under this Section S or elsewhere provided
by agreement or applicable law, each Debtor hereby grants to the Collateral Agent, for the benefit of the Collateral Agent and
the Secured Parties, an irrevocable, nonexclusive license (exercisable without payment of royalty or other compensation to such
Debtor) to use, license or sublicense during the continuance of an Event of Default, any Intellectual Property now owned or hereafter
acquired by such Debtor, and wherever the same may be located, and including in such license access to all media in which any of
the licensed items may be recorded or stored and to al: computer soft-ware and programs used for the compilation or printout thereof

 

9            Applications of Proceeds. The proceeds of any such sale,
lease or other disposition of the Collateral hereunder or from payments made on account of ally insurance policy insuring any portion
of the Collateral shall be applied first, to the expenses of retaking, holding, storing, processing and preparing for sale, selling,
and the like (including, without limitation, any taxes, fees and other costs incurred in connection therewith) of the Collateral,
if any, to the reasonable attorneys’ fees and expenses incurred by the Collateral Agent in enforcing the Secured Parties’
rights hereunder and in connection with collecting, storing and disposing of the Collateral, and then to satisfaction of the Obligations
pro rata among the Secured Parties (based on then-outstanding principal amounts of Notes at the time of any such determination),
and then to the payment of any other amounts required by applicable law, after which the Secured Parties shall pay to the applicable
Debtor any surplus proceeds. If, upon the sale, license or other disposition of the Collateral, the proceeds thereof are insufficient
to pay all amounts to which the Secured Parties are legally entitled, the Debtors Will be liable for the deficiency, together with
interest thereon, at the rate of IS% per annum or the lesser amount permitted by applicable law (the “Default Rate”),
and the reasonable fees of any attorneys employed by the Secured Parties to collect such deficiency. To the extent permitted by
applicable law, each Debtor waives all claims, damages and demands against the Secured Parties arising out of the repossession,
removal, retention or sale of the Collateral, unless due solely to the gross negligence or willful misconduct of the Secured Panics
as determined by a final judgment (not subject to further appeal) of a court of competent jurisdiction.

 

    D-15

     

    

 

10            Securities Law Provision. Each Debtor recognizes that
Collateral Agent may be limited in its ability to effect a sale to the public of all or part of the Pledged Securities by reason
of certain prohibitions in the Securities Act of :933, as amended, or other federal or state securities laws (collectively, the
“Securities Laws”). and may reasonably be obliged to resort to one or more sales to a restricted group of purchasers
who may be required to agree to acquire the Pledged Securities for their own account, for investment and not with a view to the
distribution or resale thereof. Each Debtor agrees that sales so made•may be at prices and on terms less favorable than if
the Pledged Securities were sold to the public, and that Collateral Agent has no obligation to delay the sale of any Pledged Securities
for the period of time necessary to register the Pledged Securities for sale to the public under the Securities Laws. Each Debtor
shall cooperate with Collateral Agent in its attempt to satisfy any requirements under the Securities Laws (including, without
limitation, registration thereunder if requested by Collateral Agent) applicable to the sale of the Pledged Securities by Collateral
Agent.

 

11            Costs and Expenses. Each Debtor agrees to pay all reasonable
out-of-pocket fees, costs and expenses incurred in connection with any filing required hereunder, including without limitation,
any financing statements pursuant to the LTCC, continuation statements, partial releases and/or termination statements related
thereto or any expenses of any searches reasonably required by the Collateral Agent. The Debtors shall also pay all other clairns
and charges which in the reasonable opinion of the Collateral Agent is reasonably likely to prejudice, imperil or otherwise affect
the Collateral or the Security Interests therein. The Debtors will also, upon demand, pay to the Collateral Agent the amount of
any and all reasonable expenses, including the reasonable fees and expenses of its counsel and of any’ experts and agents,
which the Collateral Agent, for the benefit of the Secured Parties, may incur in connection with (i) the enforcement of this Agreement,
(ii) the custody or preservation of; or the sale of, collection from, or other realization upon, any of the Collateral, or (iii)
the exercise or enforcement of any of the rights of the Secured Parties under the Notes. Until so paid, any fees payable hereunder
shall be added to the principal amount of the Notes and shall bear interest at the Default Rate,

 

12            Responsibility for Collateral. The Debtors assume all
liabilities and responsibility in connection with all Collateral, and the Obligations shall in no way be affected or diminished
by reason of the loss, destruction, damage or theft of any of the Collateral or its unavailability for any reason. Without limiting
the generality of the foregoing, (a) neither the Collateral Agent nor any Secured Party (i) has any duty (either before or after
an Event of Default) to collect any amounts in respect of the Collateral or to preserve any rights relating to the Collateral,
or (ii) has any obligation to clean-up or otherwise prepare the Collateral for sale, and (b) each Debtor shall remain obligated
and liable under each contract or agreement included in the Collateral to be observed or performed by such Debtor thereunder. Neither
the Collateral Agent nor any Secured Party shall have any obligation or liability under any such contract or agreement by reason
of or arising out of this Agreement or the receipt by the Collateral Agent or any Secured Party of any payment relating to any
of the Collateral, nor shall the Collateral Agent or any Secured Party be obligated in any manner to perform any of the obligations
of any Debtor under or pursuant to any such contract or agreement, to make inquiry as to the nature or sufficiency of any payment
received by the Collateral Agent or any Secured Party in respect of the Collateral or as to the sufficiency of any performance
by any patty under any such contract or agreement, to present or file any claim, to take any action to enforce any performance
or to collect the payment of any amounts which may have been assigned to the Collateral Agent or to which the Collateral Agent
or any Secured Parry may be entitled at any time or times.

 

    D-16

     

    

 

13            Security Interests Absolute. All rights of the Secured
Parties and all obligations of the Debtors hereunder, shall be absolute and unconditional, irrespective of: (a) any lack of validity
or enforceability of this Agreement, the Notes or any agreement entered into in connection with the foregoing, or any portion hereof
or thereof; (5) any change in the time, manner or place of payment or performance of, or in any other term of, all or any of the
Obligations, or any other amendment or waiver of or any consent to any departure from the Notes or any other agreement entered
into in connection with the foregoing; (c) any exchange, release or non-perfection of any of the Collateral, or any release or
amendment or waiver of or consent to departure from any other collateral for, or any guarantee, or any other security, for all
or any of the Obligations; (d) any action by the Secured Parties to obtain, adjust, settle and cancel in its sole discretion any
insurance claims or matters made or arising in connection with the Collateral; or (e) any other circumstance which might otherwise
constitute any legal or equitable defense available to a Debtor, or a discharge of all or any part of the Security Interests granted
hereby. Until the Obligations shall have been paid and performed in full, the rights of the Secured Parties shall continue even
if the Obligations are barred for any reason, including, without limitation, the running of the statute of limitations or bankruptcy.
Each Debtor expressly waives presentment, protest, notice of protest, demand, notice of nonpayment and demand for performance.
In the event that at any time any transfer of any Collateral or any payment received by the Secured Parties hereunder shall be
deemed by final order of a court of competent jurisdiction to have been a voidable preference or fraudulent conveyance under the
bankruptcy or insolvency laws of the United States, or shall be deemed to be otherwise due to any party other than the Secured
Parties, then, in any such event, each Debtor’s obligations hereunder shall survive cancellation of this Agreement, and shall
not be discharged or satisfied by any prior payment thereof and/or cancellation of this Agreement, but shall remain a valid and
binding obligation enforceable in accordance with the terms and provisions hereof Each Debtor waives all right to require the Secured
Parties to proceed against any other person or entity or to apply any Collateral which the Secured Parties may hold at any time,
or to marshal assets, or to pursue any other remedy. Each Debtor waives any defense arising by reason of the application of the
statute of :imitations to any Obligations secured hereby.

 

14            Term of Agreement. This Agreement and the Security Interest
shall terminate on the date on which all payments under the Notes have been indefeasibly paid in frill and all other Obligations
have been paid or discharged; provided, however, that all indemnities of the Debtors contained in this Agreement (including, without
limitation, Annex B hereto) shall survive and remain operative and in full force and effect regardless of the termination of this
Agreement.

 

    D-17

     

    

 

15            Power of Attorney; Further Assurances.

 

(a)          Each
Debtor authorizes the Collateral Agent, and does hereby make, constitute and appoint the Collateral Agent and its officers, agents,
successors or assigns with full power of substitution, as such Debtor’s true and lawful attorney-in-fact, with power, in
the name of the Collateral Agent or such Debtor, after the occurrence and during the continuance of an Event of Default, (i) to
endorse any note, checks, drafts, money orders or other instruments of payment (including, without limitation, payments payable
under or in respect of any policy of insurance) in respect of the Collateral that may come into possession of the Collateral Agent;
(ii) to sign and endorse any financing statement pursuant to the UCC or any invoice, freight or express bill, bid of lading, storage
or warehouse receipts, drafts against debtors, assignments, verifications and notices in connection with accounts, and other documents
relating to the Collateral; (iii) to pay or discharge taxes, liens, security interests or other encumbrances at any time levied
or placed on or threatened against the Collateral; (iv) to demand, collect; receipt for, compromise, settle and sue for monies
due in respect of the Collateral; (v) to transfer any Intellectual Property or provide licenses respecting any Intellectual Property;
and (vi) generally, at the option of the Collateral Agent, and at the expense of the Debtors, at any time, or from time to time,
to execute and deliver any and all documents and instruments and to do all acts and things which the Collateral Agent deems necessary
to protect, preserve and realize upon the Collateral and the Security Interests granted therein in order to effect the intent of
this Agreement and the Notes all as fully and effectually as the Debtors might or could do; and each Debtor hereby ratifies all
that said attorney shall lawfully do or cause to be done by virtue hereof. This power of attorney is coupled with an interest and
shall be irrevocable for the term of this Agreement and thereafter as long as any of the Obligations shall be outstanding. The
designation set forth herein shall be deemed to amend and supersede any inconsistent provision in the Organizational Documents
or other documents or agreements to which any Debtor is subject or to which any Debtor is a party. Without limiting the generality
of the foregoing, after the occurrence and during the continuance of an Event of Default, each Secured Party is specifically authorized
to execute and file any applications for or instruments of transfer and assignment of any patents, trademarks, copyrights or other
Intellectual Property with the United States Paten’: and Trademark Office and the United States Copyright Office.

 

(b)          On
a continuing basis, each Debtor will make, execute, acknowledge, deliver, file and record, as the case may be, with the proper
filing and recording agencies in any jurisdiction; including, without limitation, the jurisdictions indicated on Schedule C attached
hereto, all such instruments, and take all such action as may reasonably be deemed necessary or advisable, or as reasonably requested
bv the Collateral Agent, to perfect the Security Interest granted hereunder and otherwise to cany out the intent and purposes of
this Agreement, or for assuring and confirming to the Collateral Agent the grant or perfection of a perfected security interest
in all the Collateral under the UCC.

 

(c)          Each
Debtor hereby irrevocably appoints the Collateral Agent as such Debtor’s attorney-in-fact, with full authority in the place
and instead of such Debtor and in the name of such Debtor, from time to time in the Collateral Agent’s discretion, to take
any action permitted under this Agreement and to execute any instrument which the Collateral Agent may reasonably deem necessary
or advisable to accomplish the purposes of this Agreement, including the filing, in its sole discretion, of one or more financing
or continuation statements and amendments thereto, relative to any of the Collateral without the signature of such Debtor where
permitted by law, which financing statements may (but need not) describe the Collateral as “al: assets” or “all
personal property” or words of like import, and ratifies all such actions taken by the Collateral Agent. This power of attorney
is coupled with an interest and shall be irrevocable for the term of this Agreement and thereafter as long as any of the Obligations
shall be outstanding.

 

    D-18

     

    

 

16            Notices. All notices, demands, requests, consents, approvals,
and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (a)
personally served, (b) deposited in the mail, registered or certified, return receipt requested, postage prepaid, (c) delivered
by a reputable overnight courier service with charges prepaid, or (d) transmitted by hand delivery, telegram, or facsimile, addressed
as set forth below or to such other address as such party shah have specified most recently by written notice. Any notice or other
communication required or permitted to be given hereunder shall be deemed effective (i) upon hand deliver>., or delivery by
facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number designated below
(if delivered on a Business Day during normal business hours), or the first Business Day following such delivery (if delivered
other than on a Business Day during normal business hours), (ii) on the first Business Day following the date deposited with an
overnight courier service with charges prepaid, or (iii) on the fifth Business Day following the date of mailing pursuant to subpart
(b) above, or upon actual receipt of such mailing:, whichever shall first occur. The addresses for such communications shall be:

 

	To Debtor, to:	Accelerated Pharma, Inc.
	 	15W155 81st Street
	 	Burr Ridge, IL 60527
	 	Attn: Michael Fonstein, and CEO
	 	Fax:(630)325-4179
	 	 
	With a copy by fax only to	 
	(which shall not constitute notice):	Polsinelli PC
	 	161 N. Clark Avenue, Suite 4200
	 	Chicago, IL 60601
	 	Attn: Teddy C. Scott, Jr., Ph.D.
	 	Fax:(312)873-2913
	 	 
	To the Collateral Agent:	Patricia Watkins
	 	230 Park Avenue, Suite 539
	 	New York, NY 10169
	 	Fax: (212) 867-6204

 

17            Other Security. To the extent that the Obligations are
now or hereafter secured by property other than the Collateral or by the guarantee, endorsement or property of any other person,
firm, corporation or other entity, then the Collateral Agent shall have the right, in its sole discretion, to pursue, relinquish,
subordinate, modify or take any other action with respect thereto, without in any way modifying or affecting any of the Secured
Parties’ rights and remedies hereunder.

 

18            Appointment of Collateral Agent. The Secured Parties hereby
appoint Patricia Watkins to act as their agent (“Collateral Agent”) for purposes of exercising any and all rights and
remedies of the Secured Parties hereunder. Such appointment shall continue until revoked in writing, by a Majority in Interest,
at which time a Majority in Interest shall appoint a new Collateral Agent. The Collateral Agent shall have the rights, responsibilities
and immunities set forth in Annex B hereto.

 

    D-19

     

    

 

19            Miscellaneous.

 

(a)          No
course of dealing between the Debtors and the Collateral Agent, nor any failure to exercise, nor any delay in exercising:, on the
part of the Collateral Agent, any right, power or privilege hereunder or under the Notes shall operate as a waiver thereof; nor
shall any single or partial exercise of any right, power or privilege hereunder or thereunder preclude any other or further exercise
thereof or the exercise of any other right, power Cr privilege.

 

(b)          All
of the rights and remedies of the Collateral Agent with respect to the Collateral, whether established hereby or by the Notes or
by any other agreements, instruments or documents or by law shah be cumulative and may be exercised singly or concurrently.

 

(c)          This
Agreement, together with the exhibits and schedules hereto, contain the entire understanding of the parties with respect to the
subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which
the parties acknowledge have been merged into this Agreement and the exhibits and schedules hereto. No provision of this Agreement
may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Debtors
and Collateral Agent or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought.

 

(d)          If
any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shah use their commercially reasonable
efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such
term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.

 

(e)          No
waiver of any default with respect to any provision, condition or requirement of this Agreement shah be deemed to be a continuing
waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof,
nor shall any delay or omission of any party to exercise any right Hereunder in any manner impair the exercise of any such right.

 

(f)          This
Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Debtors
may not assign this Agreement or any rights or obligations hereunder without the prior written consent of a Majority in Interest
(other than by merger). Any Secured Party may assign any or a.:1 of its rights under this Agreement to any Person to whom such
Secured Party assigns or transfers any Obligations, provided such transferee agrees in writing to be bound, with respect to the
transferred Obligations, by the provisions of this Agreement that apply to the “Secured Parties.”

 

(g)          Each
party shah take such further action and execute and deliver such further documents as may be necessary or appropriate in order
to carry out the provisions and purposes of this Agreement.

 

    D-20

     

    

 

(h)          All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law
thereof Each Debtor agrees that all proceedings concerning the interpretations, enforcement and defense of the transactions contemplated
by this Agreement and the Notes (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New
York, Borough of Manhattan. Each Debtor hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or
with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such proceeding is improper. Each party
hereto hereby irrevocably waives personal service of process and consents to process being served in any such proceeding by mailing
a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address
in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process
and notice thereof Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted
by law. Each party hereto hereby irrevocably \valves, to the fullest extent permitted by applicable law, any and all right to trial
by jury in any legal proceeding arising out of or relating to this Agreement Or the transactions contemplated hereby. If any party
shall commence a proceeding to enforce any provisions of this Agreement, then the prevailing party in such proceeding shall be
reimbursed by the other party for its reasonable attorney’s fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such proceeding.

 

(i)          This
Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and,
all of which taken together shall constitute one and the same Agreement. In the event that any signature is delivered by facsimile
or other electronic transmission, such signature shall create a valid binding obligation of the party executing (or on whose behalf
such signature is executed) the same with the same force and effect as if such signature were the original thereof.

 

(j)          All
Debtors shall jointly and severally be liable for the obligations of each Debtor to the Secured Parties hereunder.

 

(k)          Each
Debtor shall indemnify, reimburse and hold harmless the Collateral Agent and the Secured Parties and their respective partners,
members, shareholders, officers, directors, employees and agents (and any other persons with other titles that have similar functions)
(collectively, “Indemnitees”) from and against any and all losses, claims, liabilities, damages, penalties, suits,
costs and expenses, of any kind or nature, (including fees relating to the cost of investigating and defending any of the foregoing)
imposed on, incurred by or asserted against such Indemnitee in any way related to or arising from or alleged to arise from this
Agreement or the Collateral, except any such losses, claims, liabilities, damages, penalties, suits, costs and expenses which result
from the gross negligence or willful misconduct of the Indemnitee as determined by a final, nonappealable decision or a court or
competent jurisdiction. This indemnification provision is in addition to, and not in limitation of, any other indemnification provision
in the Notes, the Securities Purchase Agreement (as such term is defined in the Notes) or any other agreement, instrument or other
document executed or delivered in connection herewith or therewith.

 

    D-21

     

    

 

(l)          Nothing
in this Agreement shall he construed to subject Collateral Agent or any Secured Party to liability as a partner in any Debtor or
any if its direct or indirect subsidiaries that is a partnership or as a member in any Debtor or any of its direct or indirect
subsidiaries that is a limited liability company, nor shall Collateral Agent or any Secured Party he deemed to have assumed any
obligations under any partnership agreement or limited liability company agreement, as applicable, of any such Debtor or any if
its direct or indirect subsidiaries or otherwise, unless and until any such Secured Party exercises its right to be substituted
for such Debtor as a partner or member, as applicable, pursuant hereto.

 

(m)          To
the extent that the grant of the security interest in the Collateral and the enforcement of the terms hereof require the consent,
approval or action of any partner or member, as applicable, of any Debtor or any direct or indirect subsidiary of any Debtor or
compliance with any provisions of any of the Organizational Documents, the Debtors hereby grant such consent and approval and waive
any such noncompliance with the terms of said documents.

 

    D-22

     

    

 

IN WITNESS WHEREOF, the parties hereto have caused this Security
Agreement to be duly executed on the day and year first above written.

 

	ACCELERATED PHARMA, INC.	 
	 	 
	By:	 
	 	 
	Name: Title:	 
	 	 
	COLLATERAL AGENT	 
	 	 
	PATRICIA WATKINS	 

 

    D-23

     

    

 

IN WITNESS WHEREOF; the parties hereto have caused this
Security Agreement to be duly executed on the day and year first above written.

 

	ACCELERATED PHARMA,	 
	 	 
	Bv:	 
	 	 
	Name: Title:	 
	 	 
	COLLATERAL AGENT	 
	 	 
	PATRICIA WATICINS	 

 

    D-24

     

    

 

OMNIBUS SECURED PARTY SIGNATURE PAGE TO ACCELERATED PHARMA,

 

SECURITY AGREEMENT

 

The undersigned, in its capacity as a Secured Party, hereby
executes and delivers the Security Agreement to which this signature page is attached and agrees to be bound by the Security Agreement
on the date set forth on the first page of the Security Agreement. This counterpart signature page, together with all counterparts
of the Security Agreement and signature pages of the other parties named therein, shall constitute one and the same instrument
in accordance with the terms of the Security Agreement.

 

Curber international Ltd.

 

    D-25

     

    

 

OMNIBUS SECURED PARTY SIGNATURE PAGE TO ACCELERATED PHA RMA,

 

SECURITY AGREEMENT

 

The undersigned, in its capacity as a Secured Party, hereby
executes and delivers the Security Agreement to which this signature page is attached and agrees to be bound by the Security Agreement
on the date set forth on the first page or the Security Agreement. This counterpart signature page, together with all counterparts
of the Security Agreement and signature pages of the other parties named therein, shall constitute one and the same instrument
in accordance with the terms of the Security Agreement.

 

	Morris Fuchs	 
	 	 
	 	 	 
	[Print Name of Investor]	 
	 	 
	 	 
	[Signature]	 

 

	Name	 	 
	 	 	 
	Title:	 	 

 

	Address:	 	 
	 	 	 
	Email:	 	 

 

	 	 
	Taxpayer ID# (if applicable): ###-##-####	 

 

    D-26

     

    

 

OMNIBUS SECURED PARTY SIGNATURE PAGE TO

ACCELERATED PHARMA, ENC.

SECURITY AGREEMENT

 

The undersigned, in its capacity as a Secured Parry, hereby
executes and delivers the Security Agreement to which this signature page is attached and agrees to be bound by the Security Agreement
on the date set faith on the first page of the Security Agreement, This counterpart signature page, together with all counterparts
of the Security Agreement and signature pages of the other parties nanted therein, shah constitute one and the same instrument
in accordance with the terms of the Security Agreement.

 

	Print Name of Investor	 
	 	 
	[Signature]	 
	 	 
	Name	 
	 	 
	Address:	 
	 	 
	Email:	 
	 	 
	Taxpayer ID (if applicable):	 

 

    D-27

     

    

 

OMNIBUS SECURED PARTY SIGNATURE PAGE TO

ACCELERATED PHARMA, INC.

SECURITY AGREEMENT

 

The undersigned, in its capacity as a Secured Party, hereby
executes and delivers the Security Agreement to which this signature page is attached and agrees to be bound by the Security Agreement
on the date set forth on the first page of the Security Agreement. This counterpart signature page, together with all counterparts
of the Security Agreement and signature pages of the other parties named therein, shall constitute one and the same instrument
in accordance with the terms of the Security Agreement.

 

	Nachum Stein	 
	 	 
	[Print Name of Investor]	 
	 	 
	[Signature]	 
	 	 
	Name:	 
	 	 
	Title:	 
	 	 
	Address:	 
	 	 
	Taxpayer lia4 (if applicable): ###-##-####	 

 

    D-28

     

    

 

OMNIBUS SECURED PARTY SIGNATURE PACE TO

ACCELERATED l’11ARMA, INC.

SECURITY AGREEMENT

 

The undersigned, in its capacity as a Secured Party, hereby
executes and delivers the Security Agreement to which this signature page is attached and agrees to be bound by the Security Agreement
on the date set forth on the first page of the Security Agreement. This counterpart signature page, together with all counterparts
of the Security Agreement and signature pages of the other parties named therein, shall constitute one and the same instrument
in accordance with the terms of the Security Agreement.

 

	American European Insurance Co	 
	 	 
	[Print Name of Investor]	 
	 	 
	[Signature]	 
	 	 
	Name: Nachum Stein	 
	 	 
	Title: Chairman	 
	 	 
	Address:	 
	 	 
	Email:	 
	 	 
	Taxpayer 1D# (if applicable):  02-600005008	 

 

    D-29

     

    

 

OMNIBUS SECURED PARTY SIGNATURE PAGE TO

ACCELERATED PHARMA, INC.

SECURITY AGREEMENT

 

The undersigned, in its capacity as a Secured Party, hereby
executes and delivers the Security Agreement to which this signature page is attached and agrees to be bound by the Security Agreement
on the date set forth on the first page of the Security Agreement. This counterpart signature page, together with all counterparts
of the Security Agreement and signature pages of the other parties named therein, shall constitute one and the same instrument
in accordance with the terms of the Security Agreement.

 

	HSI Partnership	 
	 	 
	[Print Name of Investor]	 
	 	 
	[Signature]	 
	 	 
	Name:  Nachum Stein	 
	 	 
	Title:  Chairman	 
	 	 
	Address:	 
	 	 
	Email:	 
	 	 
	Taxpayer Mt/ (if applicable):  13-3403183	 

 

    D-30

     

    

 

Schedule A

 

Collateral Location

 

15W155 81st Street

 

Burr Ridge, II 60527

 

    D-31

     

    

 

Schedule B

 

Permitted Liens

 

None

 

    D-32

     

    

 

SCHEDULE C

 

Jurisdictions

 

Delaware.

 

    D-33

     

    

 

Schedule D

 

Name of Debtor: State of Incorporation

 

1.          Accelerated
Phamca, Inc., a Delaware corporation #5531713

 

Schedule E

Trade Names

 

None

 

Schedule F

Intellectual Property

 

Exclusive Licensed Agreement between Tallikut Pharmaceuticals.
Inc. and Accelerated Pharma, Inc. of June 17, 2014 and, as amended, December 9, 2014.

 

    D-34

     

    

 

Schedule G

 

Governmental Authority Account Debtors

 

None.

 

    D-35

     

    

 

Schedule H

 

Pledged Securities

 

None.

 

    D-36

     

    

 

ANNEX A

to

SECURITY

AGREEMENT

 

FORM OF ADDITIONAL DEBTOR JOINDER

 

Security Agreement dated as of December
   • 2014 made by

 

Accelerated Pharma, Inc.

and its Subsidiaries party thereto from time to time, as Debtors

to and in favor of

the Secured Parties identified therein (the “Security Agreement”)

 

Reference is made to the Seoul-hi Agreement as defined above;
capitalized terms used herein and not otherwise defined herein shah have the meanings given to such terms in; or by reference in,
the Security Agreement.

 

The undersigned hereby agrees that upon delivery of this Additional
Debtor Joiner to the Secured Parties referred to above, the undersigned shall (a) be an Addition?: Debtor under the Security Agreement.
(b) have all the rights and obligations of the Debtors under the Security Agreement as fully and to the same extent as if the undersigned
was an original signatory thereto and (c) be deemed to have made the representations and warranties set forth therein as of the
date of execution and delivery of this Additional Debtor Joinder (except to the extent such representation or warranty specifically
refers to an earlier date). WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, THE UNDERSIGNED SPECIFICALLY GRANTS TO THE SECURED
PARTIES A SECURITY INTEREST IN THE COLLATERAL AS MORE FULLY SET FORTH IN THE SECURITY AGREEMENT AND ACKNOWLEDGES AND AGREES TO
THE WAIVER OF JURY TRIAL PROVISIONS SET FORTH THEREIN.

 

Attached hereto are supplemental and/or replacement Schedules
to the Security Agreement, as applicable.

 

Attached hereto is an original Subsidiary Guaranty executed
by the undersigned and delivered herewith.

 

An executed copy of this Additional Debtor Joinder shall be
delivered to the Secured Parties, and the Secured Parties may rely on the matters set forth Herein on or after the date hereof.
This Additional Debtor Joinder sha:1 not be modified, amended or terminated without the prior written consent of the Secured Parties.

 

    D-37

     

    

 

IN WITNESS WHEREOF, the undersigned has caused this Joiner to
be executed in the name and on behalf of the undersigned.

 

	Name of Additional Debtor]	 
	 	 
	By:	 
	 	 
	Name: Title:	 
	 	 
	Address:	 
	 	 
	Dated:	 

 

    D-38

     

    

 

FORM OF SUBSIDIARY GUARANTY

 

1.    Identification.

 

This Guaranty (the -Guaranty”) dated as of [REQUIRES COMPLETION], is entered into by [REQUIRES COMPLETION],
a [REQUIRES COMPLETION] corporation (“Guarantor-) for the benefit of the Collateral Agent identified below and the parties
identified on Schedule A hereto (each a “Lender” and collectively, the “Lenders”).

 

2.    Recitals.

 

2.1.          Guarantor
is a direct or indirect subsidiary of Accelerated Pharma, Inc., a Delaware corporation (“Parent”). The Lenders have
made and/or are making loans to Parent (the “Loans”). Guarantor will obtain substantial benefit from the proceeds of
the Loans.

 

2.2.          The
Loans are and will be evidenced by certain Secured Convertible Promissory Notes (collectively, “Note” or the “Notes”)
issued by Parent on, about or after the date of this Guaranty pursuant to those certain Securities Purchase Agreements dated at
or about the date hereof (“Securities Purchase Agreements”). The Notes issued on the Closing Date are further described
on Schedule A hereto and were and or will be executed by Parent as “Borrower” for the benefit of each Lender as the
“Holder” thereof

 

2.3.          In
consideration of the Loans made and to be made by Lenders to Parent and for other good and valuable consideration, and as security
for the performance by Parent of its obligations under the Notes and as security for the repayment of the Loans and all other sums
due from Debtor to Lenders arising under the Notes (collectively, the “Obligations”) Guarantor, for good and valuable
consideration, receipt of which is acknowledged, has agreed to enter into this Guaranty.

 

2.4.          The
Lenders have appointed Patricia Watkins as Collateral Agent pursuant to that certain Security Agreement dated at or about the date
of this Agreement (“Security Agreement”), among the Lenders and Collateral Agent.

 

2.5.          Upper
case terms employed but not defined herein shall have the meanings ascribed to them in the Transaction Documents (as defined in
the Securities Purchase Agreement).

 

3.    Guaranty.

 

3.1.          Guaranty.    Guarantor
hereby unconditionally and irrevocably guarantees; jointly and severally with any other guarantor of the Obligations, the punctual
payment, performance and observance when due; whether at stated maturity; by acceleration or otherwise, of all of the Obligations
now or hereafter existing, whether for principal, interest (including, without limitation, all interest that accrues after the
commencement of any insolvency, bankruptcy or reorganization of Parent; whether or not constituting an allowed claim in such proceeding),
fees, commissions, expense reimbursements, liquidated damages, indemnifications or otherwise arising under the Notes, Security
Agreement, or any other Transaction Document (as defined in the Securities Purchase Agreement) (such obligations, to the extent
not paid by Parent being the “Guaranteed Obligations” and included in the definition of Obligations), and agrees to
pay any and all reasonable costs, fees and expenses (including reasonable counsel fees and expenses) incurred by Collateral Agent
and the Lenders in enforcing any rights under the Guaranty set forth herein. Without limiting the generality of the foregoing,
Guarantor’s liability shall extend to all amounts that constitute part of the Guaranteed Obligations and would be owed by
Parent to Collateral Agent and the Lenders, but for the fact that they are unenforceable or not allowable due to the existence
of an insolvency, bankruptcy or reorganization involving Parent.

 

    D-39

     

    

 

3.2.          Guaranty
Absolute. Guarantor guarantees that the Guaranteed Obligations will be paid strictly in accordance with the terms of the Notes,
regardless of any law, regulation or order now or hereafter in effect in any jurisdiction affecting any of such terms or the rights
of Collateral Agent or the Lenders with respect thereto. The obligations of Guarantor under this Guaranty are independent of the
Guaranteed Obligations, and a separate action or actions may be brought and prosecuted against Guarantor to enforce such obligations,
irrespective of whether any action is brought against Parent or any other guarantor or whether Parent or any other guarantor is
joined in any such action or actions. The liability of Guarantor under this Guaranty constitutes a primary obligation, and not
a contract of surety, and to the extent permitted by law, shah be irrevocable, absolute and unconditional irrespective of, and
Guarantor hereby irrevocably waives any defenses it may now or hereafter have in any way relating to, any or all of the following:

 

(a)        any
lack of validity of the Notes or any agreement or instrument relating thereto;

 

(b)        any
change in the time, manner or place of payment of, or in any other term of, all or any of the Guaranteed Obligations, or any other
amendment or waiver of or any consent to departure from the Notes, including, without limitation, any increase in the Guaranteed
Obligations resulting from the extension of additional credit to Parent or otherwise;

 

(c)        any
taking, exchange, release, subordination or non-perfection of any Collateral, or any taking, release or amendment or waiver of
or consent to departure from any other guaranty, for all or an)’ of the Guaranteed Obligations;

 

(d)        any
change, restructuring or termination of the corporate, limited liability company or partnership structure or existence of Parent;
or

 

(e)        any
other circumstance (including, without :imitation, any statute of limitations) or any existence of or reliance on any representation
by Collateral Agent or the Lenders that might otherwise constitute a defense available to, or a discharge of, Parent or any other
guarantor or surety.

 

This Guaranty shall continue to be effective
or be reinstated, as the case may be, if at any time any payment of any of the Guaranteed Obligations is rescinded or must otherwise
be returned by Collateral Agent, the Lenders or any other entity upon the insolvency, bankruptcy or reorganization of the Parent
or otherwise (and whether as a result of any demand, settlement, litigation or otherwise), all as though such payment had not been
made.

 

    D-40

     

    

 

3.3.          Waiver.
Guarantor hereby waives promptness, diligence, notice of acceptance and any other notice with respect to any of the Guaranteed
Obligations and this Guaranty and any requirement that Collateral Agent or the Lenders exhaust any right or take any action against
any Borrower or any other person or entity or any Collateral. Guarantor acknowledges that it will receive direct and indirect benefits
from the financing arrangements contemplated herein and that the waiver set forth in this Section 3.3 is knowingly made in contemplation
of such benefits. Guarantor hereby waives any right to revoke this Guaranty, and acknowledges that this Guaranty is continuing
in nature and applies to all Guaranteed Obligations, whether existing now or in the future.

 

3.4.          Continuing
Guaramx: Assignments. This Guaranty is a continuing guaranty and shall (a) remain in full force and effect until the later of the
indefeasible cash or other payment in full of the Guaranteed Obligations , (b) be binding upon Guarantor, its successors and assigns,
and (0) inure to the benefit of and be enforceable by the Lenders and their successors, pledgees, transferees and assigns. Without
limiting the generality of the foregoing clause (0), any Lender may pledge, assign or otherwise transfer all or any portion of
its rights and obligations under this Guaranty (including, without limitation, all or any portion of its Notes owing to it) to
any other Person, and such other Person shall thereupon become vested with all the benefits in respect thereof granted such Collateral
Agent or Lender herein or otherwise.

 

3.5.          Subrogation.
Guarantor will not exercise any rights that it may now or hereafter acquire against the Collateral Agent or any Lender or other
guarantor (if any) that arise from the existence, payment, performance or enforcement of such Guarantor’s obligations under
this Guaranty, including, without limitation, any right of subrogation, reimbursement, exoneration, contribution or indemnification,
whether or not such claim, remedy or right arises in equity or under contract, state or common law, including, without limitation,
the right to take or receive from the Collateral Agent or any Lender or other guarantor (if any), directly or indirectly, in cash
or other property or by set-off or in any other manner, payment or security solely on account of such claim; remedy or right, unless
and until all of the Guaranteed Obligations and all other amounts payable under this Guaranty shall have been indefeasibly paid
in full.

 

3.6.          Maximum
Obligations. Notwithstanding any provision herein contained to the contrary, Guarantor’s liability with respect to the Obligations
shall be limited to an amount not to exceed, as of any date of determination, the amount that could be claimed by Lenders from
Guarantor without rendering such claim voidable or avoidable under Section 548 of the Bankruptcy Code or under any applicable state
Uniform Fraudulent Transfer Act, Uniform Fraudulent Conveyance Act or similar statute or common law.

 

4.    Miscellaneous.

 

4.1.          Expenses.
Guarantor shall pay to the Lenders, on demand, the amount of am’ and all reasonable expenses, including, without limitation,
reasonable attorneys’ fees, reasonable legal expenses and reasonable brokers’ fees, which the Lenders may incur in
connection with exercise or enforcement of any the rights, remedies or powers of the Lenders hereunder or with respect to any or
all of the Obligations.

 

    D-41

     

    

 

4.2.          Waivers.
Amendment and Remedies. No course of dealing by the Lenders and no failure by the Lenders to exercise, or delay by the Lender in
exercising, any right, remedy or power hereunder shall operate as a waiver thereof, and no single or partial exercise thereof shall
preclude any other or further exercise thereof or the exercise of any other right, remedy or power of the Lenders. No amendment,
modification or waiver of any provision of this Guaranty and no consent to any departure by Guarantor therefrom, shall, in any
event, be effective unless contained in a writing signed by the Guarantor and the Majority in Interest (as such term is defined
in the Security Agreement) or Lenders against whom such amendment, modification or waiver is sought, and then such waiver or consent
shah be effective only in the specific instance and for the specific purpose for which given. The rights, remedies and powers of
the Lenders, not only hereunder, but also under any other Transaction Documents and under applicable law are cumulative, and may
be exercised by the Lenders from time to time in such order as the Lenders may elect.

 

4.3.          Notices.         All
notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and;
unless otherwise specified herein, shall be (a) personally served, (b) deposited in the mail, registered or certified, return receipt
requested, postage prepaid, (c) delivered by a reputable overnight courier service with charges prepaid, or (d) transmitted by
hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified
most recently by written notice. Any notice or other communication required or permitted to be Riven hereunder shall be deemed
effective (i) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine,
at the address or number designated below if delivered on a Business Day during normal business hours, or the first Business Day
following such delivery (if delivered other than on a Business Day during normal business hours), (ii) on the first Business Day
following the date deposited with an overnight courier service with charges prepaid, or (iii) on the fifth Business Day following
the date of mailing pursuant to subpart (b) above, or upon actual receipt of such mailing, whichever shall first occur. The addresses
for such communications shall be:

 

	To Guarantor3 to:	Accelerated Pharma, Inc.
	 	15W155 81st Street
	 	Burr Ridge, IL 60527
	 	Fax:(630)325-4179
	 	Attn: Michael Fonstein, CEO
	 	 
	With a copy by fax only to	 
	(which shall not constitute notice):	Polsinelli PC
	 	161 N. Clark Avenue, Suite 4200
	 	Chicago, IL 60601
	 	Attn: Teddy C. Scott, Jr., Ph.D.
	 	Fax: (312) 873-2913

 

    D-42

     

    

 

	To the Collateral Agent:	Patricia Watkins
	 	230 Park Avenue, Suite 539
	 	New York, NY 10169
	 	Fax:(212)867-6204
	 	 
	To Lenders:	To the addresses and telecopier numbers set forth on Schedule A

 

Any party may change its address by written notice in accordance
with this paragraph.

 

4.4.          Term:
Binding Effect. This Guaranty shall (a) remain in full force and effect until payment and satisfaction in full of all of the Guaranteed
Obligations; (b) be binding upon Guarantor and its successors and permitted assigns; and (c) inure to the benefit of the Lenders
and their respective successors and assigns. All the rights and benefits granted by Guarantor to the Collateral Agent and Lenders
hereunder and other agreements and documents delivered in connection therewith are deemed granted to both the Collateral Agent
and Lenders. Upon the payment in full of the Guaranteed Obligations, (i) this Guaranty shall terminate and (ii) the Lenders will,
upon Guarantor’s request and at Guarantor’s expense, execute and deliver to Guarantor such documents as Guarantor shall
reasonably request to evidence such termination, all without any representation, warranty or recourse whatsoever.

 

4.5.          Captions.
The captions of Paragraphs, Articles and Sections in this Guaranty have been included for convenience of reference only, and shall
not define or limit the provisions hereof and have no legal or other significance whatsoever.

 

4.6.          Governing
Law; Venue: Severability. This Guaranty shall be governed by and construed in accordance with the laws of the State of New York
without regard to principles of conflicts or choice of law. Any legal action or proceeding against Guarantor with respect to this
Guaranty may be brought in the courts of the State of New York or of the United States for the Southern District of New York, and,
by execution and delivery of this Guaranty, Guarantor hereby irrevocably accepts for itself and in respect of its property, generally
and unconditionally, the jurisdiction of the aforesaid courts. Guarantor hereby irrevocably waives any objection which it may now
or hereafter have to the laying of venue of any of the aforesaid actions or proceedings arising out of or in connection with this
Guaranty brought in the aforesaid courts and hereby further irrevocably waives and agrees not to plead or claim in any such court
that any such action or proceeding brought in any such court has been brought in an inconvenient forum. If any provision of this
Guaranty, or the application thereof to any person or circumstance, is held invalid, such invalidity shall not affect any other
provisions which can be given effect without the invalid provision or application, and to this end the provisions hereof shall
be severable and the remaining, •valid provisions shall remain of full force and effect. This Guaranty shall be deemed an
unconditional obligation of Guarantor for the payment of money and, without limitation to any other remedies of Lenders, may be
enforced against Guarantor by summary proceeding pursuant to New York Civil Procedure Law and Rules Section 3213 or any similar
rule or statute in the jurisdiction where enforcement is sought. For purposes of such rule or statute, any other document or agreement
to which Lenders and Guarantor are parties or which Guarantor delivered to Lenders, which may be convenient or necessary to determine
Lenders’ rights hereunder or Guarantor’s obligations to Lenders are deemed a part of this Guaranty, whether or not
such other document or agreement was delivered together herewith or was executed apart from this Guaranty. Each party hereby irrevocably
waives personal service of process and consents to process being served in any suit, action or proceeding- in connection with this
Agreement or any other Transaction Document by mailing a copy thereof via registered or certified mail or overnight delivery (with
evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service
shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in
any way any right to serve process in any other manner permitted by law, Guarantor irrevocably appoints Parent its true and lawful
agent for service of process upon whom all processes of Ian’ and notices may be served and given in the manner described
above; and such service and notice shall be deemed valid personal service and notice upon Guarantor with the same force and validity
as if served upon Guarantor,

 

    D-43

     

    

 

4.7.          Satisfaction
of Obligations. For all purposes of this Guaranty, the payment in ful: of the Obligations shall be conclusively deemed to have
occurred when the Obligations Have been paid pursuant to the terms of the Notes and the Securities Purchase Agreements.

 

4.8.          Counterparts/Execution,
This Agreement may be executed in any number of counterparts and by the different signatories hereto on separate counterparts,
each of which, when so executed, shall be deemed an original, but all such counterparts shal: constitute but one and the same instrument.
This Agreement may be executed by facsimile signature and delivered by electronic transmission.

 

THE BALANCE OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK]

 

    D-44

     

    

 

IN WITNESS WHEREOF, the undersigned have executed and delivered
this Guaranty, as of the date first written above.

 

“GUARANTOR”

 

This Guaranty Agreement may be signed by
facsimile signature and

delivered by confirmed facsimile transmission.

 

    D-45

     

    

 

SCHEDULE A TO GUARANTY

 

    D-46

     

    

 

ANNEX B

to

SECURITY

AGREEMENT

 

THE COLLATERAL AGENT

 

1            Appointment. The Secured Parties (all capitalized terms
used herein and not otherwise defined shall have the respective meanings provided in the Security Agreement to which this Annex
B is attached (the “Agreement”), by their acceptance of the benefits of the Agreement, hereby designate Patricia Watkins
(“Collateral Agent”) as the Collateral Agent to act as specified herein and in the Agreement. Each Secured Party shall
be deemed irrevocably to authorize the Collateral Agent to take such action on its behalf under the provisions of the Agreement
and any other Transaction Document (as such term is defined in the Notes) and to exercise such powers and to perform such duties
hereunder and thereunder as are specifically delegated to or required of the Collateral Agent by the terms hereof and thereof and
such other powers as are reasonably incidental thereto. The Collateral Agent may perform any of its duties hereunder by or through
its agents or employees.

 

2            Nature of Duties. The Collateral Agent shall have no duties
or responsibilities except those expressly set forth in the Agreement. Neither the Collateral Agent nor any of its partners, members,
shareholders, officers, directors, employees or agents shall be liable for any action taken or omitted by it as such under the
Agreement or hereunder or in connection herewith or therewith, be responsible for the consequence of any oversight or error of
judgment or answerable for any loss, unless caused solely by its or their gross negligence or willful misconduct as determined
by a final judgment (not subject to further appeal) of a court of competent jurisdiction. The duties of the Collateral Agent shall
be mechanical and administrative in nature; the Collateral Agent shall not have by reason of the Agreement or any other Transaction
Document a fiduciary relationship in respect of any Debtor or any Secured Party; and nothing in the Agreement or any other Transaction
Document, expressed or implied, is intended to or shall be so construed as to impose upon the Collateral Agent any obligations
in respect of the Agreement or any other Transaction Document except as expressly set forth herein and therein.

 

3            Lack of Reliance on the Collateral Agent. Independently
and without reliance upon the Collateral Agent, each Secured Party, to the extent it deems appropriate, has made and shall continue
to make (i) its own independent investigation of the financial condition and affairs of the Company and its subsidiaries in connection
with such Secured Party’s investment in the Debtors, the creation and continuance of the Obligations, the transactions contemplated
by the Transaction Documents, and the taking or not taking of any action in connection therewith, and (ii) its own appraisal of
the creditworthiness of the Company and its subsidiaries, and of the value of the Collateral from time to time, and the Collateral
Agent shall have no duty or responsibility, either initially or on a continuing basis, to provide any Secured Party with any credit,
market or other information \Yid: respect thereto, whether coming into its possession before any Obligations are incurred or at
any time or times thereafter. The Collateral Agent shall not be responsible to the Debtors or any Secured Party for any recitals,
statements, information, representations or warranties herein or in any document, certificate or other -writing delivered in connection
herewith, or for the execution, effectiveness, genuineness, validity, enforceability, perfection, collectability, priority or sufficiency
of the Agreement or any other Transaction Document, or for the financial condition of the Debtors or the value of any of the Collateral,
or be required to make any inquiry concerning either the performance or observance of any of the terms, provisions or conditions
of the Agreement or any other Transaction Document, or the financial condition of the Debtors, or the value of any of the Collateral,
or the existence or possible existence of any default or Event of Default under the Agreement, the Notes or any of the other Transaction
Documents.

 

    D-47

     

    

 

4            Certain Rights of the Collateral Agent. The Collateral
Agent shall have the right to take any action with respect to the Collateral, on behalf of all of the Secured Parties. To the extent
practical, the Collateral Agent shall request instructions from the Secured Parties with respect to any material act or action
(including failure to act) in connection with the Agreement or any other Transaction Document, and shall be entitled to act or
refrain From acting in accordance with the instructions of Secured Parties holding a majority in principal amount of Notes (based
on then-outstanding principal amounts of Notes at the time of any such determination); if such instructions are not provided despite
the Collateral Agent’s request therefor, the Collateral Agent shall be entitled to refrain from such act or taking such action,
and if such action is taken, shall be entitled to appropriate indemnification from the Secured Parties in respect of actions to
be taken by the Collateral Agent; and the Collateral Agent shall not incur liability to any person or entity by reason of so refraining.
Without limiting the foregoing, (a) no Secured Party shall have any right of action whatsoever against the Collateral Agent as
a result of the Collateral Agent acting or refraining from acting hereunder in accordance with the terms of the Agreement or any
other Transaction Document, and the Debtors shall have no right to question or challenge the authority of, or the instructions
given to, the Collateral Agent pursuant to the foregoing and (b) the Collateral Agent shall not be required to take any action
which the Collateral Agent believes (i) could reasonably be expected to expose it to personal liability or (ii) is contrary to
this Agreement, the Transaction Documents or applicable law,

 

5            Reliance. The Collateral Agent shall be entitled to rely,
and shall be fully protected in relying, upon any writing: resolution, notice: statement, certificate, telex, teletype or telecopier
message, cablegram, radiogram, order or other document or telephone message signed, sent or made by the proper person or entity,
and, with respect to all legal markers pertaining to the Agreement and the other Transaction Documents and its duties thereunder,
upon advice of counsel selected by it and upon all other matters pertaining to this Agreement and the other Transaction Documents
and its duties thereunder, upon advice of other experts selected by it. Anything to the contrary notwithstanding, the Collateral
Agent shall have no obligation whatsoever to any Secured Party to assure that the Collateral exists or is owned by the Debtors
or is cared for, protected or insured or that the liens granted pursuant to the Agreement have been properly or sufficiently or:
awfully created, perfected, or enforced or are entitled to any particular priority.

 

    D-48

     

    

 

6            Indemnification. To the extent that the Collateral Agent
is not reimbursed and indemnified by the Debtors, the Secured Parties will jointly and severally reimburse and indemnify the Collateral
Agent, in proportion to their initially purchased respective principal amounts of Notes, from and against any and all liabilities,
obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind or nature whatsoever
which may be imposed on, incurred by or asserted against the Collateral Agent in performing its duties hereunder or under the Agreement
or any other Transaction Document, or in any way relating to or arising out of the Agreement or any other Transaction Document
except for those determined by a final judgment (not subject to further appeal) of a court of competent jurisdiction to have resulted
solely from the Collateral Agent’s own gross negligence or willful misconduct. Prior to taking any action hereunder as Collateral
Agent, the Collateral Agent may require each Secured Party to deposit with it sufficient sums as it determines in good faith is
necessary to protect the Collateral Agent for costs and expenses associated with taking such action.

 

7            7. Resignation by the Collateral Agent

 

		(a)	The Collateral Agent may resign from the performance of
all its functions and duties under the Agreement and the other Transaction Documents at any time by giving 5 days’ prior
written notice (as provided in the Agreement) to the Debtors and the Secured Parties. Such resignation shall take effect upon
the appointment of a successor Collateral Agent pursuant to clauses (b) and (c) below.

 

		(b)	Upon any such notice of resignation, the Secured Parties,
acting by a Majority in Interest, shall appoint a successor Collateral Agent hereunder.

 

		(c)	If a successor Collateral Agent shall not have been so
appointed within said 5-day period, the Collateral Agent shall then appoint a successor Collateral Agent who shall serve as Collateral
Agent until such time, if any, as the Secured Parties appoint a successor Collateral Agent as provided above. If a successor Collateral
Agent has not been appointed within such 5-day period, the Collateral: Agent may petition any court of competent jurisdiction
or may inter-plead the Debtors and the Secured Parties in a proceeding for the appointment of a successor Collateral Agent, and
all fees, including, but not limited to, extraordinary fees associated with the filing of interpleader and expenses associated
therewith, shall be payable by the Debtors on demand.

 

8              Rights with respect to Collateral. Each Secured Party agrees
with all other Secured Parties and the Collateral Agent (i) that it shall not, and shall not attempt to, exercise any rights with
respect to its security interest in the Collateral, whether pursuant to any other agreement or otherwise (other than pursuant to
this Agreement), or take or institute any action against the Collateral Agent or any of the other Secured Parties in respect of
the Collateral or its rights hereunder (other than any such action arising from the breach of this Agreement) and (ii) that such
Secured Party has no other rights with respect to the Collateral: other than as set forth in this Agreement and the other Transaction
Documents. Upon the acceptance of any appointment as Collateral Agent hereunder by a successor Collateral Agent, such successor
Collateral: Agent shall thereupon succeed to and become vested with all the rights, powers, privileges and duties of the retiring
Collateral Agent and the retiring Collateral Agent shall be discharged from its duties and obligations under the Agreement. After
any retiring Collateral Agent’s resignation or removal hereunder as Collateral Agent, the provisions of the Agreement including
this Annex B shall inure to its benefit as to any actions taken or omitted to be taken by it while it was Collateral Agent.

  

    D-49

     

    

 

Exhibit
E

Form of Investor Questionnaire

 

ACCREDITED INVESTOR QUESTIONNAIRE

IN CONNECTION WITH INVESTMENT IN NOTES AND WARRANTS

OF ACCELERATED PHARMA, INC.,

A DELAWARE CORPORATION

PURSUANT TO SECURITIES PURCHASE AGREEMENT DATED DECEMBER ___, 2014

 

	TO:	Palladium Capital Advisors, LLC	 
	 	230 Park Avenue, Suite 539	 
	 	New York, NY 10169	 
	 	Fax: (646) 390-6328	 

 

INSTRUCTIONS

 

PLEASE ANSWER ALL QUESTIONS.
If the appropriate answer is “None” or “Not Applicable”, so state. Please print or type your answers to all
questions. Attach additional sheets if necessary to complete your answers to any item.

 

Your answers will be
kept strictly confidential at all times. However, Palladium Capital Advisors, LLC (the “Company”) may present this Questionnaire
to such parties as it deems appropriate in order to assure itself that the offer and sale of securities of the Company will
not result in a violation of the registration provisions of the Securities Act of 1933, as amended, or a violation of the securities
laws of any state.

 

	1.	Please provide the following information:

 

	Name: 	 

 

	Name of additional purchaser: 	 

(Please complete information in Question 5)

 

	Date of birth, or if other than an individual, year of organization or incorporation:
	 
	 
	 
	 

 

	2.	Residence address, or if other than an individual, principal office address:
	 	 
	 	 
	 	 
	 	 
	 	 
	 	 

 

	Telephone number:	 

 

	Social Security Number:	 

 

    E-1

     

    

  

	Taxpayer Identification Number: 	 

 

	3.	Business address:	 

 

	 
	 
	 

 

	Business telephone number:	 

 

	4.	Send mail to:	Residence _____	Business ______

 

5.          With
respect to tenants in common, joint tenants and tenants by the entirety, complete only if information differs from that above:

 

	Residence address:	 

 

 

 

 

 

 

  

	Telephone number:	 

 

	Social Security Number:	 

 

	Taxpayer Identification Number:   	 

 

	Business address:	 

 

	 
	 
	 

 

	Business telephone number:	 

 

	Send Mail to:	Residence _______	Business _______

 

6.          Please
describe your present or most recent business or occupation and indicate such information as the nature of your employment, how
long you have been employed there, the principal business of your employer, the principal activities under your management or supervision
and the scope (e.g. dollar volume, industry rank, etc.) of such activities:

	 
	 
	 
	 
	 
	 

 

    E-2

     

    

  

7.          Please
state whether you (i) are associated with or affiliated with a member of the Financial Industry Regulatory Association, Inc. (“FINRA”),
(ii) are an owner of stock or other securities of FINRA member (other than stock or other securities purchased on the open market),
or (iii) have made a subordinated loan to any FINRA member:

 

	_______	______
	Yes	No

 

If you answered yes to any of (i) — (iii) above,
please indicate the applicable answer and briefly describe the facts below:

 

 

 

 

 

 

 

8A.           Applicable
to Individuals ONLY. Please answer the following questions concerning your financial condition as an “accredited investor”
(within the meaning of Rule 50: of Regulation D). If the purchaser is more than one individual, each individual must initial an
answer where the question indicates a “yes” or “no” response and must answer any other question fully, indicating
to which individual such answer applies. If the purchaser is purchasing jointly with his or her spouse, one answer may be indicated
for the couple as a whole:

 

8.1           Does
your net worth* (or joint net worth with your spouse) exceed $1,000,000?

 

	_______	______
	Yes	No

 

8.2Did you have an individual income** in
excess of 5200,000 or joint income together with your spouse in excess of 5300,000 in each of the two most recent years and
do you reasonably expect to reach the same income level in the current year?

 

	_______	______
	Yes	No

 

8.3           Are
you an executive officer of the Company?

 

	_______	______
	Yes	No

 

* For purposes hereof, net worth shall be deemed
to include ALL of your assets, liquid or illiquid MIYLTS any liabilities.

 

** For purposes hereof, the
term “income” is not limited to “adjusted gross income” as that term is defined for federal income tax purposes,
but rather includes certain items of income which are deducted in computing “adjusted gross income”. For investors who
are salaried employees, the gross salary of such investor, minus any significant expenses personally incurred by such investor
in connection with earning the salary, plus any income from any other source including unearned income, is a fair measure of “income”
for purposes hereof. For investors who are self-employed, “income” is generally construed to mean total revenues received
during the calendar year minus significant expenses incurred in connection with earning such revenues.

 

    E-3

     

    

 

8.B       Applicable
to Corporations, Partnerships, Trusts, Limited Liability Companies and other Entities ONLY:

 

The purchaser is an accredited investor because the purchaser
falls within at least one of the following categories (Check all appropriate lines):

 

	 	___	(i) a bank as defined in Section 3(a)(2) of the Act or a savings and loan association or other institution as defined in Section 3(a)(5)(A) of the Act whether acting in its individual or fiduciary capacity;
	 	 	 
	 	___	(ii) a broker-dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934, as amended;
	 	 	 
	 	___	(iii) an insurance company as defined in Section 203) of the Act;
	 	 	 
	 	___	(iv) an investment company registered under the Investment Company Act of 1940, as amended (the “Investment Act”) or a business development company as defined in Section 2(a)(48) of the Investment Act;
	 	 	 
	 	___	(v) a Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958, as amended;
	 	 	 
	 	___	(vi) a plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, where such plan has total assets in excess of $5,000,000;
	 	 	 
	 	___	(vii) an employee benefit plan within the meaning of Title 1 of the Employee Retirement Income Security Act of 1974, as amended (the “Employee Act”), where the investment decision is made by a plan fiduciary, as defined in Section 3(21) of the Employee Act, which is either a bank, savings and loan association, insurance company, or registered investment adviser, or an employee benefit plan that has total assets in excess of $5,000,000, or a self-directed plan the investment decisions of which are made solely by persons that are accredited investors;
	 	 	 
	 	___	(viii) a private business development company, as defined in Section 202(a)(22) of the Investment Advisers Act of 1940, as amended;
	 	 	 
	 	___	(ix) an organization described in Section 501(c)(3) of the Internal Revenue Code, a corporation, a Massachusetts or similar business trust, or a partnership, not formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000;
	 	 	 
	 	___	(x) a trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the securities offered, whose purchase is directed by a “sophisticated” person, as described in Rule 506(b)(2)(ii) promulgated under the Act, who has such knowledge and experience in financial and business matters that he or she is capable of evaluating the merits and risks of the prospective investment;

 

    E-4

     

    

  

	 	___	(xi) an entity in
    which all of the equity investors are persons or entities described above     (“accredited investors”). ALL
    EQUITY OWNERS MUST COMPLETE “EXHIBIT A” ATTACHED HERETO.

 

9.A          Do you have sufficient knowledge and
experience in financial and business matters so as to be capable of evaluating the merits and risks associated with investing
in the Company?

 

	_______	______
	Yes	No

 

ANSWER QUESTION 9B ONLY IF THE ANSWER TO QUESTION
9A WAS “NO.”

 

9.B        If the answer to Question 9A was “NO,”
do you have a financial or investment adviser (a) that is acting in the capacity as a purchaser representative and (b) who has
sufficient knowledge and experience in financial and business matters so as to be capable of evaluating the merits and risks associated
with investing in the Company?

 

	_______	______
	Yes	No

 

If you have a financial or investment
adviser(s), please identify each such person and indicate his or her business address and telephone number in the space below.
(Each such person must complete, and you must review and acknowledge, a separate Purchaser Representative Questionnaire which will
be supplied at your request).

 

 

 

 

 

 

 

10.         You
have the right, will be afforded an opportunity, and are encouraged to investigate the Company and review relevant factors and
documents pertaining to the officers of the Company, and the Company and its business and to ask questions of a qualified representative
of the Company regarding this investment and the properties, operations, and methods of doing business of the Company.

 

Have you or has your purchaser
representative, if any, conducted any such investigation, sought such documents or asked questions of a qualified representative
of the Company regarding this investment and the properties, operations, and methods of doing business of the Company?

 

	_______	______
	Yes	No

 

	If so, briefly describe:	 

 

 

 

 

If so, have you completed your investigation and/or
received satisfactory answers to your questions?

 

	_______	______
	Yes	No

 

11.         Do
you understand the nature of an investment in the Company and the risks associated with such an investment?

 

	_______	______
	Yes	No

 

    E-5

     

    

  

12.         Do
you understand that there is no guarantee of any financial return on this investment and that vou will be exposed to the risk of
losing your entire investment?

 

	_______	______
	Yes	No

 

13.         Do
you understand that this investment is not liquid?

 

	_______	______
	Yes	No

 

14.         Do
you have adequate means of providing for your current needs and personal contingencies in view of the fact that this is not a liquid
investment?

 

	_______	______
	Yes	No

 

15.         Are
you aware of the Company’s business affairs and financial condition, and have you acquired all such information about the Company
as you deem necessary and appropriate to enable you to reach an informed and knowledgeable decision to acquire the Interests?

 

	_______	______
	Yes	No

 

16.         Do
you have a “pre-existing relationship” with the Company or any of the officers of the Company?

 

	_______	______
	Yes	No

 

(For purposes hereof; “pre-existing
relationship” means any relationship consisting of personal or business contacts of a nature and duration such as would enable
a reasonably prudent investor to be aware of the character, business acumen, and general business and financial circumstances of
the person with whom such relationship exists.)

 

If so, please name the individual or other person
with whom you rave a pre-existing relationship and describe the relationship:

  

 

 

 

 

 

 

 

    E-6

     

    

  

17.         Exceptions
to the representations and warranties made in Section 3.2 of the Securities Purchase Agreement (if no exceptions, write “none”
— if left blank, the response will be deemed to be “none”): _______________________

 

 

 

 

Dated: ________________, 2014

 

If purchaser is one or more individuals (all individuals
must sign):

 

 

 

(Type or print name of prospective purchaser)

 

 

 

Signature of prospective purchaser

 

 

 

Social Security Number

 

 

 

(Type or print name of additional purchaser)

 

 

 

Signature of spouse, joint tenant, tenant in common
or other signature, if required

 

 

 

Social Security Number

 

    E-7

     

    

  

Annex A

 

Definition of Accredited Investor

 

The securities
will only be sold to investors who represent in writing in the Securities Purchase Agreement that they are accredited investors,
as defined M Regulation U. Rule 501 under the Act which definition is set forth below:

 

1.          A
natural person whose net worth, or joint net worth with spouse, at the time of purchase exceeds $1 million (excluding home); or

 

2.          A
natural person whose individual gross income exceeded S200,000 or whose joint income with that person’s spouse exceeded S300,000
in each of the last two years, and who reasonably expects to exceed such income level in the current year; or

 

3.          A
trust with total assets in excess of 85 million, not formed for the specific purpose of acquiring the securities offered, whose
purchase is directed by a sophisticated person described in Regulation D; or

 

4.          A
director or executive officer of the Company; or

 

5.          The
investor is an entity, all of the owners of which are accredited investors; or

 

6.          (a)
bank as defined in Section 3(a)(2) of the Act, or any savings and loan association or other institution as defined in Section 3(a)(5)(A)
of the Act, (b) any broker or dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934, (c) an insurance
Company as defined in Section 2(13) of the Act, (d) an investment Company registered under the Investment Company Act of :940 or
a business development Company as defined in Section 2(a)(48) of such Act, (c) a Small Business Investment Company licensed by
the United States Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958, (f) an
employee benefit plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a
state or its political subdivisions, if such plan has total assets in excess of 85 in on, (g) an employee benefit plan within the
meaning of Title I of the Employee Retirement Income Securities Act of 1974, and the employee benefit plan has assets in excess
of $5 million, or the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such act, that is either
a bank, savings and loan institution, insurance Company, or registered investment advisor, or, if a self-directed plan, with an
investment decisions made solely by persons that are accredited investors, (h) a private business development company as defined
in Section 202(a)(22) of the Investment Advisers Act of 1940, or (i) an organization described in Section 501(c)(3) of the Internal
Revenue code, corporation, Massachusetts or similar business :rust, or partnership, not formed for the specific purpose of acquiring
the securities offered, with assets in excess of $5 million.

 

    E-8

     

    

  

EXHIBIT “A” TO ACCREDITED INVESTOR
QUESTIONNAIRE

 

ACCREDITED CORPORATIONS, PARTNERSHIPS,
LIMITED LIABILITY COMPANIES, TRUSTS OR OTHER ENTITLES INITIALING QUESTION 313(xi) MUST PROVIDE THE FOLLOWING INFORMATION.

 

I hereby certify that set forth
below is a complete list of a:I equity owners in __________________________ [NAME OF ENTITY], a _________________________ [TYPE
OF ENTITY] formed pursuant to the laws of the State of ___________________. I also certify that EACH SUCH OWNER HAS INITIALED
THE SPACE OPPOSITE HIS OR HER NAME and that each such owner understands that by initialing: that space he or she is representing
that he or she is an accredited individual investor satisfying the test for accredited individual investors indicated under “Type
of Accredited Investor.”

 

	 	 
	 	signature of authorized corporate officer, general partner or trustee

 

	 	Name
    of Equity Owner	 	Type
    of Accredited Investor l
	 	 	 	 
	1.	 	 	 
	 	 	 	 
	2.	 	 	 
	 	 	 	 
	3.	 	 	 
	 	 	 	 
	4.	 	 	 
	 	 	 	 
	5.	 	 	 
	 	 	 	 
	6.	 	 	 
	 	 	 	 
	7.	 	 	 
	 	 	 	 
	8.	 	 	 
	 	 	 	 
	9.	 	 	 
	 	 	 	 
	10.	 	 	 

  

 

		1	Indicate which Subparagraph of 8.1 - 8.3 the equity owner
satisfies.

  

    E-9

     

    

  

Exhibit F

Third Waiver and Consent

 

THIRD AMENDMENT, WAIVER AND CONSENT

 

This Third Amendment, Waiver
and Consent (“Third Consent”) is made and entered into as of March ___, 2016, by and among Accelerated Pharma, Inc.,
a Delaware corporation (the “Company”), and the parties identified on the signature page hereto (each a “Prior
Purchaser” and collectively, “Prior Purchasers”). Capitalized terms used but not defined herein will have the
meanings assigned to them in the Securities Purchase Agreements and Transaction Documents (as defined below). Capitalized terms
defined herein shall be incorporated in the Transaction Documents, as appropriate.

 

WHEREAS, the Company and
Prior Purchasers identified on Schedule A entered into Securities Purchase Agreements (“Securities Purchase Agreements”)
and other Transaction Documents (collectively, “Transaction Documents”) dated as of December 23, 2014, May 8, 2015,
June 11, 2015 and November 6, 2015; and

 

WHEREAS, the Transaction
Documents were previously amended and certain consents and waivers were granted pursuant to a certain Amendment, Waiver and Consent
entered into as of May 8, 2015 and as further amended on November 6, 2015 pursuant to a Second Amendment, Waiver and Consent; and

 

WHEREAS, the Company issued
to the Prior Purchasers Secured Convertible Notes (“Prior Notes”) and Warrants (the “Prior Warrants”);
and

 

WHEREAS, the Company intends
to sell secured convertible notes (“Proposed Offering Notes”) and Common Stock purchase warrants (“Proposed Offering
Warrants”) for an aggregate purchase price of up to $1,500,000 (the “Proposed Offering”) as set forth in certain
securities purchase agreements and related transaction documents (collectively, “Proposed Offering Securities Purchase Agreements”
and “Proposed Offering Transaction Documents”), dated at or after the date of this Third Consent, between the Company
and the purchasers thereto (“Proposed Offering Purchasers”), and the exhibits and schedules attached thereto; and

 

WHEREAS, in connection
with the Proposed Offering, the Prior Purchasers are entitled to certain rights; and

 

WHEREAS, in connection
with the Proposed Offering, the Company and Prior Purchasers agree to the following amendments, waivers, and consents, which amendments,
waivers and consents shall be effective, the approval of a Majority in Interest which shall be binding on all Prior Purchasers,
and only upon the closing of the Proposed Offering (“Effective Date”).

 

NOW, THEREFORE, the Company
and Prior Purchasers hereby agree as follows:

 

1.          The
Amended and Restated Security Agreement dated May 8, 2015 is hereby replaced by the Second Amended and Restated Security Agreement
dated as of the date hereof.

 

2.           The
definition of “Qualified Offering” in Section 1.1 of the Securities Purchase Agreements is deleted and replaced with
the following:

 

    F-1

     

    

 

 

““Qualified Offering”
means the first occurrence of an offering of the Company’s Common Stock which closes in one or more closings in connection
with which the Company receives not less than $5,000,000 of gross cash proceeds from the sale of Common Stock on or before November
15, 2016 by Palladium Capital Advisors, LLC pursuant to the terms of an investment banking agreement between the Company and Palladium
Capital Advisors, LLC, and thereafter by the Company or other placement agent until the Maturity Date (as defined in the Note)
accelerated or otherwise.”

 

3.           Until
_______, 2016, the Prior Purchasers waive the delivery of the audits and financial statements as further described in Section 4.3
of the Securities Purchase Agreements.

 

4.           In
connection with the Proposed Offering, the Prior Purchasers waive the prohibition against the Company from engaging in Subsequent
Equity Sales as defined in Section 4.9 of the Securities Purchase Agreements.

 

5.          The
meaning of “End Date” as defined in Section 4.9 of the Securities Purchase Agreements shall be amended to mean the
later to occur of (i) a Going Public Event, or (ii) December 31, 2017.

 

6.          
Section 4.10 of the Securities Purchase Agreements will be deleted in its entirety and replaced with the following:

 

“4.10 Equal Treatment of
Purchasers. No consideration (including any modification of any Transaction Document) shall be offered or paid to any Person
to amend or consent to a waiver or modification of any provision of any of the Transaction Documents or Proposed Offering Transaction
Documents (which means the Proposed Offering by the Company of up to $1,500,000 (“Proposed Offering”) in secured convertible
notes (“Proposed Offering Notes”), and Common Stock purchase warrants (“Proposed Offering Warrants”) pursuant
to the terms of the securities purchase agreements (“Proposed Offering Securities Purchase Agreements”) dated at or
after the date of this Agreement but before _____ and other transaction documents (“Proposed Offering Transaction Documents”))
unless the same or substantially similar consideration is also offered, mutatis mutandis, on a ratable basis to all of the
parties to this Agreement and the Proposed Offering Securities Purchase Agreements. For clarification purposes, this provision
constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended
for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or
as a group with respect to the purchase, disposition or voting of Securities or otherwise.”

 

7.          
Section 5.5 of the Securities Purchase Agreements is deleted and replaced with the following language, which will aggregate
the Prior Purchasers of the Notes issued on December 23, 2014, May 8, 2015, June 11, 2015 and November 16, 2015 together with
the Proposed Offering Purchasers in connection with determining a Majority in Interest (prior to this Third Consent, the
December 23, 2014 Prior Purchasers were not aggregated with the balance of the Prior Purchasers in determining a Majority in
Interest):

 

    F-2

     

    

 

“Amendments; Waivers.
Except with respect to the Amended and Restated Security Agreement dated May 8, 2015 as further amended pursuant to the Second
Amended and Restated Security Agreement dated March __, 2016, no provision of this Agreement nor any other Transaction Document
may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company
and the Purchasers holding at least a majority in interest (“Majority in Interest”) of the component of the
affected Securities then outstanding or, in the case of a waiver, by the party against whom enforcement of any such waived provision
is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement nor any other Transaction
Document shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement thereof, nor shall any delay or omission of any party to exercise any right thereunder in any
manner impair the exercise of any such right. For purposes of determining a Majority in Interest with respect to the Notes issued
on December 23, 2014, May 8, 2015, June 11, 2015 and November 6, 2015 (collectively, Prior Notes”), the holders of
Prior Notes and Proposed Offering Notes (as defined in the Third Amendment Waiver and Consent) shall be aggregated. A Majority
in Interest with respect to the Second Amended and Restated Security Agreement shall mean a majority based on the aggregate of
the Prior Purchasers of December 23, 2014, May 8, 2015, June 11, 2015 and November 6, 2015 and Proposed Offering Purchasers.”

 

8.          Section
2(e) of the Prior Notes will be deleted in its entirety and replaced with the following:

 

“(e) Pari Passu. Except
as otherwise set forth herein, all payments made on this Note, the Other Notes, the Prior Notes (as defined in the Third Amendment
Waiver and Consent), and the Proposed Offering Notes (as defined in the Third Amendment Waiver and Consent) and all actions taken
by the Borrower with respect to this Note, the Other Notes, the Prior Notes and Proposed Offering Notes, including but not limited
to Mandatory Conversion, if such action may or must be taken with respect to this Note, Other Notes, the Prior Notes or Proposed
Offering Notes, shall be made and taken pari passu with respect to this Note, the Other Notes, and the Prior Notes. Notwithstanding
anything to the contrary contained herein or in the Transaction Documents, it shall not be considered non-pari passu for a Holder,
Other Holder, Holder of Prior Notes or Proposed Note Holder to elect to receive interest paid in shares of Common Stock or for
the Borrower to actually pay interest in shares of Common Stock to such electing Holder, Other Holder, Holder of Prior Notes or
Proposed Note Holder.”

 

9.          The
last sentence of Section 4(d) of the Prior Notes shall be deleted and replaced with the following:

 

			“The limitation contained in this paragraph shall apply at any time with respect to a mandatory
exchange as described in Section 6(a) and otherwise, only from and after the occurrence of a Going Public Event.”

 

10.          Section
8(a)xxi of the Prior Notes shall be deleted in its entirety and replaced with the following: “the occurrence of an Event
of Default under any Other Note, any other Prior Note (as defined in the Third Amendment Waiver and Consent) or any Proposed Offering
Note.”

 

11.          The
Termination Date (as defined in the Warrant) of the Prior Warrants issued on May 8, 2015, June 11, 2015 and November 6, 2015 is
amended to December 23, 2019.

 

12.          The
undersigned consents to the Company completing the Proposed Offering pursuant to the terms of this Third Consent.

 

    F-3

     

    

 

13.          The
undersigned represents to the Company that it is the holder of the Prior Notes and Prior Warrants in the amounts set forth on Schedule
A hereto, it has not sold, transferred or otherwise assigned any of the Prior Notes and Prior Warrants and it has the authority
to enter into and deliver this Consent.

 

14.          The
Company represents that Schedule A hereto identifies all of the holders and sets forth the amounts as of the closing date
of the Proposed Offering of all of the securities issued or issuable pursuant to the Securities Purchase Agreements and that the
Transaction Documents have not been previously amended nor any waiver of any term thereof granted by any party thereto other than
as set forth in the Amendment Waiver and Consent, the Second Amendment, Waiver and Consent and this Third Consent.

 

15.          This
Third Consent may be executed in counterparts, each of which shall be deemed an original but all of which shall together constitute
one and the same instrument. This Third Consent may be signed and delivered by facsimile or electronically and such facsimile or
electronically signed and delivered Third Consent shall be enforceable.

 

16.          This
Third Consent shall be included in the definition of Transaction Documents as such term is defined in the Securities Purchase Agreements.

 

17.          Sections
5.4, 5.5, 5.12 and 5.21 of the Securities Purchase Agreements are incorporated herein by reference.

 

18.          The
parties acknowledge that this Third Consent is being entered into for the benefit of the Proposed Offering Purchasers and who are
hereby made third party beneficiaries of this Third Consent with rights of enforcement until the sooner of the abandonment of the
Proposed Offering or ____, 2016. This Third Consent may not be amended without the consent of such investors described in the Securities
Purchase Agreement to the Proposed Offering, which consent may be withheld for any reason.

 

19.          The
parties acknowledge that the additional notice party for the Company is: Randy Saluck, Esq., c/o Mortar Rock Capital, 767 Third
Avenue, 11th Floor, New York, NY 10017, fax: (212) 308-3625.

 

21.          Except as expressly
set forth herein, this Third Consent shall not be deemed to be a waiver, amendment or modification of any provisions of the Transaction
Documents or of any right, power or remedy of the Purchaser, or constitute a waiver of any provision of the Transaction
Documents (except to the extent herein set forth), or any other document, instrument and/or agreement executed or delivered in
connection therewith and any other agreement to which the Purchaser may be parties to, in each case whether arising before or after
the date hereof or as a result of performance hereunder or thereunder. Except as set forth herein, the Purchaser reserves
all rights, remedies, powers, or privileges available under the Transaction Documents and any other agreement to which the
Purchaser may be parties to, at law or otherwise. This Third Consent shall not constitute a novation or satisfaction and accord
of the Transaction Documents or any other document, instrument and/or agreement executed or delivered in connection therewith
and any other agreement to which the Purchaser may be a party to.

 

(Signatures to follow)

 

    F-4

     

    

 

IN WITNESS WHEREOF, the Company and the undersigned
Prior Purchasers have caused this Third Consent to be executed as of the date first written above.

 

	 	ACCELERATED PHARMA, INC.
	 	the “Company”
	 	 	 
	 	By:	 

 

“PRIOR PURCHASER”

 

Name of Prior Purchaser: ______________________________________________________________

 

Signature of Authorized Signatory of Prior
Purchaser: _______________________________________

 

Name of Authorized Signatory: ___________________________________________________________

 

Title of Authorized Signatory: ____________________________________________________________ 

 

    	F-5

     

    

 

Schedule
3.1(a)

Subsidiaries

 

Axeler,
LLC, a Russian limited liability company which is one hundred percent (100%) owned by the Company

 

    	F-6

     

    

  

Schedule 3.1(g)

Capitalization

 

	Authorized Capital:	5,000,000
	 	 
	Common Stock:	4,000,000, $0.00001 par value per share
	 	 
	Preferred Stock:	1,000,000 $0.0001 par value per share - undesignated

 

See Capitalization Table sent under prior email

 

Options, Warrants and other Commitments to issue Shares of Stock
(also reflected attached Capitalization Table:

 

I.      Placement Agent Agreement
dated September 16, 2014, as amended (the “Placement Agent Agreement”)
between Palladium Capital Advisors, LLC (“Palladium”) and the Company. Pursuant to the Placement Agent Agreement, the
Company is obligated to issue to Palladium a series of warrants as contemplated by Section 4 of the Placement Agent Agreement.
These warrants will have a nominal exercise price, and by this reference, these warrants and the stock issued upon exercise will
each be an “Exempt Issuance” for purposed of the Agreement, the Notes, and the Warrants.

 

2.      The
Agreement contemplates and the Company is obligated to conduct subsequent offering of its securities.

 

3.      The
150,000 shares of common stock owned by Palladium is subject to performance vesting pursuant to that certain Restricted Stock Award
Agreement dated as of September 16, 2014 between Palladium and the Company.

 

4.      Prior
Offering Notes

 

5.      Prior
Offering Warrants

 

6.      Compensation
payable to Palladium in connection with the Offering.

 

7.      See
Schedule 3.1(o).

 

    	F-7

     

    

  

Schedule 3.1(h)

 

Financial Statements

 

ACCELERATED PHARMA, INC.

CONSOLIDATED BALANCE SHEETS

DECEMBER 31, 2015 AND 2014

 

	 	 	2015	 	 	2014	 
	 	 	 	 	 	 	 
	ASSETS	 	 	 	 	 	 	 	 
	Current assets:	 	 	 	 	 	 	 	 
	Cash and cash equivalents	 	S	657,925	 	 	5 	01,025	 
	Prepaid and other
    current assets	 	 	97
                                         516	 	 	 	 	_
	Total
    current assets	 	 	755,441	 	 	 	501,025	 
	 	 	 	 	 	 	 	 	 
	Property and equipment,
    net	 	 	10
                                         346	 	 	 	 	 
	Total assets	 	 	_$
                                         ils.a,212	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	LIABILITIES AND STOCKHOLDERS’
    DEFICIT	 	 	 	 	 	 	 	 
	Current liabilities:	 	 	 	 	 	 	 	 
	Accounts payable	 	$	597,253	 	 	5	750	 
	Accrued interest payable	 	 	160,016	 	 	 	 	 
	Accrued obligation to acquire licensing
    rights (Note 5)	 	 	2,165,994	 	 	 	50,000	 
	Convertible debt, net of discount of
    S1,159,004 (Note 6)	 	 	2,190,996	 	 	 	 	 
	Warrant liability
    (Note 4)	 	 	960,494	 	 	 	446,512	 
	Total current liabilities	 	 	6,073,983	 	 	 	497,262	 
	 	 	 	 	 	 	 	 	 
	Long term debt:	 	 	 	 	 	 	 	 
	Convertible debt,
    net of discount of 5747,232 (Note 6)	 	 	 	 	 	 	2
                                         768	 
	Total liabilities	 	 	6,073,983	 	 	 	500,030	 
	 	 	 	 	 	 	 	 	 
	Commitment and contingencies (Note 9)	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	Stockholders’ (deficit) equity:	 	 	 	 	 	 	 	 
	Preferred stock, 50.00001 par value,
    1,000,000 shares authorized, none designated issued or outstanding as of December 31, 2015 and 2014	 	 	 	 	 	 	 	 
	Common stock, 50.00001 par value, 4,000,000 shares authorized,
    1,000,000 shares issued and outstanding as of December 31, 2015 and 2014	 	 	10	 	 	 	10	 
	Additional paid in capital	 	 	3,828,122	 	 	 	3,348,987	 
	Accumulated deficit	 	 	(9,056,213	)	 	 	(3,348,002	)
	Accumulated other
    comprehensive loss	 	 	(80,115	)	 	 	 	 
	Total stockholders’
    (deficit) equity	 	 	(5,308,196	)	 	 	995	 
	 	 	 	 	 	 	 	 	 
	Total liabilities
    and stockholders’ (deficit) equity	 	 S	365-782	 	 	 	 	 

 

    	F-8

     

    

 

ACCELERATED PHARMA,
INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

 

	 	 	Year ended
 December 31,
 2015	 	 	From May 9, 2014
 (date of inception)
 Through
 December 31,
 2014	 
	OPERATING EXPENSES:	 	 	 	 	 	 	 	 
	General and administrative	 	$	1,482,506	 	 	$	3,024,383	 
	Research and development	 	 	3.223.359	 	 	 	150.000	 
	Total operating expenses	 	 	4,705,865	 	 	 	3,174,383	 
		 	 	 	 	 	 	 	 
	Loss from operations	 	 	(4,705,865	)	 	 	(3,174,383	)
	Other income (expenses):	 	 	 	 	 	 	 	 
	Foreign currency exchange gain	 	 	101,957	 	 	 	-	 
	Gain on change in fair value of warrant liability	 	 	80,200	 	 	 	2,724	 
	Interest expense	 	 	(1,184,503	)	 	 	(176,343	)
	Total other expense	 	 	(1,002,346	)	 	 	(173,619	)
	 	 	 	 	 	 	 	 	 
	Net loss before provision for income taxes	 	 	(5,708,211	)	 	 	(3,348,002	)
	 	 	 	 	 	 	 	 	 
	Income tax (benefit)	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	Net loss	 	 	S—C12Q,L2—th	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	Net loss per common share, basic and diluted	 	 	 	 	 	 	14 41)	 
	 	 	 	 	 	 	 	 	 
	Weighted average common shares outstanding, basic and diluted	 	 	1.9.9 9_0_Q	 	 	 	758333	 
	 	 	 	 	 	 	 	 	 
	Comprehensive loss:	 	 	 	 	 	 	 	 
	Net loss	 	$	(5,708,211	)	 	S	(3,348,002)	 
	Foreign currency translation loss	 	 	(80,115	)	 	 	 	 
	Comprehensive loss	 	 	i_xnacao	 	 	 	1—L2.3S=	 

    	F-9

     

    

 

ACCELERATED PHARMA,
INC.

CONSOLIDATED STATEMENT OF’ CHANGES IN STOCKHOLDERS’ (DEFICIT) EQUITY

FROM MAY 9, 2014 (DATE OF INCEPTION) THROUGH DECEMBER 31, 2015

 

	 	 	Common stock	 	 	Additional
 Paid in	 	 	Accumulated
 Other
 Comprehensive	 	 	Accumulated	 	 	 	 
	 	 	Shares	 	 	Amount	 	 	Capital	 	 	Loss	 	 	Deficit	 	 	Total	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Shares issued to founders	 	 	750,000	 	 	 	8	 	 	 	 	 	 			 	 			 	 	8	 
	Shares issued for advisory services	 	 	250,000	 	 	 	2	 	 	 	2,999,998	 	 	 	 	 	 	 	 	 	 	3,000,000	 
	Beneficial conversion feature associated with convertible note payable	 	 	 	 	 	 	 	 	 	 	348,989	 	 	 	 	 	 	 	 	 	 	348,989	 
	Net loss	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	(3,348,002	)	 	(3,348,002	)
	Balance, December 31, 2014	 	 	1,000,000	 	 	 	10	 	 	 	3,348,987	 	 	 	 	 	 	 	(3,348,002	)	 	995	 
	Beneficial conversion feature associated with convertible note payable	 	 	 	 	 	 	 	 	 	 	479,135	 	 	 	 	 	 	 	-	 	 	479,135	 
	Foreign currency translation adjustment	 	 	 	 	 	 	 	 	 	 	 	 	 	 	(S0,115)	 	 	 	-	 	 	(80,115	)
	Net loss	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	(5 708 211)	 	 	(5,708,211	)
	Balance, December 3 I, 2015	 	 	1 000 000	 	 	 	 	 	 	 	1.2,a122		 	 	 	 	 	 	 	 	 	3 (5 30a126	)

 

    	F-10

     

    

 

ACCELERATED PHARMA,

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

	 	 	Year ended
 December 31,
 2015	 	 	From (date
 December
 May 9, 2014
 of inception)
 Through
 31, 2014	 
	 	 	 	 	 	 	 	 	 
	CASH FLOWS FROM OPERATING ACTIVITIES:	 	 	 	 	 	 	 	 
	Net loss	 	$	(5,708,212	)	 	S	(3,348,002)	 
	Adjustments to reconcile net loss to net cash provided by operating activities:	 	 	 	 	 	 	 	 
	Amortization and depreciation	 	 	3,022	 	 	 	 	 
	Amortization of debt discounts	 	 	1,024,488	 	 	 	2,763	 
	Financing costs	 	 	 	 	 	 	125,350	 
	Fair value of warrants issued in connection with financing	 	 	 	 	 	 	48,225	 
	Stock based compensation	 	 	 	 	 	 	3,000,008	 
	Gain on change in fair value of warrant liability	 	 	(80,200	)	 	 	(2,724	)
	Changes in operating assets and liabilities:	 	 	 	 	 	 	 	 
	Prepaid expenses and other current assets	 	 	(100,062	)	 	 	-	 
	Accounts payable	 	 	596,504	 	 	 	750	 
	Accrued interest	 	 	160,016	 	 	 	-	 
	Accrued obligation to purchase research and development	 	 	2,115,224	 	 	 	30.000	 
	Net cash used in operating activities	 	 	(1,989,221	)	 	 	(123,625	)
	 	 	 	 	 	 	 	 	 
	CASH FLOWS FROM INVESTING ACTIVITIES:	 	 	 	 	 	 	 	 
	Purchase of equipment	 	 	(13,677	)	 	 	 	 
	Net cash used in investing activities	 	 	(13,677	)	 	 	 	 
	CASH FLOWS FROM FINANCING ACTIVITIES:	 	 	 	 	 	 	 	 
	Net proceeds from convertible notes payable, net of financing costs of $362,942 and $125,350	 	 	2 237,058	 	 	 	624.650	 
	Net cash provided by financing activities	 	 	2,237,058	 	 	 	624,650	 
	 	 	 	 	 	 	 	 	 
	Effect of currency rate change on cash	 	 	(77,260	)	 	 	 	 
	 	 	 	 	 	 	 	 	 
	Net increase in cash and cash equivalents	 	 	156,900	 	 	 	501,025	 
	 	 	 	 	 	 	 	 	 
	Cash and cash equivalents, beginning of period	 	 	501,025	 	 	 	 	 
	Cash and cash equivalents, end of period	 	,$	651225		 	 	 	 
	SUPPLEMENTAL INFORMATION:	 	 	 	 	 	 	 	 
	Cash paid for interest	 	 	 	 	 	 	 	 
	Cash paid for income taxes	 	•S		 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	Non-cash investing and financing activities:	 	 	 	 	 	 	 	 
	Fair value of conversion option issued in connection with convertible debt	 	$	479,134	 	 	 	142 98Q	 

 

    	F-11

     

    

  

Schedule 3.1(i)

 

Material Changes; Undisclosed Events, Liabilities
or Developments

 

None. All liabilities in the ordinary course of business.

 

    	F-12

     

    

  

Schedule
3.1(o)

 

Intellectual Property

 

Exclusive Licensed Agreement between Tallikut
Pharmaceuticals, Inc and Accelerated Pharma, Inc. of June 17, 2014 and, as amended, December 9, 2014 and as of February 16, 2015,
copies of which are attached hereto. In connection with the February 16, 2015 amendment, the Company issued to Tallikut Pharmaceuticals
80,000 shares of common stock, and a warrant for 80,000 shares of common stock.

 

    	F-13

     

    

 

Schedule 3.1(r)

 

Finder Fees

 

1.              The
Company is oto pay Palladium various and significant fees pursuant to the Placement
Agent Agreement in connection with the transaction contemplated by the Transaction Documents.

 

    	F-14

     

    

 

Schedule 3.1(q)

 

Employment Agreements

 

None

 

    	F-15

     

    

 

Schedule 4.5

 

Use of Proceeds

 

The Company will use the proceeds of the offering for general working
capital purposes.

 

    	F-16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]